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The hepatitis B virus (HBV) was discovered in 1966 with the identification of the Australia antigen in
Aboriginals by Dr. Baruch Blumberg, who received the 1976 Nobel Prize in Medicine for his work.
We now know the Australia antigen as hepatitis B surface antigen (HBsAg).
The hepatitis B virus
HBV belongs to a family of closely related DNA viruses called the hepadnaviruses. The viral ge-
nome of HBV is a partially double- stranded circular DNA of approximately 3200 base pairs that
encodes four overlapping open reading frames: the surface or envelope gene, the core gene, the
polymerase gene and the X gene. The core gene can also produce a soluble small molecular
weight protein called hepatitis B e antigen (HBeAg) by an alternate start codon and post-transla-
tional modification. After entry in the hepatocyte, the HBV DNA is transported to the nucleus and
converted to covalently closed circular DNA (cccDNA), which serves as the stable template for
transcription of both messenger RNA (for translation of viral proteins) and pre-genomic RNA (for
reverse transcription into genomic DNA). Because the cccDNA is highly resistant to antiviral therapy
and the host's immunological response, complete eradication of HBV from the liver is probably not
feasible.1 HBV is non-cytopathic, cellular injury in HBV infected persons appears immune-medi-
ated.2
Acute hepatitis B
Acute hepatitis B virus (HBV) infection is usually asymptomatic, less than 30% of adults present
with icteric hepatitis and symptomatic disease is even less frequent in younger patients. The risk of
chronic infection is highly dependent on the age of infection. Perinatal infection from the infected
mother evolves to chronicity in 90% of cases.3 Infection in early childhood (1-5 years) is also asso-
ciated with a high risk of chronic infection of about 30%. In adults, in contrast, infection resolves
with development of anti-HBs in 95% of cases.4 Chronic infection is characterized by the persis-
tence of serum HBsAg and anti-HBc.
Chronic hepatitis B
Chronic hepatitis is always associated with active HBV replication. There are two types of chronic
hepatitis B, which differ by the HBeAg and anti-HBe status. Seroconversion from HBeAg to anti-
HBe is the key event in the natural course of chronic hepatitis B since HBeAg seroconversion is
followed by resolution of biochemical and histologic signs of inflammatory activity in the 67-80% of
patients.5, 6 Some patients may have persistence or recurrence of disease activity with elevated
serum ALT and high serum HBV DNA levels despite HBeAg clearance. HBeAg seroconversion,
whether spontaneous or after antiviral therapy, reduces the risk of hepatic decompensation and
improves survival.6-8
Epidemiology
Chronic HBV infection is an important health problem. Current estimates are that about one-third of
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world's population has evidence of past or present infection with HBV and that 400 million people
are chronically infected.9, 10 Primary liver cancer is ranked the 6th most common cancer globally
and over 50% of cases are caused by chronic HBV infection.11 The prevalence of HBV infection
and patterns of transmission vary greatly throughout the world. Approximately 45% of the global
population live in areas of high HBV endemicity (HBV prevalence >8%).12 These areas include
many African and Asian countries. In these countries the source of infection is mainly through
perinatal transmission from the chronically infected mother or through infection during early child-
hood. The source of infection in areas with low prevalence of HBV infection is mainly through
unsafe sexual contacts and needle sharing among injecting drug users. Eight genotypes of HBV
have been identified (A-H), each with a specific geographic distribution. HBV genotype A is most
common in the United States and Northern Europe, B and C in Asia, and D in Mediterranean coun-
ties and the Middle East.13, 14 Recent data suggest that HBV genotypes may play an important role
in the progression of HBV-related liver disease as well as response to interferon (IFN) therapy.13, 15
Antiviral therapy for chronic hepatitis B
The goal of therapy for hepatitis B is to improve quality of life and survival by preventing progression
to cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC) and death. This goal can
be achieved if HBV replication can be suppressed in a sustained manner. Reduction in serum HBV
DNA levels is generally accompanied by a reduction in necroinflammatory activity, thereby limiting
the risk of cirrhosis and decreasing the risk of HCC.8, 16 Seven drugs are now licensed for the
treatment of chronic hepatitis B (conventional interferon alpha, pegylated interferon alpha, lamivudine,
adefovir, entecavir, telbivudine and tenofovir). The practicing clinician has to choose between two
therapeutical approaches: a strategy aimed at inducing sustained off-treatment response (mainly
IFN-based therapy) versus a strategy aimed at maintained viral suppression during prolonged an-
tiviral therapy (nucleoside and nucleotide analogues).
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SUMMARY
The development of this guideline was initiated and coordinated by the Dutch Society of
Gastroenterologists and Hepatologists (Nederlands Genootschap van Maag-Darm-Leverartsen).
The aim is the establishment of National standards in the evaluation and antiviral treatment of
patients with chronic hepatitis B virus (HBV) infection. This includes recommendations on the
initial evaluation of patients, choice and duration of antiviral therapy, follow-up after antiviral therapy
and monitoring of patients not currently requiring antiviral therapy.
The initial evaluation of chronic HBV infected patients should include testing of liver biochemistry,
virus serology and abdominal imaging. In patients without cirrhosis, antiviral treatment is
recommended for those with serum HBV DNA of at least 1.0 x 105 copies/mL (>=2.0 x 104 IU/mL)
in combination with: a) elevation of serum alanine aminotransferase (ALT) level above twice the
upper limit of normal during at least three months, and/or b)  histological evidence of porto-portal
septa or interface hepatitis on liver histology. In patients with cirrhosis, antiviral treatment is
recommended if serum HBV DNA is 1.0 x 104 copies/mL (>=2.0 x 103 IU/mL) or higher, independent
of ALT levels or histological findings. If the patient has decompensated cirrhosis, antiviral treatment
is recommended if serum HBV DNA is 1000 copies/mL (>=200 IU/mL) or higher.
Patients who do not have an indication for antiviral treatment should be monitored because there
is a risk of (re)activation of disease activity. Monitoring every three to six months is recommended
for HBeAg positive and HBeAg negative patients with high viremia (HBV DNA >=1.0 x 105 copies/
mL or >=2.0 x 104 IU/mL) and normal ALT levels. For patients with serum HBV DNA below 1.0 x
105 copies/mL (<2.0 x 104 IU/mL) the recommended frequency of monitoring is every three to six
months for HBeAg positive patients and every six to 12 months for HBeAg negative patients.
Peginterferon (PEG-IFN) therapy should be considered as initial therapy in both HBeAg positive
and HBeAg negative patients without contraindications for treatment with this drug because of the
higher chance of achieving sustained response compared to nucleos(t)ide analogue therapy. In
patients starting nucleos(t)ide analogue therapy, the use of lamivudine is not preferred if long-term
antiviral treatment is expected due to the high risk of antiviral resistance against this drug. Of
currently licensed nucleos(t)ide analogues, entecavir has the lowest risk of antiviral resistance
(compared to lamivudine, adefovir and telbivudine), while suppression of viral replication seems
most profound with either entecavir or telbivudine.
The recommended duration of treatment with PEG-IFN is one year for both HBeAg positive and
HBeAg negative patients. In HBeAg positive patents, nucleos(t)ide analogue therapy should be at
least continued until HBeAg seroconversion and a decline in HBV DNA to below 400 copies/mL
(80 IU/mL) has been achieved and maintained for six months during therapy. Whether nucleos(t)ide
analogue therapy can be safely discontinued in HBeAg negative patients is unknown, usually
prolonged or indefinite antiviral treatment is necessary.
Patients receiving PEG-IFN should be monitored once monthly, while three monthly monitoring
suffices for those receiving nucleos(t)ide analogues. Genotypic analysis of the HBV polymerase is
17Dutch national guidelines for the treatment of chronic hepatitis B
indicated if an increase in serum HBV DNA of at least 1 log10 copies/mL (IU/mL) compared to the
nadir value is observed during nucleos(t)ide analogue therapy. Antiviral therapy should be changed
as soon as possible in case of confirmed genotypic resistance. Adding a second antiviral agent
seems beneficial over switching to another agent.
With the availability of multiple new antiviral drugs for the treatment of chronic hepatitis B, effective
treatment is now possible for more patients and for longer periods. However, the complexity of
HBV therapy has also increased. Nowadays, virtually all chronic HBV infected patients can be
effectively managed, either by inducing sustained off-treatment response or by maintaining an on-
treatment response.
INTRODUCTION
About one-third of the world's population has evidence of HBV infection and chronic hepatitis B
affects about 400 million people worldwide.1,2 More than 500,000 people yearly die of HBV related
liver disease, largely due to complication of cirrhosis or hepatocellular carcinoma.3 The Nether-
lands is a low endemic country for HBV infection, the estimated seroprevalence of HBsAg and anti-
HBc is about 0.2% and 2.1%, respectively.4 Risk groups with a higher prevalence of HBV infection
include immigrants from areas with intermediate or high prevalence of HBV infection, males who
have sex with males and people with multiple sexual contacts. Despite the availability of a safe and
effective vaccine for over 20 years now, HBV infection remains an important health problem. Anti-
viral treatment of chronic hepatitis B has dramatically changed over the last decade; with the avail-
ability of multiple new antiviral agents the treatment of chronic HBV infection has become more
effective, but more complex as well.
Multiple consensus guidelines for the treatment of chronic hepatitis B have been published in the
last few years.3,5,6 However, there currently is no standard of care for the management and antiviral
treatment of chronic HBV infected patients in the Netherlands. Therefore, a committee was con-
vened by the Dutch Society of Gastroenterologists and Hepatologists (Nederlands Genootschap
van Maag-Darm-Leverartsen) to formulate consensus based guidelines for the management and
treatment of chronic HBV infected adults.
The guideline provides recommendations on the initial evaluation of chronic HBV infected patients,
choice of (initial) antiviral therapy, follow-up during and after antiviral therapy and monitoring of
patients currently not requiring antiviral therapy. Management of patients with coinfections of HBV
and hepatitis C virus (HCV), hepatitis delta virus (HDV) or human immunodeficiency virus (HIV) is
not discussed in this guideline. The recommendation in this guideline have been defined in accor-
dance with recent international literature, data presented at international symposia and guidelines
of the American Association for the Study of Liver Diseases (AASLD), the European Association for
the Study of the Liver (EASL) en the Asian-Pacific Association for the Study of the Liver (APASL).3,5,6
The level of recommendation was performed according to the Dutch Institute for Healthcare Im-
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provement (CBO) (http://www.cbo.nl/product/ richtlijnen/handleiding_ebro/article20060207153532)
(table 1a and 1b).
NATURAL HISTORY
Infection with HBV at adulthood is usually not associated with symptomatic disease and results in
chronic infection in less than 5% of cases.3 However, infection during childhood is associated with
a much higher risk of chronicity, up to 90% in case of perinatal transmission.3 Chronic HBV infec-
tion is defined as detectable hepatitis B surface antigen (HBsAg) in serum for at least six months.
Phases of infection
Chronic HBV infected patients typically present in one of four phases of infection (figure 1).7 In the
immunotolerant phase, hepatitis B e antigen (HBeAg) is detectable and serum HBV DNA is high
(>1.0 x 105 copies/mL or >2.0 x 104 IU/mL), while serum alanine aminotransferase (ALT) is normal.
Patients infected in early childhood usually remain in this phase of infection for 10-30 years.8 In the
immuno-active phase, an active host's immune response against the virus results in a rise in ALT
accompanied by a decline in HBV DNA; loss of HBeAg with seroconversion to anti-HBe can occur.
The immune control phase follows HBeAg seroconversion and is characterised by low viremia
(<1.0 x 104 copies/mL or <2.0 x 103 IU/mL) and normalization of ALT. Although HBV replication
persists, it is profoundly suppressed by an active immune response. In a significant proportion of
HBeAg negative patients, viral replication and hepatic inflammation persist or recur, usually due to
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the selection of HBV variants with mutation in the HBV genome (precore or core promoter mu-
tants) which hamper the production of HBeAg. These patients develop HBeAg negative chronic
hepatitis. Patients with chronic hepatitis B who acquire infection in adulthood often skip the
immunotolerant phase and enter the immuno-active phase shortly after the infection.
Reactivation of HBV infection can occur in case of immunosuppression, it is therefore recommened
to determine HBV status in all patients prior to the start of chemotherapy or treatment with selective
antibodies.
Cirrhosis
The annual incidence of cirrhosis in patients with chronic hepatitis B is about 6%, with a 5-year
cumulative incidence of 20%.9 The course of disease strongly varies among individual patients,
progression of liver damage particularly occurs in those with persistent hepatic inflammation.10
Factors associated with an increased risk of developing liver cirrhosis include high serum HBV
DNA, coinfection with HCV, HDV or HIV, repeated episodes of acute exacerbation and severe
necroinflammation at diagnosis.3,11,12 The annual risk of hepatic decompensation is about 3% in
patients with pre-existent cirrhosis.3 Presence of liver cirrhosis is associated with a diminished 5-
year survival rate of about 84%, for patients with decompensated cirrhosis this is only 14-30%.13-15
Hepatocellular carcinoma
Cirrhosis is a major risk factor for the development of hepatocellular carcinoma (HCC), the major-
ity of patients with HCC has underlying cirrhosis (80-90%).16 The annual incidence of HCC in
Figure 1. Phases of chronic hepatitis B virus infection
This figures shows the phases of chronic HBV infection. Patients can be categorised based on HBeAg-
status, serum HBV DNA and ALT levels.
Immunotolerant
phase
HBeAg
Immuno-active
phase
Immune-control
phase
HBeAg-negative
chronic hepatitis
HBV DNA
Anti-HBe
ALAT
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European chronic hepatitis B patients is about 2%. In patients from Asia, the risk of developing
HCC is higher, with an annual incidence of about 3%.16 Factors associated with an increased risk
of developing HCC in patients with cirrhosis include high age, male sex, persistent hepatic inflam-
mation, HBV DNA >1.0 x 104 copies/mL (>2.0 x 103 IU/mL), HBeAg positivity, coinfection with HCV
or HIV, and alcohol abuse.16-19
INITIAL EVALUATION
The initial evaluation of patients with chronic HBV infection should include a detailed history, with
special emphasis on risk factors for infection with blood-borne viruses and sexual transmitted
diseases, alcohol use, and family history of HBV infection and liver cancer. Physical examination
should emphasize signs of chronic liver disease and cirrhosis (palmar erythema, spider nevi,
gynaecomasty, flapping tremor and testicular atrophy), portal hypertension (ascites, splenomegaly
and abdominal wall collaterals) and liver failure (jaundice and hepatic encephalopathy).
Laboratory tests should include assessment of liver enzymes (aminotransferases), liver function
tests (albumin, bilirubin and prothrombin time), full blood count and kidney function tests. Virus
serology should include markers of HBV replication (quantification of HBV DNA, HBeAg and anti-
HBe) and in patients at increased risk, also tests for coinfection with HCV, HDV, or HIV. Determina-
tion of HBV genotype may be of use in patients starting antiviral therapy, as this may guide the
choice of therapy.
Abdominal ultrasound should be performed in all patients, with special emphasis on signs of cir-
rhosis (irregular liver surface, blunt liver edge and narrowed hepatic veins), portal hypertension
(diminished portal flow speed, splenomegaly, venous collaterals and ascites) and focal liver le-
sions.
Performing a liver biopsy is often indicated, but does not have to be routinely performed in all
chronic HBV infected patients. A liver biopsy should particularly be considered in patients with an
indication for antiviral therapy in order to assess baseline necroinflammatory activity and fibrosis
stage. In case there is doubt about the need of starting antiviral therapy, liver biopsy is probably of
even greater value as it may give additional information as to whether antiviral therapy or a conser-
vative approach is justified. For patients in the immune-control phase (inactive HBsAg carrier state)
a liver biopsy should be considered in case presence of cirrhosis is suspected. Patients in the
immune-control and HBeAg negative hepatitis phase are usually older, are infected with HBV longer
and more often have developed advanced fibrosis or cirrhosis as compared to patients in other
phases of infection.20 If liver histology shows presence of cirrhosis it is not recommended to dis-
charge the patient because of the risk of developing HCC in these patients, even in patients with
inactive disease. Patients in the immunotolerant phase on the other hand rarely have significant
fibrosis and progression of disease should only be suspected in case of transition to the
immunoactive phase.21 Performing a liver biopsy can therefore usually be postponed in such cases.
Surveillance for HCC, by abdominal ultrasound every 6 to 12 months, is recommended for all
21Dutch national guidelines for the treatment of chronic hepatitis B
chronic HBV infected patients with cirrhosis, in particular in those at increased risk of develop-
ing.6,22 Patients at increased risk of developing HCC include Asian males over 40 years, Asian
females over 50 years, patients with a family history of HCC, Africans over 20 years, patients with
high HBV DNA levels and those with persistent hepatic inflammation.23 Also in patients without
cirrhosis but with an increased risk of developing HCC, surveillance for HCC should be consid-
ered. Surveillance for HCC results in detection of HCC at an earlier stage and thereby improved
survival.24 Routine measurement of alfa-fetoprotein is in general not useful as this does not im-
prove the efficacy of screening and leads to increase in false-positive findings.23 In patients with
cirrhosis, upper gastrointestinal endoscopy should be considered to confirm or exclude the pres-
ence of esophageal varices.25
Hepatitis A virus (HAV) immunity should be established in all patients with chronic hepatitis B, since
the risk of a fulminant course of acute HAV infection is increased compared to healthy controls.26,27
Despite the fact that the actual risk of fulminant HAV is low, HAV vaccine is recommended for all
chronic HBV infected patients not immune to HAV.
INDICATIONS FOR ANTIVIRAL THERAPY
In a considerable proportion of chronic HBV infected patients there is no need for antiviral treat-
ment.28 Whether or not antiviral treatment should be started depends on multiple factors (table 2).
First, active viral replication should be present, as shown by serum HBV DNA of at least 1.0 x 105
copies/mL (2.0 x 104 IU/mL). In HBeAg negative patients, the risk of (re)activation of disease activity
and progression of disease seems already increased in those with serum HBV DNA above 1.0 x
104 copies/mL (2.0 x 103 IU/mL) compared to patients with lower HBV DNA levels.29 In addition to
HBV DNA, the degree of hepatic fibrosis and inflammation plays an important role in assessing the
need for antiviral therapy. This is represented by serum ALT levels and necroinflammatory activity
on liver histology. Serum ALT of at least two times the upper limit of normal (ULN) during three to six
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months is usually considered an indication for antiviral therapy. In patients with serum HBV DNA
above 1.0 x 105 copies/mL (2.0 x 104 IU/mL) and persistent mild hepatic inflammation (ALT 1-2 x
ULN), but with significant liver fibrosis (porto-portal septa) or interface hepatitis antiviral therapy
should also be considered. If serum ALT is elevated but serum HBV DNA is low, other causes of
hepatitis should be considered. If no other underlying aetiology can be found and liver biopsy shows
hepatitis B virus associated inflammation, antiviral treatment should be considered.
In patients with compensated cirrhosis, antiviral treatment should be considered if HBV DNA is 1.0
x 104 copies/mL (2.0 x 103 IU/mL) or higher. HBV DNA above this level is associated with an in-
creased risk of progression to decompensated cirrhosis or HCC.17 Patients with decompensated
cirrhosis should be offered antiviral therapy if HBV DNA is 1,000 copies/mL (200 IU/mL) or higher,
as suppression of viral replication can significantly improve liver function and survival in these
patients.30,31
Over 90% of babies born to HBsAg positive mothers is effectively protected by passive-active
immunization. However, in pregnant patients with very high viremia (HBV DNA >=1.0 x 109 copies/
mL or >=2.0 x 108 IU/mL), the risk of vaccination failure in the newborn is about 30%.32,33 In these
women, nucleos(t)ide analogue therapy from week 32 of pregnancy can significantly lower this
risk.33,34 Lamivudine is the antiviral agent of choice because of extensive clinical experience in
pregnancy, particularly in HIV infection.33-35 Switching to another antiviral agent after delivery can be
considered if prolongation of antiviral therapy is indicated. In patients becoming pregnant during
nucleos(t)ide analogue therapy, the risks of stopping antiviral therapy (in particular acute exacerba-
tion) should be balanced against the risk for the unborn child when continuing the drug. Recom-
mendations on what to do in such cases are not possible as scientific evidence is lacking, consult-
ing a centre with expertise on treatment of chronic HBV infection is recommended.
In HBsAg positive patients starting chemotherapy or treatment with selective antibodies, prophy-
lactic antiviral treatment with a nucleos(t)ide analogue is recommended until six months after the
completion of the immunosuppressive therapy. Prophylactic antiviral therapy has been shown to
significantly reduce the risk of reactivation and hepatitis B related death.6,36 In patients requiring
prophylactic antiviral treatment, who have baseline HBV DNA of above 1.0x 104 copies/mL (>2.0 x
103 IU/mL), the regular endpoints of antiviral therapy should be applied (see also Choice and dura-
tion of antiviral therapy).6 Prophylactic antiviral therapy can also be considered in anti-HBc positive
patients, since these patients are also at risk for reactivation in case of severe immunosuppres-
sion.36
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MONITORING OF PATIENTS NOT REQUIRING ANTIVIRAL THERAPY
Patients who do not have an indication for antiviral therapy should be monitored since disease
activity may fluctuate over time (table 2). Three to six monthly monitoring of serum ALT is recom-
mended for HBeAg positive patients with high viremia (HBV DNA >=1.0 x 105 copies/mL or >=2.0 x
104 IU/mL) and normal ALT, with more frequent monitoring when ALT becomes elevated. For HBeAg
negative patients with high serum HBV DNA (>=1.0 x 105 copies/mL or >=2.0 x 104 IU/mL) and
normal ALT, monitoring is also recommended every three to six months. In those with low viremia,
six to 12 monthly monitoring suffices.
GOALS OF ANTIVIRAL THERAPY
The ultimate goal of antiviral therapy for chronic HBV infected patients is clearance of HBsAg and
appearance of anti-HBs. However, since HBsAg-seroconversion can only be achieved in a small
proportion of patients, other surrogate endpoints of antiviral therapy have been chosen. These
endpoints can generally be assessed after one year of treatment and are associated with favourable
long-term outcome. The most important endpoints of antiviral therapy include HBeAg seroconversion
(loss of HBeAg with appearance of anti-HBe) in previously positive patients, decline in serum HBV
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DNA below the lower limit of detection of a sensitive polymerase chain reaction (PCR) assay (or
comparable test), biochemical response (normalisation of ALT) and improvement of liver histology
(decrease in necroinflammatory activity and no increase in fibrosis). These endpoints indicate the
presence of inactive disease in patients with previous active hepatitis. Furthermore, responses
can be distinguished in those sustained after discontinuation of therapy versus those that need to
be maintained by antiviral therapy. In case of sustained response there is an active immune-re-
sponse against the virus, as shown by HBeAg or HBsAg seroconversion. In case of treatment-
maintained response there is persistent suppression of viral replication by the antiviral drug, but no
active immune-response. Sustained response is particularly achieved with (peg)interferon therapy,
while treatment-maintained response can be achieved with long-term nucleos(t)ide analogue therapy
in the majority of patients. Higher rates of sustained HBeAg seroconversion have been achieved
with interferon compared to lamivudine.37 It is not clear whether with the new potent nucleos(t)ide
analogues, substantial rates of sustained response can be reached after HBeAg seroconversion
and subsequent withdrawal of therapy.
ANTIVIRAL DRUGS FOR THE TREATMENT OF CHRONIC HBV INFECTION
Peginterferon
Interferon-alfa (IFN-alfa) has been used for the treatment of chronic HBV infection since the 1980's.
Figure 2: Management of chronic hepatitis B virus infected patients.
This flowchart shows the recommendations on the management of chronic HBV infected patients based on
HBeAg status, serum HBV DNA and ALT levels. #Significant fibrosis: at least porto-portal septa on liver
histology.
Chronic hepatitis B
HBeAg(+) HBeAg(-)
Reevaluation
3-6 months
ALT
1-2xULN
Reevaluation
1-3 months
HBV DNA
≥1,0 x 105 copies/ml
(≥2,0 x 104 IU/ml)
Antiviral
therapy
HBV DNA
<1,0 x 105 copies/ml
(<2,0 x 104 IU/ml)
HBV DNA
<1,0 x 105 copies/ml
(<2,0 x 104 IU/ml)
ALT
<2xULN
ALT
≥2xULN
Exclusion other
causes hepatitis
Reevaluation
6-12 months
ALT
<2xULN
ALT
≥ 2xULN
Exclusion other
causes hepatitis
Significant
fibrosis# /
interface hepatitis
No significant
fibrosis /
interface hepatitis
ALT<2xULN
ALT
<1xULN
Reevaluation
3-6 months
ALT
≥ 2xULN
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Interferons are natural occurring cytokines with immunomodulatory, antiproliferative and antiviral
activity.38 IFN-alfa has been a mainstay in the treatment of chronic HBV infection since it was
licensed for this indication in the early 1990's, both in HBeAg positive and HBeAg negative chronic
hepatitis B. In the majority of HBeAg positive patients IFN-induced HBeAg seroconversion is du-
rable (87%) and eventually leads to HBsAg loss in about 50% of these responders.39 The risk of
developing and HCC is significantly lower for responders to IFN therapy compared to non-respond-
ers.39
The addition of a polyethylene glycol molecule (PEG) to the IFN has resulted in a significant in-
crease of half-life, thereby allowing administration once weekly. The last few years clinical re-
search has focussed on the use of peginterferon (PEG-IFN) for the treatment of chronic hepatitis
B. Two types of peginterferons have been developed (peginterferon alfa-2a and peginterferon alfa-
2b), of which peginterferon-alfa-2a has been licensed for the treatment of chronic HBV infection in
the Netherlands in a weekly dose of 180 microgram (subcutaneous) for 48 weeks in both HBeAg
positive and HBeAg negative patients.
In HBeAg positive patients, PEG-IFN appears at least as effective as conventional IFN with loss of
HBeAg in 35% and seroconversion to anti-HBe in 29-32% of patients.40-43 Addition of lamivudine did
not lead to an increase in sustained response rates compared to PEG-IFN monotherapy. PEG-IFN
induced HBeAg loss is sustained in 80-86% of HBeAg-positive patients.44,45 HBsAg-seroconversion
occurs in 3-7% of PEG-IFN treated patient within six months after the end of therapy (10-20% of
those with HBeAg loss). The likelihood of HBeAg loss after PEG-IFN therapy is associated with the
HBV genotype; patients with genotype A or B have a higher chance of achieving HBeAg loss than
those with genotype C or D.42,46 Genotype A infected patients significantly more often show loss of
HBeAg and HBsAg than those infected with genotype D.42,47
Only one large randomised trial of PEG-IFN therapy has been performed in HBeAg negative chronic
hepatitis B.48 Combined response of HBV DNA below 2.0 x 104 copies/mL and normalization of ALT
occurred in 36% of patients. At 24 weeks post-treatment, serum HBV DNA below 400 copies/mL
was observed in 19%. As in HBeAg positive chronic hepatitis B, the addition of lamivudine did also
not increase response rates in these patients. HBsAg seroconversion occurred in 4% of PEG-IFN
treated HBeAg negative patients (over 10% of those with combined response).48
Major disadvantages of PEG-IFN therapy are the subcutaneous administration and frequent side
effects (table 3). Particularly flu-like symptoms, cytopenia and psychiatric adverse events are fre-
quently observed,49 but rarely require discontinuation of therapy.49,50
PEG-IFN is contraindicated in patients with advanced cirrhosis (albumin <35g/l, bilirubin >34 μmol/
l or prolongation of prothrombin time by more than 4 seconds) because of the increased risk of
decompensation in case of acute exacerbation.51,52 Other important contraindications of treatment
with PEG-IFN are severe psychiatric comorbidity (depression and suicidal ideation), severe car-
diac disease and autoimmune hepatitis (or other autoimmune disorders). A major advantage of
PEG-IFN therapy is the high rate of sustained of response (over 80% in HBeAg positive patients
and about 40% of HBeAg negative patients who initially responded to the treatment).44,45,53
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Nucleos(t)ide analogues
In the last decade there has been a major advance in the treatment of chronic hepatitis B with
nucleos(t)ide analogues. These antiviral agents inhibit the viral polymerase and thereby viral repli-
cation. Advantages of nucleos(t)ide analogues are the oral administration, rapid decline in HBV
DNA and minimal side effects. A major disadvantage is that the majority of patients needs pro-
longed or even indefinite therapy, as sustainability of response after discontinuation of therapy is
limited. Furthermore, the risk of antiviral resistance increases with the duration of antiviral therapy.
Antiviral resistance is caused by the selective selection of naturally occurring mutations in the HBV
polymerase. Rapid and profound viral suppression reduce the risk of antiviral resistance.54
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Lamivudine
Lamivudine was the nucleoside analogue licensed for the treatment of chronic HBV infection in
1999. Lamivudine should be given is a dosage of 100mg daily and has excellent safety and toler-
ability. In HBeAg positive patients, treatment with lamivudine for one year results in HBeAg
seroconversion plus serum HBV DNA below 1.0 x 105 copies/mL (2.0 x 104 IU/mL) in 16-22% of
patients.55-60 The rate of HBeAg seroconversion increases with increasing duration of therapy to
29%, 40% and 47% after two, three and four years of therapy, respectively.57,58,61 Decline in HBV
DNA below 7,0 x 105 copies/mL (1,4 x 105 IU/mL) was observed in 65% of patients.62
In HBeAg negative patients, serum HBV DNA below 400 copies/mL (<80 IU/mL) was observed in
68-73% of patients after one year of lamivudine. Sixty-eight to 96% of these patients also had
biochemical response.48,63,64 In HBeAg negative patients the rate of virological response declined
with increasing duration of therapy, largely due to the increasing risk of antiviral resistance. Re-
sponse rates at year two, three and four were 67%, 60% and 39%, respectively.63,65,66 Treatment
with lamivudine has been shown to result in a decrease of disease progression and development
of HCC in patients with advanced fibrosis or cirrhosis compared to untreated controls.67
The major disadvantage of lamivudine is the high incidence of antiviral resistance. The majority of
patients with viral breakthrough has mutations in the tyrosine-methionine-aspartate-aspartate mo-
tif (YMDD) of the HBV polymerase.66 The most frequently observed mutation is a substitution of
methionine for valine or isoleucine at position 204 of the HBV polymerase.68 Lamivudine resistance
occurred in 24% of patients after one year, which increased to 71% after 5 years.69 The selection of
resistance mutations is often followed by an increase in ALT.66 Another disadvantage of lamivudine
is the high risk of relapse after discontinuation of therapy; half of patients with lamivudine induced
HBeAg seroconversion had relapse at 2-3 years after therapy.37,70
Adefovir
Adefovir is a nucleotide analogue with activity against wild-type and lamivudine-resistant HBV. Adefovir
was licensed for the treatment of chronic hepatitis B in the Netherlands in 2003 in a daily dosage of
10mg. Higher dosages may be more effective, but are associated with nephrotoxicity.71
In HBeAg positive patients, a one-year course of adefovir resulted in HBeAg seroconversion in
12%, serum HBV DNA below 1.0 x 103 copies/mL (200 IU/mL) in 21% and normalisation of ALT in
48% of patients.71 The rate of HBeAg-seroconversion increased with increasing duration of therapy
to 29% after 2 years and 43% after three years of treatment. The proportion of patients with HBV
DNA below 1.0 x 103 copies/mL (200 IU/mL) increased to 45% and 56% after two and three years,
respectively.72
Serum HBV DNA below 1.0x 103 copies/mL (200 IU/mL) and normalisation of ALT were observed in
51% and 72% of HBeAg-negative patients after one year of adefovir.73 After five years of therapy,
the proportion of patients with HBV DNA below 1.0 x 103 copies/mL (200 IU/mL) increased to 67%
and to 69% for ALT normalization.74,75 Histologic response was observed in 75-80% of adefovir
treated patients at year five.74 However, more recent studies suggested lower response rates dur-
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ing adefovir therapy, with serum HBV DNA above 1.0 x 104 copies/mL (2.0 x 103 IU/mL) in 50% of
patients after six months of therapy.76
HBeAg loss occurred in 20% of lamivudine resistant patients treated with adefovir.77 The proportion
of lamivudine resistant patients with HBV DNA below 400 copies/mL (80 IU/mL) was 19% after one
year of adefovir therapy.77
Antiviral resistance to adefovir occurs less frequent and later during the course of therapy com-
pared to lamivudine. The most important mutations in the HBV polymerase associated with adefovir
resistance include a substitution of asparagine for threonine at position 236 and a substitution of
alanine for valine or threonine at position 181.75,78 The reported incidence of adefovir resistance is
0% at year one, 22% at year two and 28% at year five of antiviral therapy.74,76 In lamivudine resistant
patients treated with adefovir monotherapy the rate of antiviral resistance was 6-18% after one
year and 21-38% after two years.77,79,80
Entecavir
Entecavir is a guanine analogue, which was licensed for the treatment of chronic hepatitis B in the
Netherlands in 2006. In nucleoside naïve patients, entecavir is given in a daily dosage of 0.5 mg. A
daily dose of 1 mg should be used in patients with pre-existent lamivudine resistance. Three large
randomised trials have compared entecavir to lamivudine for the treatment chronic hepatitis B.62,81,82
Decline in HBV DNA was significantly greater with entecavir than lamivudine in both HBeAg positive
and HBeAg negative patients.62,81
HBeAg seroconversion occurred in 21% of entecavir treated HBeAg positive patients after one
year, while serum HBV DNA below 300 copies/mL (60 IU/mL) or below 7,0x 105 copies/mL (1,4x
105 IU/mL) was observed in 67% and 91% of patients.62 The cumulative proportion of patients with
undetectable HBV DNA (300 copies/mL (60 IU/mL) increased to 82% after three years of therapy.83
After one year of entecavir treatment, serum ALT normalised in 68% of patients, which increased to
90% of patients after three years.83 The proportion of patients with HBeAg loss also increased, to
39% after three years of therapy.83
In HBeAg negative patients, treatment with entecavir resulted in normalization of ALT and HBV DNA
below 300 copies/mL (200 IU/mL) in 78% and 89%, and 90% and 94% of patients after one and two
years of therapy, respectively.81,84 Histologic response was observed in 70% of entecavir treated
patients after one year.81
Response to entecavir was lower in lamivudine resistant patients, with undetectable HBV DNA in
19% and ALT normalization in 61% of patients after 48 weeks of entecavir therapy.82 HBeAg loss
was observed in 8% of these patients.82
The rate of entecavir resistance was extremely low in nucleoside naive patients with antiviral resis-
tance observed in less than 1% of patients after 4 years of entecavir therapy.85-87 However, in
lamivudine resistant patients the risk of antiviral resistance is much higher with entecavir resis-
tance in 12%, 20%, 25% and 40% after 1-4 years of therapy, respectively.86-88 These findings impli-
cate cross-resistance of lamivudine and entecavir, entecavir resistance requires pre-existent
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lamivudine resistance mutations.
Telbivudine
Telbivudine is a nucleoside analogue belonging to the same group of antiviral agents as lamivudine.
Telbivudine is orally administrated in a daily dosage of 600 mg. Telbivudine has been licensed for
the treatment of chronic hepatitis B in the Netherlands since 2007. In both HBeAg positive and
HBeAg negative patients, telbivudine resulted in more profound viral suppression than lamivudine.89
After one year of treatment with telbivudine HBeAg seroconversion occurred in 22% of HBeAg
positive patients, increasing to 29% after two years of therapy.89,90 The proportion of patients with
serum HBV DNA below 300 copies/mL (60 IU/mL) was 60% after one year and 54% after two years
of telbivudine therapy. Eighty percent of patients who stopped telbivudine treatment after achieving
HBeAg seroconversion had sustained response after a mean period of 35 weeks post-treatment,
which was comparable to lamivudine therapy.91
Treatment with telbivudine resulted in HBV DNA below 300 copies/mL (60 IU/mL) in 88% of  HBeAg
negative patients after one year and 79% after two years. Combined response of HBV DNA below
1.0 x 105 copies/mL (<2.0 x 104 IU/mL) and normalisation of  ALT was observed in 75% and 74% of
patients after one and two years of therapy, respectively.
Since telbivudine and lamivudine belong to the same group of nucleoside analogues, there is cross-
resistance between the two drugs. A substitution of methionine for isoleucine at position 204 is
associated with telbivudine resistance. Telbivudine resistance was observed in 2-3% of patients
after one year and in 7-17% after two years of telbivudine therapy.89,90 The risk of antiviral resis-
tance was strongly associated with viral load at week 24 of treatment. The two-year rate of telbivudine
resistance was 4% in HBeAg positive patients and 2% in HBeAg negative patients if serum HBV
DNA was below 300 copies/mL (60 IU/mL) after 24 weeks of therapy. At week 24, HBV DNA below
this level was observed in 45% and 80% of HBeAg positive and HBeAg negative patients, respec-
tively.89
Choice and duration of (initial) therapy
When deciding on the antiviral drug to be given, several factors have to be taken into account
(table 4). The major advantage of PEG-IFN is the higher chance of achieving sustained response
compared to nucleos(t)ide analogues with a finite duration of therapy. Disadvantages are the sub-
cutaneous administration and the frequent occurrence of side effects. The major advantage of
nucleos(t)ide analogues are the favourable tolerability and the oral administration. Disadvantages
are the long duration of therapy and the subsequent risk of antiviral resistance. The costs of a one-
year course of nucleos(t)ide analogue therapy are lower than of PEG-IFN, but will easily be higher
when long-term therapy is needed.
PEG-IFN should be always be considered as first-line therapy in eligible patients because of the
higher chance of achieving sustained off-treatment response compared to nucleos(t)ide analogues
(table 5), particularly in HBeAg positive patients. Sustained transition to the immune-control phase
31Dutch national guidelines for the treatment of chronic hepatitis B
(inactive HBsAg carrier state) can be achieved in 30-35% of HBeAg positive patients and 25% of
HBeAg negative patients treated with PEG-IFN, implicating that treatment induced response is
sustained in about 85% and 40% of HBeAg positive and HBeAg negative patients, respectively.45,53
Relapse occurs in at least 40% and 90% of HBeAg positive and HBeAg negative patients after
discontinuation of nucleos(t)ide analogue therapy, respectively.64,73,75,92 The latter applies espe-
cially to the older nucleos(t)ide analogs. Sufficient data for the newer, more potent,  nucleos(t)ide
analogues is not available.
Patients with a high chance of response to PEG-IFN therapy are those with genotype A or B, with
serum HBV DNA below 1.0 x 109 copies/mL (2.0 x 108 IU/mL) and serum ALT above twice the upper
limit of normal.42,93,94 The licensed duration of peginterferon therapy is one year for both HBeAg
positive and HBeAg negative chronic hepatitis B. However, the optimal duration of PEG-IFN therapy
has not been established. In HBeAg positive patients, response rates after 24-32 weeks of treat-
ment course seem comparable to those observed after one year, but head-to-head comparison is
not available.40-43 Since early prediction of response to PEG-IFN is not possible in chronic HBV
infected patients, the recommended the duration of therapy is one year for all patients.
Nucleos(t)ide analogue therapy should be considered in patients not responding to or not eligible
for PEG-IFN therapy. This includes patients with autoimmune disease, pre-existent psychiatric
disorders or advanced cirrhosis (signs of diminished liver function or portal hypertension). When
choosing a nucleos(t)ide analogue, potency and risk of resistance play an important role (table 5).
Because of the high risk of antiviral resistance, lamivudine should no longer be considered as initial
therapy in patients who require long-term therapy. However, because of extensive clinical experi-
ence, lamivudine can be given to pregnant patients with very high viremia during the last trimester
of pregnancy.33
Of currently available nucleos(t)ide analogues, entecavir has the most favourable resistance pro-
file (in comparison with lamivudine, adefovir and telbivudine) (table 5),87 while entecavir and telbivudine
elbaT 4 .scitsiretcarahctneitapnodesabyparehtlaitinifoeciohC.
scitsiretcarahctneitaP norefretnigeP eugolanaedi)t(soelcuN
sutatsgAeBH evitisopgAeBH evitagengAeBH
epytonegVBH BroA DroC
ANDVBH 01x0.1=> 9 Lm/seipoc
01x0.2( 8 )Lm/UI
01x0.1> 9 Lm/seipoc
01x0.2( 8 )Lm/UI
TALA NLU01-2> NLU01>ro2-1
esaesidrevilfoytireveS detasnepmoC rodetasnepmoC
detasnepmoced
,tnegalarivitnanagnisoohcniplehfoebyamscitsiretcarahcdenoitnemevobaehT.lamronfotimilreppu=NLU
.snoitadnemmocertcirtsedivorptonodtub
  32
Ch
ap
te
r 1
seem most potent.62,89,95 However, fewest is known about the long-term safety of entecavir and
telbivudine. In patients with lamivudine resistance, treatment with entecavir is not recommended
because of the high risk of antiviral resistance. Adefovir add-on therapy is recommended for these
patients. The role of telbivudine in the treatment is not yet established, as is the role of de-novo
combination therapy of nucleos(t)ide analogues. A combination of antiviral drugs could potentially
prevent the selection of resistance mutations, but supporting scientific evidence is not available.
In HBeAg positive patients, nucleos(t)ide analogue therapy should be continued at least until HBeAg
seroconversion and HBV DNA below 400 copies/mL (80 IU/mL) have been achieved and main-
tained for six months. It is unclear when nucleos(t)ide analogue therapy can be safely discontinued
in HBeAg negative patients, this may be possible in case of HBsAg seroconversion and HBV DNA
below 400 copies/mL (80 IU/mL). Nucleos(t)ide analogue therapy therefore needs to be continued
for long periods in virtually all HBeAg negative patients.
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MONITORING OF ANTIVIRAL THERAPY
PEG-IFN treated patients should be monitored monthly; an additional visit at week two can be
considered. Frequently occurring side effects such as depression, irritability, neutropenia and throm-
33Dutch national guidelines for the treatment of chronic hepatitis B
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bocytopenia require monthly monitoring and blood count. If necessary, PEG-IFN dosage should be
reduced or treatment temporarily discontinued. PEG-IFN dosage should be reduced if the neutro-
phil count is below 0.75 x 109/l or platelet count below 50 x 109/l. The dose can reduced by 25% of
the original dose until the respective cell fractions have normalised. Temporary discontinuation of
PEG-IFN therapy is indicated if the neutrophil count is below 0.50 x 109/l or platelet count below 25
x 109/l. Severe side-effects such as depression or severe flu-like may also require dose-reduction
or even (temporary) discontinuation of therapy.
Recommendations on laboratory testing during PEG-IFN and nucleos(t)ide analogue therapy are
shown in table 6. The recommended frequency of HBV DNA quantification during antiviral therapy
is every three to six months, dependent on the risk of antiviral resistance. Testing of serum ALT is
recommended every 3 months. Prior to the start of nucleos(t)ide analogue therapy a quantitative
HBV DNA test and HBV serology should be performed in order to evaluate response to therapy.
The recommended frequency of monitoring during nucleos(t)ide analogue therapy is every 3 months,
particularly for the early detection of antiviral resistance. Monitoring of serum creatinin is indicated
every 3 months and nucleos(t)ide analogue dosage or frequency of administration should be re-
duced in case of severely decreased creatinin clearance (<50 ml/min) (table 7). Although nucleos(t)ide
analogue therapy generally has an excellent safety and tolerability profile, severe side-effects such
as lactic acidosis have been described.96
ANTIVIRAL RESISTANCE
Primary non-response is defined as a less than 2log10 copies/mL (or IU/mL) decline in HBV DNA
after 24 weeks of nucleos(t)ide analogue therapy [6]. Potential causes of primary non-response
include antiviral resistance, but also non-compliance, decreased absorption or rapid breakdown
[97]. The risk of antiviral resistance is minimal if serum HBV DNA is 400 copies/mL or lower after 24
weeks of therapy. Addition of adefovir or switching to entecavir is recommended in telbivudine-
treated patients with serum HBV DNA above 400 copies/mL (80 IU/mL) after 24 weeks of therapy.
This should also be considered in patients treated with lamivudine. Antiviral resistance is rare in
adefovir treated patients during the first year of antiviral treatment. However, addition of telbivudine
or switching to entecavir should be considered in patient with serum HBV DNA above1000 copies/
mL (200 IU/mL) after 12 months of therapy because of the increasing risk of antiviral resistance in
these patients.
Antiviral resistance should be suspected if serum HBV DNA increases during nucleos(t)ide ana-
logue therapy. If virological breakthrough, defined as a 1log10 copies/mL (or IU/mL) increase in
NOITADNEMMOCER
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HBV DNA, is observed in a compliant patients, genotypic analysis of the HBV polymerase is indi-
cated.97 A rise in HBV DNA is the first sign of antiviral resistance and is often followed by a rise in
ALT without intervention.97
In case of antiviral resistance it is recommended to change antiviral therapy as soon as possible
since response to the second drug is better when started at the time of virological breakthrough
than at the time of biochemical breakthrough.98 Adding a second drug seems favourable over switch-
ing to another drug, since this significantly reduces the risk of antiviral resistance to the second
drug.99 However, adding a second nucleos(t)ide analogue does not lead to more profound viral
suppression compared to monotherapy of the new drug.99 Adding adefovir is preferred over switch-
ing to entecavir in lamivudine resistance patients because of the lower risk of antiviral resistance.
If entecavir is started, lamivudine should be discontinued. In adefovir-resistant patients, treatment
with entecavir is preferred.6 Table 8 shows the recommendations for the management of antiviral
resistance. In case of resistance to other antiviral agents or multiple drugs, consulting a centre with
expertise on this topic is recommended.
FOLLOW-UP AFTER ANTIVIRAL THERAPY
Liver biochemistry, quantification of HBV DNA and HBV serology should be repeated three to six
months post-treatment in PEG-IFN treated patients to assess the presence of sustained response.
This is also recommended for responders to nucleos(t)ide analogue treatment who stopped anti-
viral therapy, although more frequent monitoring after discontinuation can be considered because
of the higher risk of relapse compared to PEG-IFN.37
In HBeAg negative patient with serum HBV DNA below 1.0 x 105 copies/mL (2.0 x 104 IU/mL) and
normal ALT, yearly monitoring of ALT during three years suffices. These patients could also be
monitored by their general practitioner. The Dutch Society of General Practitioners (NHG) also
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recommends this frequency of follow-up in their guideline "Viral hepatitis and other liver diseases".
If a rise in serum ALT is observed, the patient should be referred to the treating specialist. In pa-
tients with HBsAg seroconversion (loss of HBsAg and anti-HBs >10 IU/l), monitoring of disease
activity and prophylactic treatment should only be considered in case of severe immunosuppres-
sion, e.g. chemotherapy or treatment with selective antibodies.
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ABSTRACT
Background
Therapy with pegylated interferon alpha (PEG-IFN) results in sustained response in a minority of
chronic hepatitis B virus (HBV) infected patients and has considerable side-effects. We combined
data from individual patients from the 2 largest global trials of hepatitis B e Antigen (HBeAg)-
positive chronic hepatitis B to determine which patients are most likely to respond to PEG-IFN
therapy.
Methods
Five-hundred-forty-two patients treated with PEG-IFN alpha-2a (180 μg/week, 48 weeks) and 266
patients treated with PEG-IFN alpha-2b (100 μg/week, 52 weeks) were included. Eighty-seven
patients were excluded, leaving 721 patients for analysis. A sustained response was defined as
HBeAg loss and HBV DNA <2.0 x 104 IU/ml at 6 months post treatment. Logistic regression analysis
was used to identify predictors of sustained response and a multivariable model was constructed.
Results
HBV genotype, high ALT (>=2 x ULN) , low HBV DNA (<2.0 x 108 IU/ml), female sex, older age, and
absence of previous IFN therapy predicted sustained response. Genotype A patients with either
high ALT and/or low HBV DNA had a high (>30%) predicted probability of sustained response. High
ALT was the strongest predictor in genotype B and low HBV DNA level in genotype C. Genotype D
patients had a low chance of sustained response, irrespective of ALT or HBV DNA.
Conclusion
The best candidates are genotype A patients with either high levels of ALT or low HBV DNA, and
genotype B and C patients with high levels of ALT and low HBV DNA. Genotype D patients have a
low chance of sustained response.
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INTRODUCTION
Hepatitis B is a major global health problem. The World Health Organization reported that there
are more than 400 million carriers in the world, approximately 75% of whom reside in Asia and the
Western Pacific.1 In this part of the world, HBV infection is usually acquired perinatally or in early
childhood. Most patients from these areas typically have HBeAg-positive chronic hepatitis B with
high HBV DNA levels and they develop moderate to severe hepatic inflammation with elevated
alanine aminotransferase (ALT) levels after 10–30 years of infection.2 In contrast, patients infected
in late childhood, adolescence or adulthood present with elevated aminotransferases after a shorter
duration of infection. Although spontaneous HBeAg seroconversion occurs in the majority of HBeAg-
positive patients, the duration of hepatic inflammation can be prolonged and severe, and may
result in liver cirrhosis. Therefore, antiviral treatment is indicated in patients who remain HBeAg
positive with high HBV DNA levels after a 3-6 month period of elevated ALT levels.3
Successful treatment of chronic hepatitis B virus (HBV) infection with loss of hepatitis B e antigen
(HBeAg), decline in serum HBV DNA and normalization of ALT is associated with favorable long-
term outcome, independent of the antiviral drug used.4, 5 In HBeAg-positive patients, sustained
clearance of HBeAg from serum is associated with a higher likelihood of losing hepatitis B surface
antigen (HBsAg), reduced incidence of cirrhosis and hepatocellular carcinoma (HCC), and improved
survival.5-8 Of currently available drugs for the treatment of chronic hepatitis B, pegylated interferon
(PEG-IFN) still results in the highest rate of off-treatment sustained response after a one-year
course of therapy.9-12 Furthermore, responders to IFN-based therapy have a considerable chance
of losing HBsAg, which has been observed in 12-65% of patients within 5 years after HBeAg loss.7,
8, 13-18
 Treatment with PEG-IFN is however often complicated by the occurrence of side-effects
such as flu-like symptoms, cytopenia and depression.19 Nucleos(t)ide analogues such as
lamivudine, adefovir, entecavir and tenofovir on the other hand are well tolerated, but because of
the modest seroconversion rate and the high risk of post-treatment relapse, prolonged therapy is
usually required.20 Nowadays, maintenance of virological response over prolonged periods is
feasible,21 but may still pose a considerable risk for resistance in the long-term.22-24
Since both treatment with PEG-IFN and nucleos(t)ide analogues has proven effective, but also
have their advantages and limitations, the question arises what treatment regimen should be used
as first-line therapy in which patients. Both the chance of achieving response and specific patient
characteristics play a role in the decision on what type of antiviral therapy should be started.
Recently performed studies with one year of PEG-IFN in HBeAg-positive patients identified high
baseline alanine aminotransferase (ALT), low baseline HBV DNA, absence of previous IFN therapy,
low baseline HBeAg and HBV genotype A or B as predictors of response.10, 25, 26 Current guidelines
do not provide specific recommendations as to which patients should be treated with peginterferon,27
the above mentioned studies were considered to provide insufficient evidence for such
recommendations. The aim of this study therefore was to develop a solid model for the prediction
of sustained response to PEG-IFN in individual HBeAg-positive patients, which will allow physicians
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throughout the globe to choose the optimal candidates for treatment with this drug.
METHODS
Patients and study design
Individual data of 542 patients treated with PEG-IFN alpha2a 180 μg per week for 48 weeks (271
patients with added lamivudine 100 mg daily) and 266 patients treated with PEG-IFN alpha2b 100
μg per week for 52 weeks (130 patients with added lamivudine 100 mg daily) were analyzed.10, 11
Post-treatment follow-up lasted six months. Addition of lamivudine did not influence response
rates at the end of follow-up (6 months post-treatment) in any way. For the current study, sustained
virological response (SVR) was defined as clearance of HBeAg from serum and HBV DNA <10,000
copies/ml at six months post-treatment.
The inclusion and exclusion criteria were reported in detail previously and were similar for the two
studies.10, 11 In short, patients were eligible if they had been HBsAg positive for at least 6 months,
were HBeAg positive, had elevated serum ALT between one and 10 times the upper limit of normal
(ULN), had serum HBV DNA >1.0 x 105 copies/ml (2.0 x 104 IU/ml) and had findings on a liver
biopsy within the preceding 12 months that were consistent with the presence of chronic hepatitis
B. Exclusion criteria included decompensated liver disease, antiviral therapy within 6 months prior
to randomization, viral coinfections (hepatitis C virus, hepatitis delta virus or human
immunodeficiency virus), or pre-existent neutropenia or thrombocytopenia.
Laboratory testing
During therapy and post-treatment follow-up, all patients were monitored monthly by routine physical
examination, as well as biochemical and hematological assessments. ALT was assessed locally
and therefore expressed as times upper limits of normal (ULN). HBV DNA was assessed monthly
using an in-house developed Taqman PCR assay based on the Eurohep standard (lower limit of
detection 373 copies/ml) or the Cobas Amplicor HBV Monitor Test (Roche Diagnostics).28 HBeAg,
anti-HBe, HBsAg and anti-HBs were measured with the use of the AxSYM test (Abbott, Abbott
Park, IL, USA). HBV genotype analysis was performed by INNO-LiPA Assay (Innogenetics, Gent,
Belgium).
Statistical analysis
Statistical analysis was performed using the SPSS 15.0 program (SPSS Inc. Chicago, IL) and the
R 2.3.1 Project for Statistical Computing (Harrell’s Design, HMisc and Foreign libraries). A p-value
<0.05 was considered statistically significant (all two-tailed). We performed univariate logistic
regression analysis to identify predictors of SVR among the variables age, sex, HBV genotype (A-
D), serum HBV DNA (log10 copies/ml), ALT (ln ALT x ULN), treatment allocation (PEG-IFN
monotherapy or combination therapy of PEG-IFN and lamivudine), and previous treatment with
interferon or lamivudine. We used multivariable logistic regression analysis with backward stepwise
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selection, using a p-value greater than 0.05 for removal of variables, to construct a multivariable
linear model that provides a natural logarithm transformed prediction of SVR. We used restricted
cubic spline functions to assess the linearity of the effect of continuous variables. Interactions
between variables were explored. Odds ratios (ORs) were calculated with 95% confidence intervals
(95%-CI). Since there were interactions between HBV genotype and other factors, ORs for HBV
genotype were calculated for 33-year old (mean age), IFN-naïve males with ALT and HBV DNA
fixed at 2 x ULN and 1.0 x 109 copies/ml (2.0 x 108 IU/ml), respectively.
Discrimination, which is the ability to distinguish patients who will achieve SVR from those who
will not, was quantified by the area under the receiver-operating characteristic curve (AUC). An
AUC of 0.5 indicates no discriminative ability at all, whereas an AUC of 1.0 indicates perfect
discrimination. Internal validity was assessed with bootstrap sampling.29, 30 Two-hundred bootstrap
samples were drawn with replacement and with the same size as the original sample. The final
prediction model was constructed by applying the penalized maximum likelihood estimation acquired
from the bootstrap samples.31 Nomograms for IFN-naïve patients were constructed based on the
logistic regression formulas. In order to develop a simple rule for each of the genotypes independent
of sex and age, the predicted probability of SVR in different patient subgroups was calculated with
the logistic regression formulas. Since sex and age also predicted SVR, but were not included in
the flowchart, age was fixed at the respective mean value of each subgroup and the mean predicted
probability of SVR for males and females was calculated. For serum ALT, a low level (<2 x ULN)
was considered to be between 1 x ULN and 2 x ULN, and a high level (>=2 x ULN) was considered
to be between 2 x ULN and 10 x ULN. For serum HBV DNA, a low level (<copies/ml [<2.0 x 108 IU/
ml]) was considered to be between 1.0 x 107 copies/ml (2.0 x 106 IU/ml) and 1.0 x 109 copies/ml
(2.0 x 108 IU/ml), and a high level (>=1.0 x 109 copies/ml [>=2.0 x 108 IU/ml]) was considered to be
between 1.0 x 109 copies/ml (2.0 x 108 IU/ml) and 1.0 x 1011 copies/ml (2.0 x 1010 IU/ml). These cut-
offs were chosen because the majority of patients had ALT (95%) and HBV DNA (80%) levels
between these values. In addition, these cut-off levels are generally used in clinical practice and
recommended by international guidelines for the treatment of chronic hepatitis B.3, 27, 32, 33
RESULTS
Of 808 patients eligible for participation in this study, 87 were excluded because of missing values
(n=76) or infection with HBV genotype other than A to D (n=11), leaving 721 patients for analysis.
There were no differences in baseline characteristics between patients enrolled and those excluded
from participation in this study, except for a lower rate of previous IFN therapy among the participants
than the excluded patients (14% vs. 24%, p=0.01). HBeAg loss, HBeAg seroconversion and HBV
DNA <10,000 copies/ml (<2.0 x 103 IU/ml) were observed in 254 (35.2%), 232 (32.2%) and 174
(24.1%) of 721 patients, respectively. Sustained virological response (SVR), defined as HBeAg
loss and HBV DNA <10,000 copies/ml (<2.0 x 103 IU/ml) at six month post-treatment, was observed
in 158 of 721 patients (21.9%). SVR was observed in 22.4% of patients treated with PEG-IFN
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alone and in 21.4% of those treated with PEG-IFN and lamivudine combination therapy (p=0.73).
Baseline characteristics of patients with and without SVR are given in table 1. Patients with SVR
were older, more often were female, had higher baseline ALT and lower HBV DNA levels, and were
more likely to have genotype A but less likely to have genotype D infection compared to those
without SVR. The proportion of patients that was previously treated with IFN or lamivudine therapy
did not differ between patients with SVR and those without.
Predictors of sustained virological response
Factors associated with an increased likelihood of SVR included HBV genotype A infection, high
baseline ALT, low baseline HBV DNA, female sex, older age, (table 1). There was no association
between SVR and previous treatment with interferon or lamivudine on univariate analysis. Using
multivariate analysis, high baseline ALT was found to be an independent predictor of SVR (OR
1.57 per 1log10 x ULN increase [95%-CI, 1.19 – 2.09], p=0.002). In addition, HBV genotype was
associated with SVR, with higher rates of SVR in patients with genotype A (OR 1, reference) than
B (ORB vs. A 0.46 [95%-CI, 0.21 – 0.99], p=0.05), C (ORC vs. A 0.30 [95%-CI, 0.16 – 0.59], p<0.001)
or D (ORD vs. A 0.08 [95%-CI, 0.02 – 0.31], p<0.001). The influence of sex, age, HBV DNA, and
previous IFN therapy was significantly different across HBV genotypes (p<0.02 for the interaction
between HBV genotype and each of these factors). These variables were therefore also included
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Figure 1: Distribution of
predicted probabilities of
sustained virological res-
ponse in patients with HBV
genotype A-D.
Boxplots show the distribution
of the predicted probabilities
of sustained virological
response (SVR), defined as
HBeAg loss and HBV DNA
<10,000 copies/ml at six
months post treatment, in
patients with genotype A
(n=115), B (n=166), C (n=333)
or D (n=107).
in the model. We here describe the most important predictive factors. Genotype C and D infected
females had a significantly higher chance of sustained response compared to males (OR 2.78
[1.51 - 5.11] and OR 7.69 [1.48 - 39.90], p<0.02). Older age was associated with a significantly
higher chance of sustained response in genotype A infected patients (OR 1.04 per year increase
in age [1.01 - 1.08], p=0.01). High baseline HBV DNA was associated with a lower likelihood of
sustained response in patients with genotype A (OR 0.57 [0.40 - 0.82], p=0.003) and C (OR 0.77
[0.65 - 0.91], p=0.002). Previous IFN therapy resulted in a significantly lower chance of sustained
response in patients with genotype A or D (OR 0.21 [0.07 - 0.58], p=0.003). We found no differences
in the predictors of response for the two treatment groups.
Performance of the model
The distribution of the predicted probabilities of SVR in genotypes A – D is shown in figure 1. The
agreement between the predicted probabilities and the observed frequency of SVR was good
(p=0.27 by the Hosmer–Lemeshow goodness-of-fit test). A multivariable model including the
variables age, sex, ALT, HBV DNA, HBV genotype and previous interferon therapy had
adequatediscriminative ability as shown by an area under the receiver-operating characteristic
curve (AUC) of 0.72 (95%-CI, 0.67 – 0.77). The AUC was 0.75 (95%-CI, 0.65 – 0.85), 0.65 (95%-
CI, 0.55 – 0.75), 0.68 (95%-CI, 0.61 – 0.75) and 0.78 (95%-CI, 0.65 – 0.92) for genotypes A to D,
respectively. After bootstrap validation, the area under the ROC curve was 0.69 (95%-CI, 0.60 –
0.77). Since the influence of the predictors was significantly different across genotypes, a validated
formula for the prediction of SVR was generated for each HBV genotype separately. The PEG-IFN
HBV Treatment Index is based on these formulas (figure 2). An automated calculator can be found
on www.liver-gi.nl/peg-ifn.
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Application of the model in clinical practice
In order to allow for application of the model in clinical practice, a nomogram for IFN-naïve patients
was generated from the validated formula for each of the HBV genotypes separately (figure 2).
These nomograms can be used for calculating the probability of SVR in individual HBeAg-positive
patients based on their sex, age, and ALT and HBV DNA level. Average response rates based on
the presence of low (<2 x ULN) or high ALT levels (e”2 x ULN), and low (<9log10 copies/ml [<2.0 x
108 IU/ml]) or high HBV DNA levels (>=9log10 copies/ml [>=2.0 x 108 IU/ml]) are shown in figure 3.
Figure 3: Flowcharts to easily obtain average predicted probabilities of sustained virological response
in patients infected with HBV genotype A-D.
These flowcharts show the average predicted probability of SVR depending on HBV genotype, ALT (above or
below 2 x ULN) and HBV DNA (above or below 9log10 copies/ml). For a precise estimate of the probability of
SVR in an individual patient, the nomograms in figure 2 can be used.
DISCUSSION
We combined the data of the two largest studies investigating PEG-IFN in HBeAg-positive chronic
hepatitis B in order to develop a model for the prediction of response to PEG-IFN in all HBV genotypes.
Although the model is based on the data of patients enrolled in randomized clinical trials with
predefined inclusion and exclusion criteria, generalizability of our results is probably good because
of the large sample size and wide geographic distribution of the patients. We provided nomograms
which can be used to calculate the predicted probability of response in individual patients. A rapid
estimate can be obtained from the provided flowcharts.
We recommend to start PEG-IFN therapy in patients with the highest chance of achieving sustained
response (table 2). We arbitrarily chose those with a predicted probability of sustained response
HBV genotype
HBV genotype
Average chance of SVR
HBV DNA (copies/ml)
ALT
HBV DNA (copies/ml)
ALT
Average chance of SVR
<9log ≥9log ≥9log
≥2 x ULN 1-2 x ULN
23%31%57%
A
1-2 x ULN
and andor
B
<9log ≥9log ≥9log
≥2 x ULN 1-2 x ULN
21%28%30%
1-2 x ULN
and andor
C
<9log ≥9log ≥9log
≥2 x ULN 1-2 x ULN
16%22%36%
1-2 x ULN
and andor
D
<9log ≥9log ≥9log
≥2 x ULN 1-2 x ULN
6%9%17%
1-2 x ULN
and andor
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of at least 30% to be good candidates for PEG-IFN therapy. About 25% of patients included in this
study had a predicted probability of sustained response above this level. This includes all HBV
genotype A infected patients except for those with low ALT and high HBV DNA levels. In addition,
genotype C infected patients with high ALT and low HBV DNA levels have a high likelihood of
response to PEG-IFN. All remaining patients are moderate candidates for PEG-IFN except for
those with genotype D, who have a rather low chance of achieving sustained response and are in
our view generally not candidates for treatment with PEG-IFN. It should be noted that table 2
provides recommendations for patient groups, not individual patients. In selected patients, the
given response rate in the table may thus slightly differ from the more accurate predicted probability
of response obtained from the nomograms.
With the licensing of pegylated interferon and an additional five nucleos(t)ide analogues for the
treatment of chronic hepatitis B in the last years, choice of antiviral therapy has become more
important and more complex at the same time. Since both treatment with IFN-based therapy and
nucleos(t)ide analogue therapy have proven effective and can improve long-term outcome, the
pros and cons of these drugs as well as patient-specific characteristics should be taken into
consideration. All of the major practice guidelines have advocated IFN-based therapy as potential
first-line therapy for both HBeAg-positive and HBeAg-negative patients,3, 27, 32, 33 particularly because
sustained response and HBsAg loss seem to occur more often with IFN and PEG-IFN than with
the direct antiviral agents.20 In order to reduce the risk of relapse, nucleos(t)ide analogue therapy
can be extended for several months after HBeAg seroconversion as this reduces relapse rates.34,
35
 HBeAg seroconversion was sustained in 86% of patients treated with telbivudine or lamivudine
who discontinued therapy after at least six months of maintenance therapy.36, 37 Whether these
responses can also be sustained in the long-term is however still unknown.
However, the use of PEG-IFN currently accounts for no more than 10% of all prescriptions for the
treatment of chronic hepatitis B.38 The relatively low usage of PEG-IFN may be explained by the it’s
significant side effects and need for administration by injection. Furthermore, recommendations
on the use of PEG-IFN in specific subsets of patients who are most likely to have a sustained
yparehtlarivitnalaitinisa)NFI-GEP(norefretnigepfoesuehtrofsnoitadnemmoceR:2elbaT
epytonegVBH stneitapBsititapehcinorhcevitisopgAeBHrofsnoitadnemmocerlareneG
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response and HBsAg seroconversion were lacking. When we are able to identify patients with a
high likelihood of response to PEG-IFN, the proportion of patients achieving sustained response
after treatment with this drug can probably be increased.
Most studies investigating IFN-based therapy in HBeAg-positive chronic hepatitis B found that high
baseline ALT, low baseline HBV DNA and HBV genotype A or B were associated with of response.10,
25, 26, 39
 In addition to these factors, we identified sex and age as predictors of response to PEG-
IFN. It should be mentioned that in both studies more men than women were included. We found
that the influence of sex, age, HBV DNA and previous IFN therapy was significantly different across
HBV genotypes. HBV genotype thus has great influence on the outcome of PEG-IFN therapy.
Therefore, contrary to a statement on this topic in the newest guidelines from the European
Association for the Study of the Liver (EASL),27 we believe that determination of HBV genotype is
essential in all patients in whom sustained off-treatment response is pursued. Other potential
approaches to tailor PEG-IFN therapy in chronic hepatitis B include quantification of serum HBeAg
and HBsAg.40 These approaches are still being validated and not routinely available to most
physicians. Because of limited availability in clinical practice, we also chose not to include liver
histology.
Previously we presented a model based on 266 HBeAg-positive patients participating in a single
randomised trial.41 However, the vast majority of these patients were infected with HBV genotype
A or D, only a small proportion of patients harboured HBV genotype B or C. To gain a good prediction
model for all HBeAg positive patients, we now combined the data of the two largest randomised
trials investigating PEG-IFN in HBeAg-positive chronic hepatitis B. We showed that a model based
on readily available baseline factors can provide an adequate prediction of sustained response.
Ideally, a large confirmatory group would have been used for external validation. Such a group is
unfortunately not available. Clinical trials that are currently still ongoing may allow for further validation
of the model in the near future.
Since substantial viral replication may persist despite HBeAg loss in some patients, a combined
endpoint of HBeAg clearance from serum and low HBV DNA is crucial in HBeAg positive chronic
hepatitis B. Particularly patients with HBV genotype non-A infection can develop mutations in the
precore or core promoter region and may still be at risk for progressive liver disease despite
HBeAg loss.6, 42 Both clearance of HBeAg and suppression of HBV replication are key events in
the natural course and during antiviral therapy in HBeAg positive chronic hepatitis B. HBeAg loss
after IFN-based therapy was associated with reduced progression to cirrhosis and HCC, and
improved survival.5, 43 In addition, large population studies have established a clear link between
HBV viremia and the risk for HBV-related complications.44, 45 Serum HBV DNA was the strongest
predictor of progression to cirrhosis and HCC, with a significantly higher risk for patients with HBV
DNA above 10,000 copies/ml (2,000 IU/ml) as compared to those with serum HBV DNA <300
copies/ml (relative risk 2.5 [95%-CI 1.6-3.8] and 2.3 [95%-CI 1.1-4.9] for developing cirrhosis and
HCC, respectively). Although the proportion of patients with undetectable HBV DNA was relatively
low shortly after PEG-IFN therapy,10 it further increased with prolonged duration of follow-up.6
  58
Ch
ap
te
r 2
Because presence of anti-HBe at 6 months post-treatment was not associated with long-term
sustainability of response to PEG-IFN,6 the combined endpoint of HBeAg loss and low HBV DNA
seems optimal.
The parties involved in this study agreed not to perform a direct comparison between the two
formulations of PEG-IFN. However, the previously reported results of two studies included in this
retrospective analysis were very similar.10, 11 Unfortunately, we cannot provide recommendations
for HBeAg-negative patients, since we only had data of HBeAg-positive patients treated with PEG-
IFN. Due to the low sustained response rate in HBeAg-negative patients,46 PEG-IFN is relatively
less often given to HBeAg-negative as compared to HBeAg positive patients. Prediction of response
to PEG-IFN therefore seems of greater importance in HBeAg-positive than in HBeAg-negative
chronic hepatitis B.
In conclusion, we provide a practical tool to calculate the probability of sustained response to
PEG-IFN in individual HBeAg-positive patients, which can be easily used in clinical practice and
can thus allow for the selection of the optimal candidates for PEG-IFN therapy. We were
unfortunately not able to perform external validation because such a database is not available.
Clearly, this should be done when an appropriate patient group is available. We recommend to
consider PEG-IFN therapy in all genotype A patients with either high ALT or low HBV DNA levels, in
genotype B and C infected patients with both high ALT and low HBV DNA. HBeAg-positive genotype
D infected patients are generally not good candidates for treatment with PEG-IFN.
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ABSTRACT
Background
Chronic hepatitis B (CHB) patients with advanced fibrosis are often not considered for treatment
with peginterferon (PEG-IFN) since IFN therapy may precipitate immunological flares, potentially
inducing hepatic decompensation.
Methods
We investigated in HBeAg-positive CHB efficacy and safety of 52 weeks of PEG-IFN alpha-2b
(100μg weekly) alone or in combination with lamivudine (100mg daily) in 70 patients with ad-
vanced fibrosis (Ishak fibrosis score 4-6) and 169 patients without advanced fibrosis, all with
compensated liver disease.
Results
Virologic response, defined as HBeAg-seroconversion and HBV DNA <10,000 copies/ml at week
78, occurred significantly more often in patients with advanced fibrosis compared to those without
(25% vs. 12%, respectively; p=0.02). Also patients with cirrhosis (n=24) exhibited a virologic re-
sponse more frequently than non-cirrhotics (30% vs. 14%, respectively; p=0.02). Improvement of
liver fibrosis occurred more frequently in patients with advanced fibrosis (66% vs. 26%, p<0.001).
HBV genotype A was more prevalent among patients with advanced fibrosis than those without
(57% vs. 24%, p<0.001). Most adverse events, including serious adverse events, were observed
equally in patients with and without advanced fibrosis. Fatigue, anorexia and thrombocytopenia
occurred more often in patients with advanced fibrosis than those without (p<0.01). Necessity for
dose reduction or discontinuation of therapy was comparable for both patient groups (p=0.92 and
p=0.47, respectively).
Conclusion
PEG-IFN is effective and safe in HBeAg-positive patients with advanced fibrosis. Since PEG-IFN
therapy results in high rates of sustained off-therapy response, patients with advanced fibrosis or
cirrhosis but compensated liver disease should not be excluded from PEG-IFN treatment.
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INTRODUCTION
Hepatitis B virus (HBV) is one of the most prevalent viral pathogens of man with almost a third of
the world's population having evidence of infection with HBV and about 400 million people being
chronically infected.1 Chronic HBV is a leading cause of cirrhosis and hepatocellular carcinoma
(HCC). The most important objective in treatment of chronic HBV is to halt progression of liver
injury by persistent suppression of the virus. Complete response, with loss of hepatitis B surface
antigen (HBsAg) and appearance of anti-HBs, is difficult to achieve with currently available antivi-
ral drugs and most likely does not imply complete eradication but rather control of residual virus by
a persistent host's immune response.2 Therefore, surrogate markers of short-term treatment re-
sponse, such as loss of HBeAg and decrease of HBV DNA, are most often used to evaluate the
effectiveness of antiviral therapy.
Treatment with interferon (IFN) results in loss of HBeAg in about one-third of patients.3 Somewhat
higher response rates have been reported for peginterferon (PEG-IFN) therapy in hepatitis B e
antigen (HBeAg) positive chronic HBV.4-6 HBeAg loss after IFN-based therapy is durable in the
majority of patients,7 and has been shown to result in decreased progression of fibrosis, reduced
risk of developing hepatocellular carcinoma and improved survival .8,9 Persistence of HBeAg on
the other hand results in unfavorable long-term outcome.10,11 IFN induces immune-mediated hepa-
titis flares in 20-40% of patients, which may precipitate hepatic decompensation in patients with
advanced liver disease.12
Studies on treatment of chronic HBV with conventional IFN or PEG-IFN have identified similar
predictors of response. These factors included high pretreatment alanine aminotransferase (ALT),
low pretreatment HBV DNA, high degree of necroinflammatory activity, infection at adult age and
HBV genotype A or B.4,5,13-16 PEG-IFN is often not given to HBV infected patients with advanced
fibrosis or cirrhosis due to the presumed lack of efficacy and fear for hepatic flares and other
toxicity.
In this study we investigated response to and safety of PEG-IFN alpha-2b with or without lamivudine
in patients with HBeAg-positive chronic hepatitis B and advanced fibrosis.
PATIENTS AND METHODS
We investigated the efficacy and safety of 52 weeks of PEG-IFN alpha-2b alone or in combination
with lamivudine in patients with HBeAg-positive chronic HBV and advanced fibrosis. The patients
and results of the multicenter randomized controlled study investigating PEG-IFN alpha-2b
monotherapy and PEG-IFN alpha-2b in combination with lamivudine in HBeAg-positive chronic
HBV have been described previously (5). All patients were positive for hepatitis B s antigen (HBsAg)
for at least 6 months prior to randomization. Patients were eligible if they were HBeAg positive on
two occasions within 8 weeks prior to randomization, had elevated serum ALT of >2 - 10 x the
upper limit of normal (ULN), and had serum HBV DNA above 1.0 x 105 copies per milliliter (copies/
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ml). Major exclusion criteria were: antiviral therapy within 6 months prior to randomization, serum
antibodies against hepatitis C virus, hepatitis D virus or human immunodeficiency virus, pre-exis-
tent leucopenia (white blood cell count <3,000/mm3, neutrophil count <1,800/mm3) or thromb-
ocytopenia (platelets <100,000/mm3), or decompensated liver disease. Patients were random-
ized in a 1:1 ratio to receive PEG-IFN alpha-2b (100μg weekly) with placebo or with lamivudine
(100mg daily) for 52 weeks.  After 32 weeks, PEG-IFN alpha-2b dosage was lowered to 50μg per
week to prevent side effects and early treatment discontinuation. Follow-up after discontinuation
of therapy lasted 26 weeks. The primary outcome measure was loss of HBeAg at week 78.
During therapy and post treatment follow-up, patients were monitored monthly by routine physical
examination, as well as biochemical and hematological assessments. ALT was assessed locally
in accordance with standardized procedures and therefore expressed as times upper limits of
normal (ULN). Hepatitis flares were defined as a threefold increase in serum ALT compared to
baseline levels.17 Serum HBV DNA levels were measured monthly using an in-house developed
Taqman PCR assay (lower limit of detection 373 copies/ml) based on the Eurohep standard.18
HBeAg and HBsAg (AxSYM, Abbott, Abbott Park, IL, USA) were assessed at week 0, 32, 52 and
week 78 (end of follow-up). HBV genotype and YMDD mutation analysis were performed by INNO-
LiPA assay (Innogenetics, Gent, Belgium). Since both HBeAg-positivity and HBV DNA above 10,000
copies/ml have been described to be detrimental,8,19 particularly in patients with advanced fibro-
sis, we defined virologic response in this study as HBeAg seroconversion (loss of HBeAg and
appearance of anti-HBe) in combination with serum HBV DNA <10,000 copies/ml. A baseline bi-
opsy sample was available for 239 patients, biopsy at the end of treatment was optional. Paired
biopsies were taken in 110 patients. Histological scoring was performed according to the modified
histological activity index (HAI) by one experienced pathologist,20 who was unaware of the chrono-
logical order of biopsies, treatment allocation and outcome measures. Advanced fibrosis was
defined as fibrosis score 4 - 6 (HAI). Improvement of liver histology was defined as a reduction of
at least two points in necroinflammatory score (range 0-18) or one point in fibrosis score (range 0-
6).
Statistical analysis was performed using the SPSS 14.0 program (SPSS Inc. Chicago, IL). Chi-
square, Fisher's exact test and Mann-Whitney U test were used where appropriate. The Kaplan-
Meier method was used to compare incidence of dose reduction and discontinuation of therapy.
The relation between characteristics at baseline and during therapy, and relapse and post treat-
ment response was examined by logistic regression analyses. Univariate analysis was used to
assess the importance of prognostic factors. To investigate the independence of these factors,
multivariate logistic regression analyses was performed with all characteristics with a p-value
<0.2 in univariate analysis. A p-value <=0.05 was considered statistically significant.
RESULTS
Of 239 patients included in this study, 70 had advanced fibrosis (29%) and 24 had cirrhosis (10%).
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Baseline demographics are shown in table 1. Five of 27 patients without a baseline liver biopsy
sample had thrombocytopenia (platelet count range: 133-144 x 109/l), which could indicate pres-
ence of cirrhosis. None of the 27 patients had signs of decompensated liver disease; bilirubin was
slightly elevated in 2 patients (17.1 and 19.5 μmol/l). Patients with advanced fibrosis were older
than those without and more often acquired their infection via sexual or parenteral transmission.
Baseline platelet count was significantly lower and necroinflammatory score higher in patients
with advanced fibrosis. Genotype A (32%) and D (40%) were the most prevalent genotypes in our
mainly Caucasian patient population. Distribution of genotypes was significantly different between
the patient groups. Patients with genotype A more often had advanced fibrosis (49%) than patients
with genotype B (19%), C (28%) or D (17%) (p=0.01, p=0.03 and p<0.001, respectively).
Response to treatment
At the end of follow-up, all treatment outcomes were observed equally in patients treated with
PEG-IFN alpha-2b alone or combination therapy with lamivudine, both in patients with and without
advanced fibrosis. Different response rates in patients with and without advanced fibrosis are
given in table 2. Virologic response at week 78, defined as HBeAg-seroconversion and HBV DNA
<10,000 copies/ml, occurred significantly more often in patients with advanced fibrosis compared
to those without (p=0.02), as well as a decrease in fibrosis score (p<0.001). Although not statisti-
cally significant, the rate of HBsAg-seroconversion was twice as high in patients with advanced
fibrosis compared to those without. Similar trends were observed for improvement of
necroinflammation and HBV DNA <400 copies/ml. Response rates were comparable between
patients who had no liver biopsy taken at baseline and those with available baseline liver histology
(18% vs. 16% for virologic response at week 78; p=0.76).
Response rates in the subgroup of patients with cirrhosis were similar to those in the total group of
patients with advanced fibrosis. Thirty-five percent of patients with cirrhosis showed virologic re-
sponse at week 78 compared to 14% in patients without cirrhosis (p=0.02). For HBsAg-
seroconversion, these rates were 13% and 5%, respectively (p=0.13).
HBV genotype was found to influence outcome at the end of follow-up. Rates of virologic response
were higher in patients with genotype A (30%) and B (26%) than genotype C (3%) or D (6%)
infection (A vs. C, p=0.002; A vs. D, p<0.001; B vs. C, p=0.02; B vs. D, p=0.02). Among patients
with advanced fibrosis a similar trend was observed for genotype A and D infection (33% vs. 8%,
p=0.14). Among patients with genotype A infection, virologic response occurred equally in  those
with or without advanced fibrosis (33% vs. 27%; p=0.54).
Logistic regression analysis of factors predicting response at week 78
For the prediction of virologic response at the end of follow-up, the following variables were in-
cluded in univariate logistic regression analysis: age, sex, weight, race, route of transmission,
baseline serum ALT, baseline HBV DNA level, HBV genotype, liver histology, previous interferon or
lamivudine therapy, and treatment allocation. Increasing age, sexual or parenteral transmission,
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presence of advanced fibrosis or cirrhosis, and high HAI scores were found to be associated with
increased likelihood of virologic response (table 3). In multivariate analysis, HBV genotype and
high necroinflammatory score (OR 1.31, CI95% 1.05-1.65, p=0.02) independently predicted viro-
logic response at week 78. HBV genotype was found to be the strongest predictor of virologic
response. Genotype A infection was associated with higher response rates compared to genotype
C (OR 11.30, CI95% 1.38-92.57, p=0.02) or D (OR 4.28, CI95% 1.39-13.21, p=0.01). Genotype B
infection also resulted in a higher likelihood of response compared to genotype C (OR 12.13,
CI95% 1.24-118.30, p=0.03) or D (OR 4.59, CI95% 1.14-18.43, p=0.03). In multivariate analysis,
presence of advanced fibrosis did not alter the likelihood of achieving virologic response (OR 0.98,
CI95% 0.17-5.23, p=0.98).
Safety
Most adverse events occurred equally in patients with or without advanced fibrosis (table 4). Fa-
tigue, anorexia and thrombocytopenia were observed more frequently in patients with advanced
fibrosis than in those without (p<0.01). These adverse events also occurred more frequently in the
subgroup of patients with cirrhosis compared to those without, as well as hepatitis flares (33% vs.
12%, p=0.008) and dizziness (21% vs. 7%, p=0.05). The higher rate of thrombocytopenia in pa-
tients with advanced fibrosis did not result in an increase of significant bleeding problems. Never-
theless, epistaxis tended to occur more often in patients with advanced fibrosis (p=0.08). Neces-
sity for PEG-IFN dose reduction was comparable for patients with (33%) and without advanced
fibrosis (34%), as well as premature discontinuation of therapy (11% and 8%, respectively) (figure
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1). The reason for dose reduction of PEG-IFN in patients with advanced fibrosis was more often
thrombocytopenia than in patients without advanced fibrosis (32% vs. 5%, p=0.01). For both pa-
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tients with and without advanced fibrosis, the majority of dose reductions took place during the
first 16 weeks of therapy (79% and 66%, p=0.25). Serious adverse events occurred equally in
patients with or without advanced fibrosis (4% and 5%, respectively, p=1.00). In patients with
cirrhosis, dose reduction was necessary more often than in patients without cirrhosis (63% vs.
30%, p=0.002), as well as premature discontinuation of therapy (21% vs. 8%, p=0.05). Timing of
dose adjustments or discontinuation of therapy did not differ between the patient groups.
DISCUSSION
In this study, using PEG-IFN therapy, virologic response, as defined by HBeAg seroconversion
and HBV DNA 10,000 copies/ml at the end of follow-up, occurred significantly more often in pa-
tients with advanced fibrosis than in those without. The rate of HBsAg-seroconversion was twice
as high in patients with advanced fibrosis, although this difference was not statistically significant.
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Because IFN-based therapy is often presumed to be less effective in patients with advanced
fibrosis, PEG-IFN is frequently withheld from these patients. In a retrospective study of standard
IFN in 200 HBeAg-positive patients, response rates were reported to be significantly lower in pa-
tients with advanced fibrosis (Metavir fibrosis score 3-4; 17.5%) compared to patients with mini-
mal or no fibrosis (Metavir 0-1; 35.5%, p=0.02).21 Lower stage of liver fibrosis and higher grade of
necroinflammation were identified as independent predictors of response to standard IFN in this
study.21 Our results clearly contradict these findings. The higher response rates in patients with
advanced fibrosis in our study might be due to the antiviral drug used (PEG-IFN vs. standard IFN),
Figure 1: Dose reduction and premature discontinuation of PEG-IFN ?-2b therapy in patients with or
without advanced fibrosis.
Frequency and timing of dose reduction (A) and premature discontinuation (B) of PEG-IFN alpha-2b therapy
was comparable for patients with or without advanced fibrosis. However, dose reduction (C) and premature
discontinuation of therapy (D) were observed more frequently in the subgroup of patients with cirrhosis than in
those without.
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the longer duration of therapy (1 year vs. 4 months) or the predominant HBV genotypes.
Multivariate analysis showed no relation between presence of advanced fibrosis and response to
PEG-IFN alpha-2b. HBV genotype was identified as strongest independent predictor of virologic
response at the end of follow-up. Previous studies also have shown a higher likelihood of re-
sponse to (PEG-)IFN therapy for patients harboring genotype A .5,14,22 The higher response rates in
patients with advanced fibrosis compared to those without appears thus also related to the higher
prevalence of genotype A in these patients. Since multivariate analysis showed no influence of
advanced fibrosis on response to PEG-IFN therapy, other factors appear to be of greater influence
on response rates in these patients. Nevertheless, our finding that the presence of advanced
fibrosis does in fact not compromise efficacy of PEG-IFN is important. Furthermore, our findings
emphasize the importance of testing for HBV genotype prior to the initiation of antiviral therapy.
Nucleos(t)ide analogues are often considered preferential over PEG-IFN in patients with advanced
fibrosis since prolonged treatment with these drugs may reduce progression to decompensated
liver disease and development of hepatocellular carcinoma in patients with advanced fibrosis.23
However, improved survival and decreased incidence of HCC have also been observed in patients
with or without preexisting cirrhosis who responded to IFN therapy.8,9,24
Concerns are often raised about the safety of PEG-IFN in patients with advanced fibrosis. We
found PEG-IFN alpha-2b to be safe in these patients; most adverse events were observed equally
among patients with and without advanced fibrosis. As expected with lower baseline platelet lev-
els, thrombocytopenia occurred more frequently in patients with advanced fibrosis. Thrombocy-
topenia also more often led to dose reduction in these patients, while the frequency and timing of
both dose reduction and premature discontinuation of therapy was comparable between patient
groups. In the subgroup of patients with cirrhosis, dose adjustment and premature treatment dis-
continuation were more often necessary, but despite less drug exposure lower response rates
were not observed. Only one patient with advanced fibrosis presented with temporarily elevated
bilirubin but no other signs of compromised liver function were encountered.
Another reason why PEG-IFN is often not given to patients with advanced fibrosis has been the
concern of the potential precipitation of hepatitis flares and subsequent hepatic decompensation.
We found a trend towards higher incidence of hepatitis flares in patients with advanced fibrosis
and flares occurred more frequently in patients with cirrhosis than those without. However, the
flares in our patients, who had well compensated liver disease at the start of therapy, did not lead
to any clinical problems. Previous studies on IFN confirm the absence of complications in patients
with compensated cirrhosis. Less than 1% of HBeAg-positive patients developed hepatic decom-
pensation, while up to 60% of patients included in these trials had cirrhosis.25,26 In contrast, IFN
therapy leads to significant side effects due to bacterial infection and exacerbation of liver disease
in patients with Child's class B or C cirrhosis.27,28 In a large European study, 9 cases of fatal
hepatic decompensation were identified among 2490 IFN treated patients. All of these patients had
documented cirrhosis and 5 of them had signs of hepatic decompensation prior to the start of IFN
therapy.29 These observations clearly show that IFN-based therapy should not be given to hepatitis
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B patients with signs of hepatic decompensation. The setting of a clinical trial and exclusion of
patients with signs of advanced liver disease or portal hypertension could have led to our finding
that serious adverse events were observed equally in patients with and without cirrhosis. In our
experience, routine monthly follow-up and anticipation for the occurrence of adverse events is
sufficient in patients with advanced fibrosis and compensated liver disease.
In conclusion, our findings show that PEG-IFN alpha-2b is at least as effective in patients with
advanced fibrosis as in those without. Although patients with cirrhosis more often require dose
reduction or early discontinuation of therapy, treatment is safe and outcome is similar to patients
without cirrhosis. Therefore, when aiming for sustained off-treatment response, patients with ad-
vanced fibrosis and well compensated liver disease, in particular those with genotype A and B,
should be offered the possibility of a finite course of PEG-IFN, rather than initiation of possibly
indefinite nucleos(t)ide analogue therapy.
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INTRODUCTION
With interest we read the paper by d'Alteroche et al. about ophthalmologic side-effects during
interferon (IFN) therapy for viral hepatitis.1 In this study retinopathy was found on fundoscopic
examination in 24% of patients after IFN therapy, none of whom experienced ophthalmologic symp-
toms. Factors associated with an increased risk of developing retinopathy included a history of
arterial hypertension, age above 45 years and treatment with pegylated alpha-interferon. Based on
their findings, d'Alteroche et al. recommended regular fundoscopic examination for all IFN treated
patients, particularly during the first months of treatment. We here present our experience on
retinopathy in chronic hepatitis B infected patients treated with peginterferon-alpha-2b (PEG-IFN).
PATIENTS AND METHODS
As part of a global randomized controlled trial we performed routine ophthalmological examination
in PEG-IFN treated patients of our own center.2 Twenty-eight HBeAg-positive chronic hepatitis B
infected patients were included in this study and randomized to PEG-IFN alone in a dosage of
100μg per week or its combination with lamivudine (table 1). Before and during treatment, cor-
rected visual acuity testing and routine examination of the retina by indirect ophthalmoscopy and
slit-lamp biomicroscopy was performed.
RESULTS
None of the patients had ophthalmological symptoms or abnormalities on pre-treatment analysis.
Ophthalmological examination during treatment was performed after a median treatment period of
14 weeks (range 5-33 weeks). During treatment, 3 patients complained of blurred vision, without
clear underlying ophthalmological etiology. Overall, visual acuity did not decrease during PEG-IFN
treatment compared to baseline (mean visual acuity 0.05 and 0.02 logMAR - logarithm of the
minimum angle of resolution, respectively, p=0.18). One of three patients with complaints of blurred
vision showed retinal hemorrhage on fundoscopic examination, which resolved spontaneously
within 5 weeks on continued therapy. No abnormalities were observed on fundoscopic examina-
tion in any of the other patients during treatment. In all three patients with ophthalmologic symp-
toms, spontaneous recovery was observed during therapy without a need for dose adjustment.
DISCUSSION
IFN associated abnormalities that can be found on fundoscopic examination include retinal hem-
orrhage, cotton wool spots, micro aneurysms, optic disc hyperemia and macular edema.3-5 The
reported incidence of retinopathy varies between studies, rates between 18% and 86% have been
reported.4,5 The observed incidence of retinopathy in our study was significantly lower compared
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to that observed by D'Alteroche et al. (4% vs. 24%, p=0.01 by Chi-Square test), and may be
explained by multiple factors. First, we performed fundoscopic examination relative early during
treatment (median 14 weeks). However, in other studies retinopathy was particularly observed
within the first three months of treatment.1,4,5 Second, in our study mean age was profoundly lower
(34 ± 4.3 years), with only 4 patients (17%) aged 45 or above, which was found to be associated
with an increased risk of retinopathy by d'Alteroche et al. Diabetes mellitus and arterial hyperten-
sion are other risk factors for developing retinopathy. In contrast to the study by d'Alteroche et al.
none of our patients had a history of either risk factor. When excluding patients with hypertension
and diabetes mellitus form analysis, our rate of retinopathy was still lower than found by D'Alteroche
et al. (4% vs. 20%, p=0.052 by Fisher's Exact test). Correction for patient age was not possible
with available data. Third, hepatitis C patients may be, irrespective of age and other risk factors,
more at risk to develop retinopathy than hepatitis B patients. Retinopathy was found in 32% of
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untreated HCV patients, compared to 6% in non-HCV-infected controls.6 A relation between retin-
opathy and type II cryoglobulinemia in HCV infection has been suggested.7,8 The rate of retinopa-
thy in our study was comparable to that in the subgroup of HBV patients in the study of D'Alteroche
et al. HCV infection in combination with diabetes mellitus, arterial hypertension and higher age
may thus predispose patients to develop retinopathy on IFN therapy.
Despite the high frequency of retinopathy in many studies, symptomatic ocular adverse events
are infrequently reported during IFN therapy (0.4% of patients).1 Although isolated cases of severe
ophthalmologic complications have been reported, the observed abnormalities in IFN associated
retinopathy are usually transient.
Based on the transient character of PEG-IFN-related retinopathy, it's association with other risk
factors and the significantly lower incidence in hepatitis B infected patients without these risk
factors in our study, we question whether routine fundoscopic examination should be performed in
this patient group. In our opinion, further studies should prove whether in hepatitis B infected pa-
tients to be treated with PEG-IFN, fundoscopic examination should be performed in all patients. So
far, we recommend to examine only those with an increased risk for developing retinopathy or in
patients with known pre-existing retinopathy.
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ABSTRACT
Background
Interferon-induced loss of HBeAg is sustained in a majority of chronic hepatitis B infected patients,
we investigated the frequency of relapse after peginterferon (PEG-IFN) alpha-2b therapy alone or
in combination with lamivudine in HBeAg positive patients.
Methods
266 HBeAg positive patients were treated with PEG-IFN alpha-2b (100μg / week) in combination
with placebo (n=136) or lamivudine (100mg / day) (n=130) for 52 weeks. Post-treatment follow-up
lasted 26 weeks. Relapse was defined as HBeAg negativity at week 52 and recurrence of HBeAg
at week 78.
Results
HBeAg loss was observed in 44% of patients on combination therapy and 29% on monotherapy at
the end of treatment (p=0.01). Relapse occurred in 39% and 13% of patients receiving combina-
tion therapy or PEG-IFN alone, respectively (p=0.005). In the combination therapy group, relapse
occurred significantly less frequently if anti-HBe was detectable at week 52 (21% vs. 63%, p=0.002);
for PEG-IFN monotherapy a similar trend was found (7% vs. 30%; p=0.09). In multivariate analy-
sis, PEG-IFN and lamivudine combination therapy (OR 3.9, CI95% 1.1-13.2, p=0.03), absence of
anti-HBe at week 52 (OR 9.8, 95% CI 3.2-30.3, p<0.001) and absence of HBsAg-loss at week 52
(OR 10.3, 95% CI 1.09-97.89, p=0.04) independently predicted HBeAg relapse.
Conclusion
HBeAg relapse occurs more frequently after PEG-IFN alpha-2b and lamivudine combination therapy
than after PEG-IFN alpha-2b monotherapy. Full HBeAg seroconversion with appearance of anti-
HBe, rather than HBeAg loss, seems the best endpoint of PEG-IFN based therapy in HBeAg
positive chronic HBV.
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INTRODUCTION
Sustained loss of hepatitis B e antigen (HBeAg) from serum is associated with loss of hepatitis B
surface antigen (HBsAg), reduced incidence of hepatocellular carcinoma (HCC) and improved
survival.1 Treatment with interferon (IFN) for chronic hepatitis B virus (HBV) infection results in
HBeAg loss in about one-third of patients.2 Interferon-induced HBeAg loss is generally sustained
in up to 90% of patients.1,3,4 A study by Song et al. in a Korean population demonstrated older age
and presumed vertical transmission of HBV to be independent predictors for relapse after conven-
tional IFN treatment.5
Nucleo(t)side analogues are well capable of inhibiting HBV replication, and have been shown to
induce HBeAg loss in 15-30% of patients after 1 to 2 years of treatment.6,7 However, prolonged
treatment with lamivudine or adefovir is associated with the emergence of therapy resistant HBV
strains and relapse occurs frequently after cessation of treatment with these drugs.8,9 Predictors
for sustained HBeAg seroconversion after lamivudine therapy include prolonged duration of therapy
after HBeAg seroconversion and HBV genotype A.10 Shorter interval of undetectable HBV DNA
(<0.7 log10 IU/ml) was found to predict relapse following lamivudine therapy.11 A prolonged period
of undetectable HBV DNA by an additional month reduced the risk of relapse by 50%.
Recently performed studies with one year of pegylated interferon (PEG-IFN) alone or in combina-
tion with lamivudine in HBeAg positive patients showed high baseline alanine aminotransferase
(ALT), low baseline HBV DNA, absence of previous IFN therapy, low baseline HBeAg and HBV
genotype as independent predictors of response.12-14 Predictors for relapse after PEG-IFN therapy
are still unknown. In this study we investigated the frequency and possible predictors of relapse
after treatment with PEG-IFN alpha-2b alone or in combination with lamivudine.
PATIENTS AND METHODS
Data for this study were extracted from a multicenter randomised controlled trial which compared
PEG-IFN alpha-2b monotherapy to its combination with lamivudine in patients with HBeAg positive
chronic hepatitis B. The inclusion and exclusion criteria were reported previously.12 In short, pa-
tients were eligible if they had been HBsAg positive for more than 6 months, were HBeAg positive
on two occasions within 8 weeks prior to randomisation, had elevated serum ALT of at least twice
the upper limit of normal (ULN), and had serum HBV DNA >1.0 x 105 copies/ml. Major exclusion
criteria were: antiviral therapy within 6 months prior to randomisation, serum antibodies against
hepatitis C virus, hepatitis D virus or human immunodeficiency virus (HIV), pre-existent leucope-
nia or thrombocytopenia (white blood cell count [WBC] <3,000/mm3, neutrophils <1,800/mm3,
platelets <100,000/mm3), or decompensated liver disease.
Patients were randomised in a 1:1 ratio to receive PEG-IFN alpha-2b (100μg weekly) with placebo
or with lamivudine (100mg daily) for 52 weeks. After 32 weeks, PEG-IFN alpha-2b dosage was
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lowered to 50μg to prevent side effects and early treatment discontinuation. Follow-up after dis-
continuation of therapy lasted 26 weeks.
During therapy and post-treatment follow-up, patients were monitored monthly by routine physical
examination, as well as biochemical and hematological assessments. ALT was assessed locally
and therefore expressed as times upper limits of normal (ULN). HBV DNA was assessed monthly
using an in-house developed Taqman PCR assay (lower limit of detection 373 copies/ml) based
on the Eurohep standard.15 HBeAg, anti-HBe, HBsAg and anti-HBs (AxSYM, Abbott, Abbott Park,
IL, USA) were assessed at week 0, 32, 52 and week 78 (end of follow-up). HBV genotype and
YMDD mutation analysis were performed by INNO-LiPA Assay (Innogenetics, Gent, Belgium).
Liver histology was assessed at baseline in all patients. Biopsy at the end of treatment was op-
tional. Paired biopsies were available for 110 patients. Histological scoring was performed by one
experienced pathologist according to the histological activity index, modified by Ishak.16 The pa-
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Figure 1: Relapse and post-treatment response
after PEG-IFN alpha-2b alone or its combina-
tion with lamivudine
HBeAg relapse (HBeAg negative at week 52 and
positive at week 78) occurred significantly more
often after PEG-IFN and lamivudine therapy com-
pared to PEG-IFN alone (p=0.005), as well as HBV
DNA relapse (HBV DNA >200,000 copies/ml at
week 78 after initial decline below this level at week
52, p=0.054) and ALT relapse after initial
normalisation (p=0.037). Post-treatment response
for HBeAg and HBV DNA <200,000 copies/ml was
observed equally among treatment groups, while
normalisation of ALT occurred more often in pa-
tients treated with PEG-IFN alone (p=0.036).
thologist was blinded for information about the chronological order of biopsies, treatment alloca-
tion and outcome measures. Improvement of histology was defined as a reduction of at least two
points in necroinflammatory score (range 0-18) or one point in fibrosis score (range 0-6).
RESULTS
At the end of treatment, 97 of 266 patients (36%) lost HBeAg, 57 (44%) in the combination therapy
group and 40 (29%) in the monotherapy group (p=0.01). Twenty-seven of these 97 responders
(28%) had recurrence of HBeAg at the end of follow-up (relapse), and 70 (72%) remained HBeAg
negative throughout post-treatment follow-up (sustained response). Virological response (HBV
DNA <200,000 copies/ml) occurred in 96 (74%) patients receiving combination therapy and 40
(29%) receiving monotherapy at the end of treatment (p<0.001); ALT normalisation was observed
in 66 (51%) and 46 (33%) patients at the end of therapy, respectively (p=0.005). Baseline charac-
teristics of patients with HBeAg relapse and sustained HBeAg response are shown in table 1. No
differences in baseline variables were found between these groups.
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Relapse and post-treatment response for HBeAg, HBV DNA and ALT
HBeAg relapse occurred more often in patients treated with PEG-IFN alpha-2b and lamivudine
combination therapy compared to PEG-IFN alpha-2b alone (figure 1A): 22 patients (39%) in the
combination therapy group and 5 (13%) in the monotherapy group relapsed (p=0.005). Post-treat-
ment response occurred in 15% of patients from both treatment groups. Relapse and post-treat-
ment response rates for biochemical and virological response are shown in figure 1B and 1C. For
both endpoints, patients in the combination therapy group more often relapsed than those in the
monotherapy group (p=0.054 and p=0.037 for virological response and biochemical response,
respectively). Patients with HBeAg relapse were more likely to have relapse of HBV DNA >200,000
copies/ml than sustained HBeAg responders (76% vs. 20%, p<0.001), as well as relapse of ALT
(69% vs. 24%, p=0.007).
Prediction of HBeAg relapse
Among patients treated with combination therapy, 7 of 33 patients (21%) with detectable anti-HBe
at the end of therapy relapsed compared to 15 of 24 patients (63%) without detectable anti-HBe
(p=0.002). A similar trend was observed in patients treated with PEG-IFN alpha-2b alone, 2 of 30
patients (7%) with detectable anti-HBe and 3 of 7 patients without (30%) relapsed (p=0.09). Seven
of 10 patients (70%) in the monotherapy group did not relapse despite the absence of anti-HBe
compared to 9 of 24 patients (38%) treated with combination therapy (p=0.13). Three patients
treated with PEG-IFN alpha-2b alone (30%) and 4 treated with combination therapy (17%), who
had no detectable anti-HBe at the end of treatment, developed anti-HBe at the end of follow-up
(p=0.39). HBV genotype tended to influence HBeAg relapse rates, 29% of patients harbouring
genotype A relapsed compared to 56% of patients with genotype D (p=0.09). Although not statisti-
cally significant, possibly due to the limited number of lamivudine resistant patients among initial
responders (with HBeAg loss at week 52), emergence of lamivudine resistance seemed to result
in an increased risk of HBeAg relapse. Three of 4 patients (75%) with lamivudine resistance showed
HBeAg relapse compared to 19 of 53 patients (36%) without lamivudine resistance (p=0.29).
Serum HBV DNA in relation to HBeAg relapse
Mean HBV DNA levels in patients with HBeAg relapse and sustained responders are shown in
figure 2 for patients treated with PEG-IFN alpha-2b alone or its combination with lamivudine. In
patients treated with PEG-IFN alone, decline in HBV DNA was 4.8 log10 copies/ml for patients with
relapse compared to 3.8 log10 copies/ml for sustained responders at the end of treatment (p=0.30).
Decline in HBV DNA was 5.8 log10 copies/ml for all patients in the combination therapy group at the
end of treatment. In both treatment groups mean HBV DNA was significantly higher in relapsers
than sustained responders at week 78 (9.2log10 vs. 4.6 log10 for monotherapy and 7.7 log10 vs. 3.7
log10 for combination therapy, p<0.001).
In patients treated with PEG-IFN alpha-2b alone, combination of HBeAg loss and HBV DNA <10,000
copies/ml at week 52 was associated with a significantly lower rate of relapse compared to partial
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Figure 2: Mean HBV DNA in
patients with HBeAg relapse
and sustained response af-
ter PEG-IFN alpha-2b alone
or its combination with
lamivudine.
Among patients treated with
PEG-IFN monotherapy, de-
cline in HBV DNA was more
pronounced in sustained re-
sponders than relapsers (A).
This difference was however
not observed in patients
treated with PEG-IFN  and
lamivudine combination
therapy (B).
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response of HBeAg loss but HBV DNA of 10,000 copies/ml or higher (table 2, p=0.01), while
HBeAg negativity in combination with other HBV DNA cut-off levels did not correlate with HBeAg
relapse. In the combination therapy group, HBeAg relapse could not be predicted by serum HBV
DNA at the end of treatment. Furthermore, in the monotherapy group, duration of low viremia also
influenced relapse rates. In none of 19 patients treated with PEG-IFN alpha-2b alone, who had
HBV DNA <10,000 copies/ml for at least 4 weeks prior to discontinuation of therapy HBeAg re-
lapse occurred, while this occurred in 5 of 20 patients (25%) with HBV DNA <10,000 copies/ml at
week 52 only (p=0.04). HBV DNA below 1.0 x 105 or 1.0 x 106 copies/ml on at least 2 consecutive
tests by the end of treatment was not related with HBeAg relapse (p=0.58 and p=0.14 for HBV
DNA <105 or <106 copies/ml, respectively). At the end of follow-up, 56% of patients with sustained
HBeAg response had HBV DNA <10,000 copies/ml compared to 4% of patients with relapse
(p<0.001).
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Logistic regression analysis of factors predicting HBeAg relapse and post-treatment HBeAg
response
For the prediction of HBeAg relapse and post-treatment HBeAg response, the following baseline
variables were included in univariate logistic regression analysis: age, sex, weight, race, mode of
transmission, serum ALT, HBV DNA level, HBV genotype, liver histology and treatment allocation.
In addition to these baseline variables, HBeAg and anti-HBe status at week 32; serum ALT, HBV
DNA, anti-HBe, HBsAg (HBeAg relapse only) and liver histology at week 52; and time points of ALT
normalisation and HBV DNA response were included (table 3). In multivariate time dependent
analysis, combination therapy of PEG-IFN alpha-2b with lamivudine (OR 3.9, 95% CI 1.1 - 13.2,
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p=0.03), absence of HBsAg loss at week 52 (OR 10.3, 95% CI 1.09-97.89, p=0.04) and absence
of anti-HBe at week 52 (OR 9.8, 95% CI 3.2 - 30.3, p<0.001) independently predicted HBeAg
relapse. Absence of anti-HBe at the end of treatment was found to be the strongest predictor of
HBeAg relapse.
DISCUSSION
In HBeAg-positive chronic hepatitis B, it is assumed that relapse occurs frequently after discon-
tinuation of nucleos(t)ide analogue therapy, while response appears more durable after interferon-
based treatment because of its immunomodulatory effects. In the current study we found 39%
relapse after discontinuation of PEG-IFN alpha-2b and lamivudine combination therapy and 13%
after PEG-IFN alpha-2b alone. These relapse rates are consistent with findings of previous stud-
ies, which showed HBeAg relapse in 22 - 40% of lamivudine treated patients3,17 and 10% of IFN
treated patients.3,18 Most likely, the higher relapse rates (preceded by higher response rates) after
cessation of combination therapy compared to PEG-IFN alpha-2b monotherapy can be explained
by lamivudine induced HBeAg loss.
In multivariate analysis, treatment allocation, absence of anti-HBe and absence of HBsAg loss at
the end of treatment independently predicted HBeAg recurrence. Factors predicting relapse after
conventional IFN have previously been described and include older age and presumable vertical
transmission.5 We did not find a relation between relapse and these factors in both univariate and
multivariate analysis. Possibly our findings differ from this Korean study because of differences in
patient population and type or duration of the antiviral therapy.
Among PEG-IFN alpha-2b and lamivudine treated patients in our study, 21% of those positive for
anti-HBe at the end of therapy relapsed compared to 63% of patients who lacked anti-HBe. In
HBeAg positive patients treated with PEG-IFN alpha-2a, HBeAg seroreversion (after full HBeAg-
seroconversion) occurred in 18% of patients treated with PEG-IFN alpha-2a monotherapy and
22% of patients on combination therapy with lamivudine.19 Response was sustained in 86% of
responders at 1 year post-treatment in this study.20 Although relapse rates in patients without
detectable anti-HBe in our study are much higher compared to PEG-IFN alpha-2a treated patients
with full HBeAg-seroconversion, relapse rates for patients with loss of HBeAg and detectable anti-
HBe at the end of treatment seem comparable between the two studies.
Presence of anti-HBe may be less important for PEG-IFN alpha-2b monotherapy than combina-
tion therapy, since the majority of patients treated with PEG-IFN alpha-2b monotherapy (7 of 10
patients) did not relapse despite the absence of anti-HBe at the end of therapy. In patients with
HBeAg relapse, HBV DNA levels declined during treatment, but less profoundly compared to sus-
tained responders (figure 2). HBV DNA <10,000 copies/ml prior to discontinuation of treatment
was found to significantly decrease the risk of relapse in PEG-IFN alpha-2b treated patients, while
other HBV DNA threshold levels did not correlate with HBeAg relapse. This is consistent with
findings on relapse after cessation of lamivudine in patients with prolonged suppression of HBV
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DNA.11 In addition to HBeAg response, decline in HBV DNA (below 10,000 copies/ml) seems thus
important for maintaining PEG-IFN induced response and may be associated with immune con-
trol of the virus. Patients with a partial response, as defined by HBeAg loss but insufficient decline
of HBV DNA (not below 10,000 copies/ml) at the end of therapy, might benefit from prolonged
therapy, as this has previously been shown to increase response to standard IFN.21 Maintaining
HBV DNA below 10,000 copies/ml after discontinuation of therapy also appears important since
recent studies showed that serum HBV DNA below this level reduces the risk of progression to
cirrhosis, decompensated liver disease and hepatocellular carcinoma.22,23 Fifty-six percent of sus-
tained responders had HBV DNA <10,000 copies/ml at the end of follow-up, while virtually all
patients with relapse had HBV DNA above this level. In HBeAg positive patients treated with
monotherapy of PEG-IFN alpha-2a, a comparable rate of HBV DNA below 10,000 copies/ml was
observed in responders (66%) at the end of follow-up.24
HBV genotype independently predicted loss of both HBeAg and HBsAg in HBeAg-positive patients
treated with PEG-IFN alpha-2b, with higher response rates in patients with genotype A compared
to those with genotype D.12,25 A similar trend was observed in a population of mainly Asian patients
treated with PEG-IFN alpha-2a.19,26 HBV genotype also tended to influence HBeAg relapse after
discontinuation of PEG-IFN alpha-2b with or without lamivudine, with genotype D infected patients
having a higher risk of relapse than those with genotype A.
In conclusion, HBeAg relapse occurs more often after treatment of PEG-IFN alpha-2b in combina-
tion with lamivudine than after PEG-IFN alpha-2b monotherapy. Absence of anti-HBe at the end of
treatment was found to be the strongest predictor of relapse, particularly in patients treated with
combination therapy. HBeAg loss thus is less suitable as sole endpoint of PEG-IFN based therapy
in HBeAg positive chronic HBV. More profound suppression of HBV DNA below 10,000 copies/ml
further decreases the risk of relapse. Patients with a partial response might benefit from pro-
longed PEG-IFN treatment, further reducing HBV DNA and thereby possibly increasing the devel-
opment of anti-HBe and reducing the risk of relapse after discontinuation of therapy.
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ABSTRACT
Background and aim
Hepatitis flares are a well-known and potentially dangerous phenomenon during interferon-based
and after nucleos(t)ide analogue therapy. We investigated the frequency of severe flares after
peginterferon (PEG-IFN) therapy in HBeAg positive chronic hepatitis B.
Methods
One-hundred-thirty-six patients were treated with PEG-IFN alpha -2b (100μg/week for 52 weeks)
and followed for 26 weeks after therapy. Hepatitis flares were defined as an increase in ALT levels
to >=10x the upper limit of normal (ULN) and >=2x the nadir value during (on-treatment flare) or
after therapy (withdrawal flare). Combined response was defined as HBeAg loss and HBV DNA
<10,000 copies/ml at 6 months post-treatment.
Results
Withdrawal flares were observed in 19 patients (14%) and on-treatment flares in 22 patients (16%).
Mean maximum ALT of withdrawal flares was 14.8 ± 6.5 x ULN compared to 15.3 ± 4.8 x ULN of on-
treatment flares (p=0.79). Withdrawal flares were particularly observed in non-genotype-A infected
patients (odds ratio [OR] 5.1, 95%-CI 1.1-23.2), those with previous lamivudine therapy (OR 3.5,
95%-CI: 1.1-10.8) or with high ALT at the end of treatment (OR 1.4, 95%-CI 1.1-1.8). No associa-
tion between baseline factors and on-treatment flares was observed. Combined response was
observed in 12% of patients without a flare, 5% of patients with a withdrawal flare and 18% of
patients with an on-treatment flare.
Conclusion
Withdrawal flares occur frequently after PEG-IFN therapy and are non-beneficial. Therefore, close
monitoring of patients at increased risk, and rapid re-initiation of nucleos(t)ide analogue therapy in
those developing a withdrawal flare is recommended.
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 INTRODUCTION
Chronic hepatitis B virus (HBV) infected patients can suffer from acute exacerbations under vari-
ous conditions. These exacerbations of inflammatory activity (hepatitis flares) in general represent
an increased host immunity against HBV infected hepatocytes due to spontaneous or treatment-
associated increases in viral replication, or as a result of therapeutic intervention with
immunomodulatory dugs such as interferon, corticosteroids, or chemotherapy.1 It has been re-
ported that viremia markedly increased before an increase in serum alanine aminotransferase
(ALT) level is observed.2 Flares have been observed in 16-19% of patients after stopping lamivudine
therapy.5, 9, 10 Hepatitis flares can be severe or even life threatening, particularly in patients with
underlying cirrhosis.3 Acute exacerbations of chronic hepatitis B are associated with hepatocellular
damage and repeated exacerbations or reactivations can lead to progressive fibrosis.1
Hepatitis flares are a well known phenomenon during treatment with (peg)interferon (PEG-IFN), as
well as in patients developing antiviral resistance or stopping nucleos(t)ide analogue therapy .1, 4, 5
During treatment with standard IFN or PEG-IFN, flares occurred in 25-40% of patients and have
been associated with an increased likelihood of virological response.4, 6-8 Flares during IFN-based
therapy are potentially associated with the increase in T cell cytolytic activity and natural killer cell
function during IFN therapy and typically occur during the second to third month of treatment.7 Two
types of flares have been distinguished during PEG-IFN therapy. Virus induced flares, which occur
after an increase in HBV DNA level, and most probably are indicative for increased expression of
viral antigens, did generally not lead to treatment response. In contrast, host induced flares which
were followed by a decrease in serum HBV DNA were highly associated with treatment response.4
A uniform definition of flares was recently proposed in the newest edition of the AASLD consensus
guideline for the treatment of chronic hepatitis B.11 The incidence of and outcome after such flares
associated with PEG-IFN monotherapy is still unknown.
PATIENTS AND METHODS
We investigated the occurrence of flares after (withdrawal flares) and during (on-treatment flares)
treatment with PEG-IFN alpha-2b in HBeAg-positive chronic hepatitis B patients.12 One-hundred-
thirty-six patients treated with PEG-IFN alpha-2b for 52 weeks were included in this study. After 32
weeks, PEG-IFN  alpha-2b dosage was lowered from 100μg to 50μg per week to prevent side
effects and early treatment discontinuation. Follow-up after discontinuation of therapy lasted 26
weeks.
Patients were eligible if they were positive for hepatitis B surface antigen (HBsAg) for at least 6
months, hepatitis B e antigen (HBeAg) positive on two occasions within 8 weeks prior to random-
ization, had elevated serum ALT of >2 to >=10 x the upper limit of normal (ULN), and had serum
HBV DNA above 1.0 x 105 copies per milliliter (copies/ml). Major exclusion criteria were: antiviral
therapy within 6 months prior to randomization, serum antibodies against hepatitis C virus (HCV),
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hepatitis delta virus (HDV) or human immunodeficiency virus (HIV), pre-existent leucopenia (white
blood cell count <=3,000/mm3, neutrophil count <=1,800/mm3) or thrombocytopenia (platelets
>=100,000/mm3), or decompensated liver disease.
During therapy and post treatment follow-up, patients were monitored monthly by routine physical
examination, as well as biochemical and hematological assessments. ALT was assessed locally
in accordance with standardized procedures and therefore expressed as times the ULN. Serum
HBV DNA levels were measured monthly using an in-house developed Taqman PCR assay (lower
limit of detection 373 copies/ml) based on the Eurohep standard.13 HBeAg and HBsAg (AxSYM,
Abbott, Abbott Park, IL, USA) were assessed at week 0, 32, 52 (end of treatment) and week 78 (end
of follow-up). HBV genotype and YMDD mutation analysis were performed by INNO-LiPA assay
(Innogenetics, Gent, Belgium).
Hepatitis flares were defined as intermittent elevations of ALT levels to at least 10 times the upper
limit of normal and at least twice the nadir value, as defined in the AASLD consensus guideline for
the treatment of chronic hepatitis B.11 A flare was defined as "virus induced" when preceded by an
increase in HBV DNA (>=1log10 copies/ml) within four months. A flare was defined as "host in-
duced" when the flare was followed by a decline in HBV DNA (>=1log10 copies/ml) within four
months. Flares that did not meet one of these criteria were classified as indeterminate.4
Statistical analysis was performed using the SPSS 15.0 program (SPSS Inc. Chicago, IL). Chi-
square, Fisher's exact test and Mann-Whitney U test were used where appropriate. The relation
between characteristics at baseline and at the end of therapy, and the occurrence of flares was
examined by logistic regression analyses. A p-value <= 0.05 (all 2-sided) was considered statisti-
cally significant.
RESULTS
Hepatitis flares were observed in 38 of 136 patients (28%); 16 patients (12%) developed a flare
within 6 months after therapy (withdrawal flare), 19 patients (14%) developed a flare during PEG-
IFN therapy (on-treatment flare), and 3 patients (2%) had a flare both during and after therapy.
Patient characteristics are shown in table 1. The mean maximum ALT of withdrawal flares was
14.8 ± 6.5 x ULN compared to 15.3 ± 4.8 x ULN of on-treatment flares (p=0.79). Withdrawal flares
occurred after a mean period of 12.2 ± 8.9 weeks after therapy, with 79% occurring within 12
weeks after stopping PEG-IFN therapy. On-treatment flares occurred after a mean treatment dura-
tion of 16.6 ± 11.9 weeks, with 50% of flares occurring in the first 12 weeks of therapy.
Patterns of flares
Different patterns of flares could be distinguished (figure 1). The observed frequency of the three
patterns of acute exacerbation (virus-induced, host-induced and indeterminate flares) was signifi-
cantly different between withdrawal flares and on-treatment flares (p=0.006). Virus-induced flares
were the most frequently observed type of withdrawal flares, while more than half of the flares that
103Withdrawal flares after peginterferon alpha-2b are non-beneficial
occurred during PEG-IFN therapy were of the host-induced type.
Factors influencing the occurrence of flares after  or during PEG-IFN therapy
The distribution of the HBV genotypes among patients with and without a flare is shown in table 1.
All withdrawal flares occurred in patients who were still HBeAg positive at the end of treatment, no
withdrawal flares were observed in those with end of treatment response (p=0.13). Withdrawal
flares occurred significantly less often in genotype A infected patients compared to those with
other genotypes (4% vs. 19%, p=0.02). Factors associated with the occurrence of withdrawal
flares include genotype non-A infection (odds ratio [OR] 5.1, 95%-CI 1.1-23.2), previous lamivudine
therapy (OR 3.5, 95%-CI 1.1-10.8) and high ALT at week 52 (OR 1.4, 95%-CI 1.1-1.8). On-treatment
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flares occurred equally across genotypes (15%, 17%, 24% and 12% in patients with genotype A-
D, respectively; p=0.44). None of the baseline factors age (p=0.39), sex (p=0.93), weight (p=0.71),
ALT (p=0.82), HBV DNA (p=0.59), genotype (p=0.48), BMI (p=0.74), previous IFN (p=0.35) or
previous lamivudine therapy (p=0.48) was associated with the occurrence of on-treatment flares
on logistic regression analysis.
Flares and response to therapy
At the end of treatment, combined response was observed in 16 of 136 patients (12%) and was
not influenced by the occurrence of on-treatment flares (9% vs. 12% in patients with and without
an on-treatment flare, p=0.67). Combined response at 6 months post-treatment was observed in
13% of patients. There was no difference in the rate of combined response at 6 months post-
treatment between patients with and those without a flare (13% vs. 12%, p=0.89). Four of 19
patients (21%) with an on-treatment flare achieved combined response at 6 months post-treatment,
all of whom had a virus-induced flare. Combined response at 6 months post-treatment was observed
in 1 of 16 patients (6%) with a withdrawal flare. None of the three patients with both an on-treatment
and a withdrawal flare showed combined response at 6 months post-treatment.
Influence of flares on liver function
Significant hepatic decompensation was not observed in patients with flares, neither in those
without. A rise in bilirubin to >=1.5 x ULN during PEG-IFN therapy was observed in 14% of patients
with an on-treatment flare compared to 11% of those without (p=0.77). Clinically overt jaundice
was not observed in any of the patients. Bilirubin elevations were also observed equally in patients
with and without a withdrawal flare (16% vs. 12%, p=0.61). A prolongation of prothrombin time was
observed in two patients. The first patient had a persistently prolonged prothrombin time throughout
therapy and post-treatment follow-up (2.1 – 2.5 x ULN) of unclear origin, no underlying etiology or
Figure 1: Patterns of hepatitis flares
occurring during or after PEG-IFN
therapy.
Three pattern of acute exacerbation can
be distin-guished: virus induced flares,
host induced flares and indeterminate
flares. The frequency of the different
patterns of acute exacerbation was
significantly different between withdrawal
flares and on-treatment flares (p=0.006).
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use of anticoagulants was reported. The other had a prolongation of prothrombin time to 1.6 x ULN
after developing a withdrawal flare with a maximum ALT level of 15.6 x ULN. Bilirubin levels remained
normal and the patient did not have underlying cirrhosis.
DISCUSSION
Hepatitis flares are a well known and potentially dangerous phenomenon after discontinuation or
development of antiviral resistance during nucleos(t)ide analogue, particularly in patients with
advanced liver disease. Acute exacerbations during PEG-IFN therapy on the other hand have
been reported to be beneficial, resulting in higher response rates.4, 8 In the current study we defined
flares as an ALT level of >=10 times the upper limit of normal and >=2 times the nadir value as
recently proposed in the AASLD practice guidelines. Such severe acute exacerbations occurred
in 16% of patients during treatment with PEG-IFN alpha-2b and in 14% of patients after
discontinuation of therapy. The maximum ALT level during the flare was comparable for the two
types of flares and no signs of hepatic decompensation were observed.
The observed frequency of withdrawal flares in our study seems comparable to the rates observed
in previous studies of lamivudine and/or interferon therapy (2-19%).5, 9, 10, 14 Recent studies with
nucleos(t)ide analogues provide little data on post-treatment follow-up, since nucleos(t)ide analogue
therapy is now generally given for longer periods.15-17 A higher frequency of withdrawal flares might
be expected in nucleos(t)ide analogue treated patients, since post-treatment virological relapse
may occur more frequently after stopping nucleos(t)ide analogue than PEG-IFN therapy.12, 18-20 In
particular a rapid increase in serum HBV DNA has been shown to precipitate hepatitis flares.2
However, in entecavir treated patients, withdrawal flares (ALT level >2x reference [lesser of the
baseline and the end-of-dosing ALT values] and >10x ULN) were observed in only 2% of the patients
who discontinued antiviral therapy.21 This low rate of withdrawal flares may be due to the high rate
of sustained HBeAg seroconversion of about 75% at six months post-treatment. Schiff et al. found
elevations of at least twice baseline levels and at least 500U/l in 11% of patients treated with
lamivudine and only 2% of patients treated with IFN and lamivudine combination therapy.14 The
differences in the observed frequency of flares may be explained by differences in the definition of
a flare and the duration of follow-up. We chose the lowest ALT level during or after treatment as the
reference value for on-treatment and withdrawal flares, respectively. If baseline and end of treatment
ALT would have been chosen as the reference value, patients with high baseline ALT levels would
by definition have had a lower risk of developing a flare.
The majority of on-treatment flares were of the host-induced type. Among patients with an on-
treatment flare, all of those who achieved combined response at six months post-treatment had a
host-induced flare. On the other hand, we frequently observed a rise in HBV DNA prior to the rise
in ALT levels among patients developing a withdrawal flare (virus-induced flares). None of the
patients with a withdrawal flare had HBeAg loss at the end of treatment. Loss of PEG-IFN induced
HBV DNA decline seems thus responsible for the observed withdrawal flares.
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We did not observe signs of hepatic decompensation in our patients, who all had fully compensated
liver disease at inclusion (no prolongation of prothrombin time by >3 seconds, albumin concentration
>=35 g/L, bilirubin <35 μmol/L and no history of ascites, variceal bleeding, or hepatic
encephalopathy). In IFN-treated patients with signs of hepatic decompensation prior to the start of
IFN therapy or with Child’s class B or C cirrhosis, severe adverse events including fatal hepatic
decompensation have been previously reported and IFN-based therapy is therefore contra-indicated
in these patients.3, 22, 23
We conclude that flares occur frequently in HBeAg positive patients during and after PEG-IFN
therapy. Withdrawal flares particularly occurred in those who are still HBeAg positive at the end of
therapy and are non-beneficial. Therefore, close monitoring of patients at increased risk for
developing withdrawal flares is recommended during the first months after discontinuation of therapy.
In addition, rapid re-initiation of nucleos(t)ide analogue therapy should be considered in patients
developing a withdrawal flare.
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ABSTRACT
Background and aims
The aim of this study was to evaluate the long-term sustainability of response in HBeAg positive
chronic hepatitis B patients treated with peginterferon alpha-2b (PEG-IFN) alone or in combination
with lamivudine.
Methods
All 266 patients enrolled in the HBV99-01 study were offered participation in a long-term follow-up
(LTFU) study. Patients were treated with PEG-IFN alpha-2b (100μg/week) alone or in combination
with lamivudine (100mg/day) for 52 weeks. Initial response was defined as HBeAg negativity at 26
weeks post-treatment. For the LTFU study, patients had one additional visit after the initial study
(mean interval 3.0 ± 0.8 years).
Results
Of 266 patients enrolled in the initial study, 172 (65%) participated in the LTFU study. At LTFU,
HBeAg and HBsAg negativity were observed in 37% and 11% of 172 patients, respectively. Sixty-
four patients were classified as initial responders and 108 as non-responders. Among the initial
responders, sustained HBeAg negativity and HBsAg loss were observed in 81% and 30%, re-
spectively. HBV genotype was associated with long-term sustainability of response, with signifi-
cantly higher rates of HBeAg negativity in genotype A infected initial responders compared to those
with genotype-non-A (96% vs. 71%, p=0.02), as well as HBsAg loss (58% vs. 11%, p<0.001).
Conclusions
HBeAg loss after treatment with PEG-IFN alone or in combination with lamivudine is sustained in
the majority of patients and is associated with a high likelihood of HBsAg loss, particularly in geno-
type A infected patients. Therefore, PEG-IFN remains an important treatment option in this era of
nucleos(t)ide analogue therapy.
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INTRODUCTION
It is estimated that 350 million persons worldwide are chronically infected with hepatitis B virus
(HBV).1 Chronic HBV infection increases the risk of developing cirrhosis, hepatic decompensation
and hepatocellular carcinoma (HCC).2 During their lifetime, about 15% to 40% of (untreated) chroni-
cally HBV infected individuals will develop serious complications from liver disease.3 Despite the
availability of a safe and effective vaccine for more than two decades, new infections with HBV
remain common and chronic HBV infection still is a major health problem.4
Hepatitis B e antigen (HBeAg) loss from serum is usually associated with a marked decrease in
serum HBV deoxyribonucleic acid (DNA) concentration and normalization of alanine aminotrans-
ferase (ALT) levels.5 Although reactivation of disease activity may occur in patients with HBeAg
negative disease, the occurrence of liver-related complications is rare.6 Since loss of hepatitis B
surface antigen (HBsAg), which is referred to as clearance of HBV infection, can be observed only
in a small proportion of patients after antiviral therapy, loss of HBeAg is often used as a surrogate
end point.
In recent studies, about 35% of patients lost HBeAg after an one-year course of pegylated inter-
feron (PEG-IFN) therapy.7-9 Adding lamivudine to PEG-IFN therapy did not result in higher rates of
HBeAg loss.7, 8 It is unknown whether PEG-IFN induced HBeAg loss is sustained over prolonged
periods and is associated with favorable long-term outcome. The aim of this study therefore was
to evaluate the long-term virological response and clinical outcome in patients treated with PEG-
IFN alpha-2b alone or in combination with lamivudine.
METHODS
Participants
All 266 patients enrolled in the HBV99-01 study (42 centers in 15 countries) were eligible for inclu-
sion in this long-term follow-up (LTFU) study.7 Patients were treated with peginterferon alpha-2b
100μg weekly (PegIntron, Schering-Plough, Kenilworth, NJ, USA) in combination with placebo or
lamivudine 100mg daily (Zeffix, GlaxoSmithKline, Greenford, UK) for 52 weeks. After 32 weeks,
PEG-IFN  alpha-2b dosage was lowered to 50μg per week to prevent early discontinuation of
therapy due to side-effects.7 The primary outcome measure was loss of HBeAg at 26 weeks post-
treatment (week 78). For the current LTFU study, patients with loss of HBeAg at week 78 were
classified as initial responders. HBeAg relapse was defined as negative serum HBeAg at 26 weeks
post-treatment and positive HBeAg at LTFU.
The inclusion and exclusion criteria were reported previously.7 In short, patients were eligible if
they had been HBsAg positive for more than 6 months, were HBeAg positive on two occasions
within 8 weeks prior to randomisation, had elevated serum ALT of at least twice the upper limit of
normal (ULN), and had serum HBV DNA >1.0 x 105 copies/ml. Major exclusion criteria were: anti-
viral therapy within 6 months prior to randomisation, viral coinfections, pre-existent cytopenia or
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decompensated liver disease.
For the LTFU study, patients were re-evaluated by one additional visit at the local participating
center. The local investigator assessed clinical signs and symptoms of liver disease, complica-
tions of liver disease (hepatocellular carcinoma, ascites, variceal bleeding, encephalopathy or
jaundice), liver transplantation, mortality and administration of (other) antiviral therapy after the
initial study according to predefined criteria on standardized questionnaires. If the patient had
been retreated, local data prior to retreatment were also collected. Patients were enrolled in the
LTFU study after they had given informed consent according to standards of the local ethics com-
mittees. Follow-up time was calculated from the end of the initial study (week 78) until the visit for
the LTFU study. The primary outcome for the LTFU study was sustainability of HBeAg negativity.
Secondary outcome measures were HBV DNA <10,000 and <400 copies/ml, ALT normalization,
HBsAg negativity, HBeAg relapse and need for retreatment. Patients who were retreated after the
initial study were considered non-responders for all categorical outcome measures, except for
HBeAg response for which the local test result at the time of restarting antiviral therapy was taken
into account.
Laboratory testing
During therapy and post treatment follow-up of the initial study, patients were monitored monthly
by routine physical examination, as well as biochemical and hematological assessments. ALT
was assessed locally in accordance with standardized procedures and therefore expressed as
times upper limits of normal (ULN). Serology and quantification of serum HBV DNA was per-
formed at the coordinating center in Rotterdam by staff unaware of treatment allocation and out-
come at the end of treatment and end of the initial study. For the initial study, serum HBV DNA
levels were measured monthly using an in-house developed TaqMan polymerase chain reaction
(PCR) assay (lower limit of detection 373 copies/ml) based on the EuroHep standard.10 Testing for
markers of HBV infection (HBeAg, anti-HBe, HBsAg and anti-HBs) was performed with a com-
mercial radioimmunoassay (AxSYM, Abbott, Abbott Park, IL, USA) at week 0, 32, 52 and 78. HBV
genotype analysis was performed by INNO-LiPA assay (Innogenetics, Gent, Belgium). Quantifica-
tion of serum HBV DNA levels for the LTFU study was performed with the Cobas TaqMan HBV
assay (Roche Molecular Systems, Branchburg, NJ, USA), with a dynamic range of quantification
of 174 - 6.4 x 108 copies/ml (30 - 1.1 x 108 IU/ml). Since serum HBV DNA was expressed in
copies/ml in the initial study, all HBV DNA measurements for the LTFU study were recalculated to
copies/ml (1 IU/ml = 5.8 copies/ml). To assure comparability of the two HBV DNA quantification
assays, 40 samples were tested with both assays and the results were compared. There was an
excellent correlation between the two assays (r=0.930, p<0.001) and plotting the difference against
the average of the assays showed no significant correlation (Bland-Altman test; r=0.12, p=0.49),
strengthening the conclusion that both assays are comparable in the dynamic range.11 All initial
responders who had serum HBV DNA >5.0 x 103 copies/ml after HBeAg loss were tested for the
presence of core promoter (A1762T/G1764A) and precore mutations (G1896A) by sequence analy-
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sis. Testing for HBeAg, anti-HBe, HBsAg and anti-HBs for the LTFU study was performed with the
commercially available Enzyme-Linked Immuno Sorbent Assays (ELISA) of DiaSorin (DiaSorin
S.p.A., Saluggia, Italy).
Statistical analysis
For the comparison of frequencies between or within groups, Chi-square test, Fisher's Exact test
and McNemar test were used where appropriate. Student's t-test and Mann-Whitney test were
used to compare means between groups. The Kaplan-Meier method was used to estimate cumu-
lative response rates, differences between groups were compared by Log Rank testing. Four-
year cumulative response rates were used, since an adequate proportion of patients was still at
risk at this time point. This method was used in addition to a cross-sectional analysis because the
timing of the LTFU visit was different for the patients enrolled. A cross-sectional analysis alone
could overestimate or underestimate response rates due to the differences in duration of follow-up
after the initial study. Cox regression analysis was used for the identification of factors influencing
HBeAg relapse in responders. The hazard ratio (HR) and 95% confidence interval (CI-95%) is
given for factors associated with HBeAg relapse. Patients with missing data and patients who
were retreated were considered non-responders. A p-value of 0.05 was considered to be statisti-
cally significant (all 2-sided). Statistical analysis was performed with the SPSS14.0 program (SPSS
Inc., Chicago, IL).
RESULTS
Patients
Of 266 patients from 41 centers participating in the HBV99-01 study, 172 patients (65%) from 28
centers (68%) were enrolled in the LTFU study. The LTFU study overview is shown in figure 1.
Patients were followed for a mean period of 3.0 ± 0.8 years (range 1.6 - 5.0) after the end of the
initial study. The majority of the 94 patients who were not enrolled in the LTFU study did not partici-
pate because the local study site did, for variable reasons, not take part in this study (n=52, 55%)
or because the patient was lost to follow-up (n=23, 24%). Three patients died after the initial study,
all three were non-responder. Baseline characteristics and outcome at the end of the initial study
of patients who did not participate in the LTFU study (n=94) and those who were included in the
LTFU study (n=172) were comparable, except for mean baseline ALT (3.7 ± 2.1 vs. 4.7 ± 4.0;
p=0.03).
Baseline characteristics and outcome in the initial study
Baseline characteristics and outcome at the end of the initial study for patients enrolled in the
LTFU study (n=172) and all patients from the initial study (n=266) are shown in table 1. The patient
groups were similar in terms of baseline demographics and disease characteristics. Ninety-one
patients treated with PEG-IFN alone and 81 patients treated with PEG-IFN in combination with
  116
Ch
ap
te
r 7
Figure 1: Study overview
This figure shows inclusion of patients from the initial study (HBV99-01 study) in the long-term follow-up
(LTFU) study and reasons for not participating for those not enrolled in the LTFU study.
lamivudine were included in the LTFU study. Outcome at the end of the initial study was compa-
rable between the two patient groups.
Sixty-four of 172 patients (37%) were HBeAg negative at the end of the initial study and were
classified as initial responders (figure 1). Fourteen of these 64 initial responders (21%) received
additional nucleos(t)ide analogue therapy compared to 67 of 108 initial non-responders (62%)
(p<0.001). Of 14 responders who were retreated, 7 had HBeAg reversion prior to the initiation of
nucleos(t)ide analogue therapy, while the remaining 7 remained HBeAg negative but had active
disease (high HBV DNA and/or elevated ALT).
HBeAg
Rates of HBeAg negativity at the end of the initial study and at LTFU are shown in figure 2 for
patients treated with PEG-IFN and lamivudine combination therapy or PEG-IFN alone. When com-
bining the two groups at LTFU, HBeAg was negative in 63 of 172 patients (37%). In 11 of 41 initial
non-responders (27%) who were not retreated, loss of HBeAg occurred after the end of the initial
study. HBeAg loss was sustained in 52 of 64 (81%) initial responders (figure 3). By Kaplan-Meier
analysis, the 4-year cumulative probability of sustained HBeAg negativity in these patients was
69% (figure 3).
At the end of the initial study, HBeAg seroconversion was observed in 53 of 172 patients (31%). At
LTFU, HBeAg seroconversion was observed in 25% and 35% of patients receiving combination
Response
(HBeAg negative)
(95)
- Center not participating (17)
- Patient not reached (7)
- Not willing to participate (4)
- Data incomplete (1)
- Unknown (2)
HBV99-01
study
(266)
Included in
LTFU study
(64)
Included in
LTFU study
(108)
Treated after
initial study
(14)
Not treated
after week 78
(50)
Treated
after week 78
(67)
Not treated
after week 78
(41)
Not included in
LTFU study
(31)
Not included in
LTFU study
(63)
- Center not participating (35)
- Patient not reached (16)
- Not willing to participate (2)
- Non-liver related death (2)
- Death (unknown cause) (1)
- Data incomplete (2)
- Unknown (5)
- Lamivudine (11)
- Adefovir (2)
- Experimental (1)
- Lamivudine (58)
- Adefovir (8)
- Experimental (1)
Non-response
(HBeAg positive)
(171)
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therapy and PEG-IFN monotherapy, respectively (p=0.14). HBeAg seroconversion was sustained
in 37 of 53 patients (70%) with HBeAg seroconversion at the end of the initial study.
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Figure 2: Response rates at the end of the initial study (week 78) and at long-term follow-up (LTFU) in
172 patients included in the LTFU study.
This figure shows the rate of HBeAg negativity, HBV DNA <400 copies/ml, and HBsAg negativity in patients
treated with PEG-IFN alone (     , n=91), its combination with lamivudine (     , n=81) and overall response rates
(     , n=172) at the end of the initial study (week 78) and at long-term follow-up (LTFU). Data for the LTFU study
were collected after a mean period of 3.0 ± 0.8 years (range 1.6 - 5.0 years) after the end of the initial study
(¥p=0.03 for the difference between the two treatment groups).
HBV DNA
At LTFU, 48 (28%) and 33 (19%) of 172 patients had HBV DNA <10,000 and <400 copies/ml,
respectively. Patients treated with PEG-IFN and lamivudine significantly more often had HBV DNA
<400 copies/ml than those treated with PEG-IFN alone (figure 2) at LTFU, while HBV DNA <10,000
copies/ml was observed equally in both treatment groups (31% vs. 25%, p=0.42). At LTFU, the
proportion of patients with HBV DNA <400 copies/ml increased in both treatment groups as com-
pared to the respective proportions at the end of the initial study (p<0.02).
HBV DNA below 10,000 copies/ml was observed significantly more often in patients with sus-
tained HBeAg negativity than in patients who remained HBeAg positive throughout follow-up (67%
vs. 6%; p<0.001). Fifty-eight percent of initial responders had HBV DNA <10,000 copies/ml at
LTFU and 45% of them had HBV DNA <400 copies/ml (figure 3). By Kaplan-Meier analysis, the 4-
year cumulative probability of HBV DNA <10,000 and <400 copies/ml in initial responders was
78% and 52%, respectively (figure 3).
ALT
At LTFU, 52 of 172 patients (30%) had normal ALT, which was similar to the proportion of patients
with normal ALT at the end of the initial study (36%; p=0.65). Normal ALT was observed equally in
patients treated with combination therapy and those receiving PEG-IFN alone at LTFU (33% vs.
28%, p=0.40). Among the 64 initial responders, 77% percent had normal ALT at LTFU, with a 4-
year cumulative rate of 85% by Kaplan-Meier analysis (figure 3).
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HBsAg
Although not statistically significant, HBsAg loss was observed almost twice as often in patients
treated with PEG-IFN and lamivudine compared to those treated with PEG-IFN alone at LTFU
(figure 2; p=0.14). Overall, HBsAg was negative in 19 of 172 patients (11%) participating in the
LTFU study (figure 2), including 11 patients who had lost HBsAg by the end of the initial study and
8 patients with HBsAg loss after the end of the initial study. HBsAg seroreversion (HBsAg positive
and anti-HBs negative) was not observed among patients with HBsAg seroconversion at the end
of the initial study, although one patient with HBsAg loss (but negative anti-HBs) had relapse of
HBsAg positivity. Among initial responders, HBsAg was negative in 19 of 64 patients (30%) at
LTFU, with a 4-year cumulative probability of 29% by Kaplan-Meier analysis (figure 3).
HBV genotype
Response rates at LTFU for initial responders with genotypes A-D are given in figure 4, five pa-
tients with other genotypes (two with genotype E, two with genotype F and two with genotype G)
were excluded. HBeAg negativity was sustained in 96% of genotype A infected patients compared
to 76% those with non-A genotype (p=0.06). Initial responders with genotype A were more likely to
maintain serum HBV DNA <10,000 copies/ml compared to those with genotype-non-A (81% vs.
42%, p=0.002). In addition, HBV DNA <400 copies/ml and ALT normalization were observed sig-
nificantly more often in patients with genotype A than in those with other genotypes (65% vs. 27%
and 96% vs. 64%, respectively; p<0.003). Finally, HBV genotype strongly influenced the likelihood
of HBsAg negativity at LTFU. Among the 172 patients enrolled, the highest rate of HBsAg negativity
of 28% was observed in genotype A infected patients as compared to 3% in those with genotype
non-A infection (p<0.001 for genotype A vs. non-A). In 64 initial responders, HBsAg negativity oc-
curred also significantly more often in genotype A infected patients than in those with genotype-
non-A infection (58% vs. 6%, p<0.001).
Figure 3: Long-term virological
and biochemical response in 64
patients with initial HBeAg re-
sponse.
This figure shows the proportion of
initial responders (patients with
HBeAg loss at 26 weeks post-
treatment) who had negative
HBeAg, HBV DNA <400 copies/
ml and negative HBsAg at long-
term follow-up. The 4-year cumu-
lative response rate by Kaplan-
Meier analysis is given for each of
the outcome measures in the table
below the figure.
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Of 64 initial responders, 8 (13%) had a mutation in the core promoter region (A1762T/G1764A)
and 12 (19%) had a mutation in precore region (G1896A). Mutations in either the core promoter or
precore region were observed in 11 of 27 HBeAg negative patients (41%) who had serum HBV
DNA above 1.0 x 104 copies/ml at LTFU and in 9 of 37 (24%) patients with HBV DNA below 1.0 x
104 copies/ml (p=0.16). The A1762T/G1764A core promoter mutation and the G1896A precore
mutation were observed in 19% and 4%, 0% and 43%, 22% and 11%, and 6% and 41% of HBeAg
negative patients with genotype A (n=26), B (n=7), C (n=9) and D (n=17), respectively (p=0.04 for
the difference of occurrence of these mutations across genotypes).
Predictors of HBeAg relapse
For the prediction of HBeAg relapse, the initial study baseline characteristics and outcome mea-
sures at 26 weeks post-treatment were included in a univariate Cox Regression model. Baseline
factors associated with an increased risk of HBeAg relapse after the initial study were younger age
(0.93 per year increase in age, CI-95% 0.87-0.99; p=0.02) and HBV genotype-non-A (HR 11.84,
CI-95%1.50-93.70; p=0.02). Elevated ALT (HR 5.10, CI-95% 1.53-17.03; p=0.008) and higher HBV
DNA (HR 1.57 per 1log10 increase, CI-95% 1.21-2.04; p=0.001) at the end of the initial study were
also associated with an increased risk of HBeAg relapse. Absence of anti-HBe in serum at the end
of the initial study was not associated with HBeAg relapse (HR 1.36, CI-95% 0.37-5.04; p=0.65).
Multivariate analysis was not possible due to the limited number of events.
Figure 4: Long-term outcome in initial responders depending on HBV genotype.
This figure shows the rates of HBeAg negativity, HBV DNA <400 copies/ml and HBsAg negativity across
HBV genotypes in 64 initial responders (patients with HBeAg loss at 26 weeks post-treatment). A signifi-
cantly higher rate of HBV DNA <400 copies/ml and HBsAg loss was observed in genotype A infected patients
as compared to those with genotype non-A (p<0.003).
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DISCUSSION
This is the first study documenting long-term outcome after treatment with PEG-IFN alone or in
combination with lamivudine in chronic hepatitis B patients. We found that 81% of patients with
loss of HBeAg at 26 weeks post-treatment remained HBeAg negative after a mean of 3 years.
About two-third of sustained HBeAg responders maintained an HBV DNA level <10,000 copies/ml
and normal ALT, reflecting inactive disease. An increase in HBsAg negativity was observed in the
LTFU study, with 30% of the initial responders being HBsAg negative at long-term follow-up. The
highest rates of both sustained HBeAg negativity (96%) as well as HBsAg negativity (58%) were
observed in genotype A infected initial responders. Although not all patients from the initial study
participated in the long-term study, the LTFU cohort was representative for the entire study popu-
lation. Duration of follow-up in the LTFU study was calculated from the end of the initial study (26
weeks post treatment), since HBeAg loss within 6 months post-treatment is generally considered
to be PEG-IFN induced.7,8
Studies on the long-term benefits of treatment with conventional IFN have shown that response is
durable in the majority of HBeAg positive patients, with reactivation occurring in only 10-20% after
4-8 years.12-14 The observed sustained response rate of 81% in our study is thus comparable to
those observed in previous studies of conventional IFN in HBeAg positive patients. A preliminary
report on sustainability of HBeAg loss after treatment with PEG-IFN alpha-2a showed that 91% of
patients with HBeAg loss at 6 months post-treatment maintained this response during another six
months of follow-up.15 Although the sustained response rate in that preliminary study, with only six
months of additional follow-up, seems higher than in our study, with three years of follow-up,
differences in duration of follow-up between the two studies should be taken into account. Al-
though the rate of HBeAg negativity is stable over time, this group of responders changed over
time due to a limited numbers of relapses, as well as a few additional late HBeAg responders. In
HBeAg positive patients treated with the nucleoside analogues entecavir or telbivudine HBeAg
seroconversion was observed in 29-31% after 2 years of therapy,16,17 with sustained response in
75-80% of patients at 6 months post-treatment.18,19 These high sustained response rates appear
promising, but long-term studies have to elucidate whether response is durable over prolonged
periods since lamivudine-induced HBeAg seroconversion was found to be durable in 46% of pa-
tients after 3 years compared to 68% for standard IFN.20
We found that in 27 of 64 (42%) responders, PEG-IFN induced HBeAg loss did not result in a
transition to the "inactive carrier state", as defined by HBeAg negativity in combination with HBV
DNA <1.0 x 104 copies/ml and normal ALT.21 Only 11 of these 27 patients (41%) harbored HBV
variants in the precore or core promoter region, which abolish HBeAg production despite persis-
tent active viral replication.22 Interestingly, the incidence of mutations in the core promoter or precore
region was not significantly different in initial responders with HBV DNA >1.0 x 104 copies/ml at
LTFU and in those with HBV DNA below this level.
We previously showed that anti-HBe negativity at the end of treatment was the strongest predictor
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of HBeAg relapse within six months post-treatment.23 In this study however we found no relation
between anti-HBe status at 6 months post-treatment and the risk of HBeAg relapse during LTFU.
In patients who still have undetectable HBeAg after a 6-month treatment-free interval, presence of
anti-HBe seems thus of less importance for the long-term sustainability of HBeAg negativity.
Studies comparing the outcome of responders to standard IFN versus non-responders found that
patients who cleared HBeAg had better survival free of hepatic complications, in particular pa-
tients with cirrhosis.13,14,24,25 In our study, the limited number of hepatic complications precluded
valid analysis for these endpoints. Previous studies in IFN treated patients from our group and
others that demonstrated improved long-term outcome in responders compared to non-respond-
ers typically had a longer duration of follow-up after therapy than our study.13,15
Delayed clearance of HBsAg has been observed in 12-65% of patients within 5 years after IFN-
induced HBeAg loss, although this seems to occur particularly in non-Asian populations.12,14,24-29 In
HBeAg negative patients treated with PEG-IFN alpha-2a, 6% of responders had loss of HBsAg
and appearance of anti-HBs at 2 years post-treatment.30 In these HBeAg negative patients, loss of
HBsAg occurred significantly more often in genotype A infected patients (28%) than those with
genotype D (0%; p=0.05).30 In our study, HBsAg loss was observed in 11% of the overall group and
in 30% of the initial HBeAg responders. High HBsAg loss rates were observed in genotype A
infected patients (28%), while HBsAg loss hardly occurred in those with genotype B, C or D infec-
tion (3%). PEG-IFN should therefore particularly be considered as first line therapy in genotype A
infected HBeAg positive patients, while for the other genotypes the potential risks and benefits
should be more carefully balanced.
A caveat of the current study was the fact that patients had their additional LTFU visit at different
time points after the initial study. The observed response rates at long-term follow-up may there-
fore overestimate or underestimate actual response rates. However, Kaplan-Meier estimates of 4
year cumulative HBeAg and HBsAg response seem comparable to observed response rates at
LTFU. Furthermore, in retrospect a relatively low dose of PEG-IFN alpha-2b was may have been
used in this study (100μg/week starting dose, reduced to 50μg/week after 32 weeks).
Adding lamivudine to PEG-IFN therapy has been reported to result in higher response rates at the
end of therapy, but not after treatment discontinuation.7,8 We also found that HBeAg loss occurred
equally in patients treated with PEG-IFN alone and those with added lamivudine, However, pa-
tients in the combination therapy group were more likely to have undetectable HBV DNA compared
to patients treated with PEG-IFN alone at LTFU. Adding lamivudine to PEG-IFN therapy might thus
be beneficial in the long-term. Future studies with long duration of follow-up after treatment with
PEG-IFN and newer (more potent) nucleos(t)ide analogues may clarify this observation. Since
lamivudine was discontinued after one year of therapy both in this study as in other large random-
ized studies investigating the effects of added lamivudine to PEG-IFN therapy,7,8,30 it is unknown
whether continuing a nucleos(t)ide analogue after PEG-IFN may be beneficial in the long-term.
We conclude that HBeAg response to PEG-IFN alpha-2b alone or in combination with lamivudine
is durable in the majority of patients and is associated with an increase in HBsAg loss. This study
123Long-term follow-up of PEG-IFN alpha-2b in HBeAg positive chronic hepatitis B
further emphasizes the importance of HBV genotype in PEG-IFN therapy, also on the long-term,
with clearance of HBsAg in more than a quarter of genotype A infected patients but rarely in those
with other genotypes.
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ABSTRACT
Background and aim
Treatment with peginterferon alpha-2b results in HBeAg loss in 36% of patients at 6 months post-
treatment. The aim of this study is to determine whether long-term response to peginterferon
(PEG-IFN) is dependent on the timing of HBeAg loss.
Methods
Ninety-one patients treated with PEG-IFN alpha-2b alone (100 μg/week) and 81 patients treated
with PEG-IFN alpha-2b and lamivudine (100 mg/day) for 52 weeks were enrolled in this study.
Patients were initially followed at 4 week intervals and had one additional long-term follow-up (LTFU)
visit (mean 3.03 ± 0.77 years after 26 weeks post-treatment).
Results
Of 172 patients included, 78 patients (46%) did not have loss of HBeAg, 47 (27%) lost HBeAg
within 32 weeks and 47 patients (27%) had loss of HBeAg after week 32. At LTFU, patients with
HBeAg loss <=32 weeks significantly more often had HBV DNA <400 copies/ml than those who
lost HBeAg after week 32 (47% vs. 21%, p=0.009). HBsAg negativity was also observed significantly
more often in patients with early HBeAg loss (36% vs. 4%, p<0.001). Early HBeAg loss tended to
occur more often in patients treated with PEG-IFN and lamivudine combination therapy than in
those treated with PEG-IFN alone (35% vs. 21%, p=0.10), as well as HBsAg loss (15% vs. 8%;
p=0.14).
Conclusion
Early PEG-IFN induced HBeAg loss results in a high likelihood of HBsAg loss and may be associated
with more profound viral suppression during the first 32 weeks of therapy in patients with added
lamivudine.
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INTRODUCTION
Worldwide more than 2 billion people have evidence of infection with hepatitis B virus (HBV) and
chronic hepatitis B affects about 400 million people.1, 2 It is estimated that between 500,000 and
one million people die annually due to HBV associated liver disease, largely because of cirrhosis
and hepatocellular carcinoma. Despite the availability of safe and effective vaccines for more than
two decades, HBV infection still is a global health problem.3
Treatment of chronic HBV infection has considerably improved over the last decade, with currently
seven antiviral drugs available.4 Treatment strategies can be divided into those providing sustained
off-treatment response after a finite course of therapy (immunomodulatory drugs) and those aiming
at maintaining on-treatment remission (direct antivirals). The effects of interferon (IFN) are
predominantly immunomodulatory, but it also has limited direct antiviral effect on HBV. Nucleos(t)ide
analogues such as lamivudine, adefovir, entecavir, telbivudine and tenofovir on the other hand are
potent inhibitors of HBV replication. IFN induced HBeAg loss is sustained in the majority of
responders due to the drug’s immunomodulatory effects.5-7
Treatment with standard IFN or pegylated IFN (PEG-IFN) results in loss of HBeAg in about one-
third of patients.8-10 Twenty-nine percent of patients treated with PEG-IFN alpha-2b lost HBeAg by
the end of an one-year treatment course, increasing to 36% at 6 months post-treatment.8 Sustained
HBeAg loss and HBsAg loss were observed in 81% and 30% of these responders, respectively,
after three years of additional follow-up. HBsAg loss was observed significantly more often in
genotype A infected responders compared to those with genotype-non-A infection (58% vs. 6%,
p<0.001).11 Other factors associated with an increased likelihood of response to PEG-IFN therapy
include low initial viral load, high ALT concentrations, absence of previous interferon therapy and
low HBeAg level.8, 12 The aim of this study is to determine whether long-term virological and
biochemical outcome is dependent on the timing of HBeAg loss in HBeAg positive patients treated
with PEG-IFN alpha-2b.
PATIENTS AND METHODS
Participants and study design
One-hundred-seventy-two of 266 patients (65%) enrolled in the HBV99-01 study were enrolled in
this LTFU study.8, 11 The majority of the 94 patients who were not enrolled in the LTFU study did not
participate because the local study site did, for variable reasons, not take part in this study (n=52,
55%) or because the patient was lost to follow-up (n=23, 24%). Informed consent was obtained
from each participant and the study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki as reflected in approval by the human research committee of all participating
centers. Patients were treated with PEG-IFN alpha-2b 100μg weekly (PegIntron, Schering-Plough,
Kenilworth, NJ, USA) in combination with placebo or lamivudine 100mg daily (Zeffix, GlaxoSmithKline,
Greenford, UK) for 52 weeks. After 32 weeks, PEG-IFN a-2b dosage was lowered to 50μg per
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week in order to prevent side effects and early treatment discontinuation.
The inclusion and exclusion criteria were reported previously.8, 11 In short, patients were eligible if
they had been HBsAg positive for more than 6 months, were HBeAg positive on two occasions
within 8 weeks prior to randomisation, had elevated serum ALT of at least twice the upper limit of
normal (ULN), and had serum HBV DNA >1.0 x 105 copies/ml. Major exclusion criteria were: antiviral
therapy within 6 months prior to randomisation, viral coinfections, pre-existent cytopenia or
decompensated liver disease.
Patients were followed at four week intervals during the initial study. For the LTFU study, patients
were re-evaluated by one additional visit at the local participating center. The local investigator
assessed clinical signs and symptoms of liver disease, complications of liver disease
(hepatocellular carcinoma, ascites, variceal bleeding, encephalopathy or jaundice), liver
transplantation, mortality and administration of (other) antiviral therapy after the initial study according
to predefined criteria on standardized questionnaires. If the patient had been retreated, local baseline
data prior to retreatment were also collected. Blood samples were obtained for hematology,
biochemistry and virology testing. Follow-up time was calculated from the end of the initial study
(week 78) until the visit for the LTFU study. Patients were re-evaluated at a mean interval of 3.0 ±
0.8 years (range 1.6 – 5.0) after the end of the initial study (week 78). Patients who were retreated
after the initial study were considered non-responders for all categorical outcome measures, except
for HBeAg response for which the local test result at the time of restarting antiviral therapy was
taken into account. Patients were classified as non-responders if they remained HBeAg positive
throughout follow-up. Responders were those with HBeAg loss and were subdivided depending
on timing of first evidence of HBeAg loss; within the first 32 weeks of therapy or after week 32. ALT
flares were defined as serum ALT of at least two times the nadir value and more than 10 x ULN.13
Laboratory testing
During therapy and post treatment follow-up of the initial study, patients were monitored monthly
by routine physical examination, as well as biochemical and hematological assessments. ALT
was assessed locally in accordance with standardized procedures and therefore expressed as
times upper limits of normal (ULN). Serology and quantification of serum HBV DNA was performed
at Erasmus MC in Rotterdam by staff unaware of treatment allocation and outcome at the end of
treatment (EOT) and end of the initial study (EOS). For the initial study, serum HBV DNA levels
were measured monthly using an in-house developed Taqman polymerase chain reaction (PCR)
assay (lower limit of detection 373 copies/ml) based on the EuroHep standard.14 Quantification of
serum HBV DNA levels for the LTFU study was performed with the Cobas TaqMan HBV assay
(Roche Molecular Systems, Branchburg, NJ, USA), with a dynamic range of quantification of 30 -
1.1 x 108 IU/ml (174 – 6.4 x 108 copies/ml). Since serum HBV DNA was expressed in copies/ml in
the initial study, all HBV DNA measurements for the LTFU study were recalculated to copies/ml (1
IU/ml = 5.8 copies/ml). The two HBV DNA quantification assays were comparable in the dynamic
range.11 Testing for markers of HBV infection (HBeAg, anti-HBe, HBsAg and anti-HBs) was
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performed with the AxSYM radioimmunoassay (Abbott, Abbott Park, IL, USA) at week 0, 32, 52 and
78, and with the commercially available Enzyme-Linked Immuno Sorbent Assays (ELISA) of DiaSorin
(DiaSorin S.p.A., Saluggia, Italy) at LTFU. HBV genotype analysis was performed by INNO-LiPA
assay (Innogenetics, Gent, Belgium). All initial responders who had serum HBV DNA >5.0 x 103
copies/ml after HBeAg loss were tested for the presence of core promoter (A1762T/G1764A) and
precore mutations (G1896A) by sequence analysis. Histological scoring was performed according
to the modified histological activity index (HAI) by one experienced pathologist, who was unaware
of the chronological order of biopsies, treatment allocation and outcome measures.15
Statistical analysis
For the comparison of frequencies between or within groups, X2 test and Fisher’s Exact test were
used where appropriate. Student’s t-test and Mann-Whitney test were used to compare means
between groups. The positive predictive value (% response if the test is positive), negative predictive
value (% non-response if test is negative), sensitivity (% responders identified by test) and specificity
(% non-responders identified by test) of various patient characteristics and outcome measures
for long-term HBsAg negativity was determined. The area under the receiver-operating characteristic
curve (AUC) was used to assess the predictive value of these factors. Cox regression analysis
was used for the identification of factors influencing HBsAg negativity at LTFU. Patients with missing
data and patients who were retreated were considered non-responders. A p-value of 0.05 was
considered to be statistically significant (all 2-sided). Statistical analysis was performed with the
SPSS14.0 program (SPSS Inc., Chicago, IL).
RESULTS
Patients and baseline characteristics
At LTFU, HBeAg and HBsAg negativity were observed in 63 (37%) and 19 (11%) of 172 patients.
HBeAg loss was observed in 1%, 2%, 11% and 27% of patients after 4, 12, 24 and 32 weeks of
therapy respectively. For HBeAg seroconversion these rates were 1%, 2%, 9% and 17%,
respectively. Patients were subdivided by timing of HBeAg loss; 78 (46%) did not have loss of
HBeAg at any time point, 47 (27%) had loss of HBeAg within 32 weeks and 47 patients (27%) had
loss of HBeAg after 32 weeks of therapy. Why the patients were subdivided like this will be discussed
later on. Baseline characteristics of these patient groups are shown in table 1. Twenty-nine patients
(17%) had HBeAg seroconversion within 32 weeks and 44 patients (26%) had HBeAg
seroconversion after week 32.
Patients with loss of HBeAg within 32 weeks were older, more often acquired HBV infection via
sexual or parenteral transmission, had higher baseline ALT levels and more often harboured genotype
A than patients who lost HBeAg after week 32 (p<0.05). Duration of follow-up was comparable in
the three patient groups (3.09 ± 0.77, 3.02 ± 0.84 and 2.95 ± 0.70 years for groups I, II and III,
respectively; p>0.32). Retreatment with other antiviral drugs was needed in 26% of patients with
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HBeAg loss within 32 weeks, in 30% of those with HBeAg loss after week 32 and in 71% of
patients without HBeAg loss (p<0.001). Lamivudine resistance was observed in 9 of 81 (11%) of
patients in the combination therapy group (with a rate of 4%, 9% and 19% among patients with
HBeAg loss <=32 weeks, HBeAg loss >32 weeks and no HBeAg loss, respectively [p=0.15])
HBeAg
The proportion of patients in each of the patient groups that was negative for serum HBeAg at
various time points is shown in figure 1A. At LTFU, serum HBeAg was still undetectable in 36 of 47
patients (77%) who were HBeAg negative within 32 weeks compared to 27 of 47 patients (57%)
who lost HBeAg after week 32 (p=0.05). At LTFU, HBeAg negativity with seroconversion to anti-
HBe was observed in 43% and 30% of patients with HBeAg loss within or after 32 weeks of
therapy, respectively (p=0.20). HBeAg seroconversion was sustained in 16 of 29 patients (55%)
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who seroconverted within 32 weeks compared to 18 of 44 patients (41%) with HBeAg
seroconversion after week 32 (p=0.23). Early HBeAg loss tended to occur more often in patients
treated with PEG-IFN and lamivudine combination therapy than in those treated with PEG-IFN
alone (35% vs. 21%, p=0.10), while HBeAg loss after week 32 occurred equally in both treatment
groups (27% vs. 28%, respectively). Among patients who were HBeAg negative at 26 weeks post-
treatment, core promoter and precore mutations were observed equally among patients who lost
HBeAg within 32 weeks compared to those with HBeAg loss after week 32 (31% vs. 32%, p=0.89).
HBsAg
In figure 1B, the proportion of patients with loss of HBsAg at various time points is shown for the
three patient groups. At LTFU, HBsAg negativity was observed in 17 of 47 (36%) patients with loss
of HBeAg within 32 weeks compared to 2 of 47 (4%) patients who lost HBeAg after week 32 and
none of 78 (0%) without HBeAg loss (p<0.001). Twelve of 19 patients (63%) with HBsAg loss at
LTFU also developed anti-HBs and 18 of them (95%) had undetectable HBV DNA. There was no
significant difference in HBsAg loss rate between patients with HBeAg loss after week 32 and
those who remained HBeAg positive (p=0.14). HBsAg loss was observed in 12 of 29 patients
(41%) and 6 of 44 patients (14%) with HBeAg seroconversion within or after 32 weeks, respec-
tively (p=0.007). Anti-HBs was detectable in 12 of 19 patients (63%) with HBsAg loss. All but one of
the HBsAg negative patients had HBV DNA <400 copies/ml at LTFU (the remaining patient had
serum HBV DNA of 1.3 x 103 copies/ml). At LTFU, HBsAg loss was observed in 15% of patients
treated with PEG-IFN and lamivudine compared to 8% of those treated with PEG-IFN alone (p=0.14).
In both treatment groups virtually all patients who were HBsAg negative at LTFU lost HBeAg within
32 weeks of therapy (92% and 86% of patients with HBsAg loss receiving combination therapy or
monotherapy, respectively).
HBV DNA
Figure 1C shows the proportion of patients with HBV DNA <400 copies/ml for the three patient
groups at week 32, 52 and 78, and at LTFU. At all time points, patients with loss of HBeAg within 32
weeks significantly more often had HBV DNA <400 copies/ml compared to patients with loss of
HBeAg after week 32 (p<0.03). At LTFU, HBV DNA <10,000 copies was observed in 5% of patients
without HBeAg loss, 55% of patients with HBeAg loss within 32 weeks and 38% of patients with
HBeAg loss after week 32 (p<0.005 for HBeAg loss within or after week 32 vs. no HBeAg loss).
Mean HBV DNA levels over time in the three patient groups are shown in figure 2. At the start of
treatment, mean serum HBV DNA was comparable in the three patient groups (see table 1). While
mean serum HBV DNA was significantly lower in patients with HBeAg loss within 32 weeks than in
those with loss of HBeAg after week 32 during therapy (3.14 ± 0.96 vs. 5.82 ± 2.41 and 3.11 ± 1.03
vs. 5.82 ± 2.41 log10 copies/ml at week 32 and 52, respectively; p<0.001), the difference was no
longer observed at week 78 (5.07 ± 2.65 vs. 6.07 ± 2.33 log10 copies/ml; p=0.08).
In both treatment groups decline in HBV DNA at week 32 was significantly more profound in patients
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Figure 2: Mean HBV DNA levels over time depending on time of HBeAg loss.
Baseline serum HBV DNA was comparable in patients without HBeAg loss (group I), patients with HBeAg
loss within 32 weeks of therapy (group II) and in patients with HBeAg loss after 32 weeks of therapy (group
III). Patients in group II had significantly lower HBV DNA than patients in group I at week 32, 52 and 78
(p<0.001). Patients in group III had significantly lower HBV DNA than patients in group I at week 52 and 78
only (p<0.001). At week 32 and 52, patient in group II had significantly lower HBV DNA than those in group III
(p<0.001), while mean HBV DNA tended to different in these patient groups at week 78 (p=0.08).
who lost HBeAg within 32 weeks than in those with delayed HBeAg loss, although the difference
was most striking in patients receiving PEG-IFN alone (-6.36 vs. -5.02 log10 and -4.95 vs. -1.12
log10 copies/ml in patients receiving combination therapy or monotherapy, respectively; p<0.001).
ALT
The proportion of patients with normal ALT at week 32, 52 and 78, and at LTFU is shown in figure
1D for the three patients groups. During therapy (week 32 and 52), normal ALT was observed
equally in patients with HBeAg loss (within or after 32 weeks) and in those who did not have loss of
HBeAg. At 26 weeks post-treatment (week 78) and at LTFU, normal ALT was observed significantly
more often in patients with loss of HBeAg within 32 weeks or after week 32 compared to those
without HBeAg loss (p<0.02). However, there was no difference in the proportion of patients with
normal ALT in patients with loss of HBeAg within 32 weeks and those with HBeAg loss after week
32 at any time point. The occurrence of ALT flares was not associated with early HBeAg loss
(p=0.63).
Predictors of HBsAg negativity at LTFU
On Cox regression analysis older age, HBV genotype A infection, HBeAg negativity at week 4 and
week 32, and HBV DNA clearance at week 24 and week 32 were found to be predictors of HBsAg
negativity at LTFU (table 2). The occurrence of ALT flares did not predict HBsAg loss at LTFU
(p=0.15). When correcting for age, HBV genotype and week 32 HBV DNA level by multivariate Cox
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regression analysis, HBeAg at week 32 was found to independently predict HBsAg loss (HR 13.15,
95%-CI 1.32-131.09).
We investigated the predictive value of HBV genotype and of various outcome measures at week
 32 for achieving HBsAg negativity at LTFU (table 3). HBeAg negativity at week 32 was found to be
the best predictor of HBsAg negativity at LTFU (AUC 0.85, 95%-CI 0.76 - 0.94), with a sensitivity,
specificity, positive predictive value and negative predictive value of 89%, 80%, 36% and 98%,
respectively. As indicated by the negative predictive value of 98%, virtually all patients who were
HBeAg positive at week 32 remained HBsAg positive throughout follow-up.
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DISCUSSION
In this long-term prospective study of PEG-IFN alpha-2b alone or in combination with lamivudine in
HBeAg positive patients we showed that early loss of HBeAg is associated with a higher rate of
undetectable HBV DNA by PCR assay and a higher likelihood of HBsAg loss compared to HBeAg
loss later during therapy or after therapy. About one-third of patients who lost HBeAg within 32
weeks of therapy was negative for serum HBsAg at LTFU, thereby having a 9-fold higher chance
of HBsAg loss compared to patients with HBeAg loss after week 32. Prediction of long-term outcome
based on either HBeAg status or HBV DNA level at an earlier time point was not possible.This is
the first study which shows that early HBeAg loss during PEG-IFN therapy is associated with an
increased likelihood of HBsAg loss. HBV genotype A was common among patients with early
HBeAg loss, but accounted for only 60% of the cases with early response. A recent study by Hou
et al. also showed that genotype A infected patients were more likely to clear HBeAg from serum
early during IFN therapy than patients harbouring other genotypes.16 Other baseline factors
associated with early HBeAg loss in our study were high ALT levels and older age. High ALT is a
well known predictor of response to PEG-IFN.8, 12  Age above 50 years has been described to be
associated with HBsAg loss in lamivudine-treated patients.17 Results of a study investigating outcome
after PEG-IFN alpha-2a in HBeAg positive patients showed that patients with loss of HBeAg within
24 weeks of therapy were more likely to have serum HBV DNA <10,000 copies/ml at 24 weeks
post-treatment compared to patients with loss of HBeAg after week 24 (79% vs. 59%).18 Interpretation
of this finding was hampered by the fact that patients with HBeAg loss after week 24 had a relatively
shorter duration of follow-up after HBeAg loss. Our study, which has a longer duration of follow-up
compared to this previous study, shows that also in the long-term, patients with early HBeAg loss
still have a higher chance of HBeAg negativity, undetectable HBV DNA (<400 copies/ml) and HBsAg
negativity than those with delayed HBeAg loss. Obviously, duration of HBeAg negativity was
somewhat shorter for patients with HBeAg loss after week 32 as compared to those with early
HBeAg loss in our study as well. However, since the difference in response rates between patients
with HBeAg loss after week 32 and those with early HBeAg loss remained stable, these differences
will most likely prevail if duration of follow-up after first evidence of HBeAg loss was comparable. In
addition, in retrospect, a relatively low dosage of PEG-IFN alpha-2b may have been used in our
study (100 ìg/wk starting dosage, reduced to 50 ìg/wk after 32 weeks).HBeAg loss was more
durable in patients who lost HBeAg within 32 weeks compared to those with HBeAg loss after
week 32. Among patients with HBeAg loss after week 32, only 57% were still HBeAg negative at
LTFU. Immune control over the virus may therefore be more profound in patients with early HBeAg
loss, of whom 77% was still HBeAg negative at LTFU. Interestingly, the incidence of mutations in
the core promoter or precore region in early responders who remained HBeAg negative was
comparable to that observed in patients with HBeAg loss after week 32. Patients with added
lamivudine tended to have higher rates of early HBeAg loss and HBsAg loss compared to those
treated with PEG-IFN alone. Decline in HBV DNA was most profound in these patients. In previous
studies of PEG-IFN in HBeAg positive chronic hepatitis B with a shorter duration of follow-up,
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these benefits of added lamivudine were not observed.8, 9, 19 In nucleoside analogue treated HBeAg
positive patients, low serum HBV DNA after six months of therapy was also associated with higher
rates of long-term virological response and a lower risk of antiviral resistance.20 Patients who had
HBV DNA below 300 copies/ml after 24 weeks of telbivudine or lamivudine therapy had a significantly
higher likelihood of achieving HBeAg seroconversion, normalization of ALT and undetectable HBV
DNA at year 2 of therapy compared to patients with higher HBV DNA levels. In HBeAg positive
patients treated with standard IFN, a profound decline in serum HBV DNA during the first weeks of
therapy was associated with a higher likelihood of HBeAg loss.21 We also found that low HBV DNA
at week 32 of PEG-IFN therapy was strongly associated with long-term HBsAg negativity on Cox
regression analysis. The magnitude of early HBV suppression by antiviral drugs is thus associated
with long-term virological response in chronic hepatitis B infected patients treated with either IFN-
based therapy or nucleos(t)ide analogues. A recent study in PEG-IFN treated patients showed that
decline in HBeAg level more accurately predicted HBeAg loss than decline in HBV DNA.22 However,
so far quantitative HBeAg measurement is not routinely available in many institutions.
We found that early HBeAg loss independently predicted long-term HBsAg negativity. The overall
test performance for the prediction of HBsAg negativity was best for HBeAg loss at week 32
compared to baseline factors and other outcome measures at week 32, although negative predictive
value was good for these other factors as well. With a negative predictive value of 98%, testing for
HBeAg at week 32 is particularly useful to identify those who will most likely not achieve HBsAg
negativity after a course of PEG-IFN therapy. The rate of HBsAg negativity may still increase with
longer duration of follow-up, as has been previously observed in studies of standard IFN in chronic
HBV.5, 6, 23-28 Delayed clearance of HBsAg has been observed in up to 65% of patients within 5
years after IFN-induced HBeAg loss. In conclusion, early HBeAg loss during PEG-IFN therapy was
associated with higher rates of sustained HBeAg and HBV DNA negativity in the long-term. We
found that HBsAg loss occurred in about one-third of patients with early HBeAg los, virtually all
patients who lost HBeAg after week 32 remained HBsAg positive. These findings are of interest for
the therapeutic management of HBV infection, since they may contribute to enhance predictive
values of early outcome measures during PEG-IFN therapy in chronic hepatitis B. In addition, we
showed that more profound viral suppression during the first 32 weeks of therapy in patients with
added lamivudine may have led to higher rates of early HBeAg loss and HBsAg loss compared to
treatment with PEG-IFN alone. These findings may reopen the perspective of combination therapy
of PEG-IFN and other nucleos(t)ide analogues in chronic hepatitis B.
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ABSTRACT
Background and aims
It is unknown whether peginterferon (PEG-IFN) and lamivudine combination therapy is superior to
PEG-IFN monotherapy in reducing intrahepatic expression of hepatitis B virus core and surface
antigen (HBcAg and HBsAg), and how this correlates to regular treatment endpoints.
Methods
Patients who had paired liver biopsies taken before and directly after 52 week of treatment with
PEG-IFN alpha-2b alone (n=51) or its combination with lamivudine (n=48) were studied. The degree
of expression of HBcAg and HBsAg in hepatocytes was expressed as a proportion of the
immunolabelled cells.
Results
In patients receiving PEG-IFN plus lamivudine there was a significant reduction in the proportion of
HBcAg and HBsAg positive hepatocytes after therapy compared to baseline (p<0.001), but not in
those treated with PEG-IFN alone (p>0.09). After therapy intrahepatic HBcAg and HBsAg were
undetectable in 67% and 75%, and 14% and 29% of patients in the monotherapy and combination
therapy group, respectively (p=0.67 and p=0.16). Baseline and post-treatment HBsAg expression
significantly correlated with serum HBV DNA level (Spearman’s rho 0.38 and 0.49, respectively;
p<0.001). Absence of HBsAg expression in hepatocytes after therapy was strongly associated
with both HBeAg and HBsAg loss. HBeAg and HBsAg loss occurred in 76% and 29% of patients
who did not have intrahepatic HBsAg expression after therapy.
Conclusion
PEG-IFN and lamivudine combination therapy results in a significant decline in intrahepatic HBcAg
and HBsAg expression. Clearance of HBsAg from the liver on immunohistochemical staining was
strongly associated with loss of HBeAg and HBsAg from serum.
145HBV immunohistochemistry in patients treated with PEG-IFN
INTRODUCTION
Immunodetection of HBcAg and HBsAg in hepatocytes may provide helpful information about the
replicative status of the hepatitis B virus (HBV) and is usually performed as part of a histopathological
diagnosis of patients with chronic hepatitis B. The presence of hepatitis B core antigen (HBcAg) in
the liver of chronic HBV infected patients detected by immunohistochemical techniques is generally
assumed to indicate high viral replication.1-4 Liver HBcAg can be present in the hepatocyte nuclei
and/or cytoplasm. Predominant cytoplasmic localisation of HBcAg has been associated with an
active and severe ongoing hepatitis.1 Pure nuclear HBcAg expression, almost always associated
with positive serum HBeAg, on the other hand was rarely associated with chronic active hepatitis.5
In addition, the degree of expression of HBcAg in hepatocyte nuclei correlated with the level of viral
replication.6
HBsAg can be detected by immunohistochemistry in liver tissue of both asymptomatic HBV carriers
and in persons with chronic active hepatitis B.7-9 Three patterns of staining, namely, membranous,
submembranous, and cytoplasmic, have been described.10 Expression of HBsAg on the membrane
of hepatocytes has been associated with high serum HBV DNA,11 while cytoplasmic expression
was mainly seen in patients with inactive disease.7
The aim of this study was to investigate the expression of HBcAg and HBsAg in hepatocytes of
HBeAg-positive chronic hepatitis B patients before and after treatment with peginterferon alpha-2b
(PEG-IFN alpha-2b) alone or its combination with lamivudine.
METHODS
Patients and study design
Ninety-nine patients were included in this study, all patients were HBeAg positive and had ALT
levels of at least two times the upper limit of normal (ULN).12 Serum HBV DNA was >1.0 x 105
copies/ml. Fifty-one patients were treated with PEG-IFN alpha-2b alone (100 μg/week) and 48
patients were treated with PEG-IFN alpha-2b and lamivudine (100 mg/day) combination therapy,
all for 52 weeks. Post-treatment follow-up lasted 26 weeks. Major exclusion criteria were antiviral
therapy within 6 months prior to randomization, serum antibodies against hepatitis C virus (HCV),
hepatitis delta virus (HDV) or human immunodeficiency virus (HIV), pre-existent leucopenia (white
blood cell count <3,000/mm3, neutrophil count <1,800/mm3) or thrombocytopenia (platelets
<100,000/mm3), or decompensated liver disease.
Laboratory testing
Patients were monitored monthly by routine physical examination, as well as biochemical and
hematological assessments. ALT was assessed locally in accordance with standardized procedures
and therefore expressed as times the ULN. Serum HBV DNA levels were measured monthly using
an in-house developed Taqman PCR assay (lower limit of detection 373 copies/ml) based on the
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Eurohep standard.13 HBeAg and HBsAg (AxSYM, Abbott, Abbott Park, IL, USA) were assessed at
week 0, 32, 52 (end of treatment) and week 78 (end of follow-up). HBV genotype and YMDD
mutation analysis were performed by INNO-LiPA assay (Innogenetics, Gent, Belgium).
Liver histology
Liver biopsies were taken in all patients before the start of therapy and directly after therapy (week
52). If a liver biopsy was taken less than 1 year before the start of therapy, no new pre-treatment
biopsy was required. All biopsies were blinded and scored by one experienced liver pathologist.
Necroinflammation and fibrosis were scored according to the Ishak system.14 Expression of HBcAg
and HBsAg in hepatocytes was studied by the avidin-biotin immunoperoxidase method. The degree
of expression of HBcAg and HBsAg in the hepatocyte nucleus or cytoplasm was expressed as a
proportion of the immunolabelled cells, without consideration for the staining intensity of individual
hepatocytes. The results were scored on a scale of 0 to 5, with values corresponding to positivity
rates of 0%, 1% to 10%, 11% to 25%, 26% to 50%, 51 to 75% and >75%, respectively.6 The
patterns of the intracellular distribution of HBcAg were classified as follows: pure nuclear, pure
cytoplasmic and mixed nuclear and cytoplasmic expression. Three patterns of HBsAg staining
were identified: pure cytoplasmic, pure (peri)membranous and mixed cytoplasmic and
(peri)membranous expression. Negative control experiments were carried out by substituting the
primary antibody with phosphate-buffered saline.
Statistical analysis
Differences in degrees of expression of HBcAg and HBsAg in hepatocytes before and after therapy
was analyzed by the Wilcoxon rank sum test. The difference in the pattern of HBsAg and HBsAg
expression before and after therapy was analyzed by the marginal homogeneity test. Correlation
of levels of HBV DNA and ALT in sera with the degrees of expression of HBcAg and HBsAg in
hepatocytes was assessed by Spearman rank correlation. A p-value of 0.05 was considered
statistically significant (all two-sided).
RESULTS
Of 99 patients included in this study, 51 were treated with PEG-IFN alone and 48 with PEG-IFN
and lamivudine combination therapy. Baseline characteristics of the two treatment groups are
shown in table 1. The groups were comparable, except for baseline fibrosis score, which was
higher in patients treated with PEG-IFN and lamivudine combination therapy.
HBcAg expression
The degree of HBcAg expression before and after PEG-IFN therapy is shown in figure 1a. There
was a significant reduction in the proportion of HBcAg positive hepatocytes after therapy compared
to baseline in the combination therapy group (p<0.001), but not in patients treated with PEG-IFN
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alone (p=0.19). There was no significant difference in the proportion of patients without HBcAg
expression in the liver between the two treatment groups after therapy (figure 1a). The pattern of
HBcAg expression did also not differ between the two treatment groups (table 2).
HBsAg expression
The degree of HBsAg expression before and after PEG-IFN therapy is shown in figure 1b. Overall,
there was a significant decline in intrahepatic HBsAg expression after therapy compared to baseline
(p<0.001 for the trend); absence of intrahepatic HBsAg expression was observed in 6% of patients
at baseline and 21% of patients after therapy. There was a significant increase in the proportion of
patients without intrahepatic HBsAg expression among those receiving combination therapy
(p<0.001). A similar trend was observed in patients receiving PEG-IFN alone (p=0.09). There were
no significant differences in the degree or pattern of HBsAg expression between the two treatment
groups before and after therapy (figure 1b and table 2).
HBV immunohistochemistry and serum HBV DNA
The mean decline in serum HBV DNA at week 52 was 2.2 ± 2.3 log10 copies/ml in patients treated
with PEG-IFN alone and 5.7 ± 2.4 log10 copies/ml in those with added lamivudine (p<0.001). At
baseline, the degree of HBsAg expression weakly correlated with serum HBV DNA level (Spearman’s
rho 0.38 for the entire group, p<0.001), but the degree of HBcAg expression did not (Spearman’s
rho 0.07 for the entire group, p=0.50). After therapy, there was a strong correlation between the
degree of HBsAg expression and serum HBV DNA levels in patients treated with combination of
PEG-IFN and lamivudine (Spearman’s rho 0.51, p<0.001), and to a lesser extend in patients
receiving PEG-IFN alone (Spearman’s rho 0.35, p=0.01). Post-treatment HBcAg expression did
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Figure 1: Degree of intrahepatic HBcAg and HBsAg expression at baseline and after therapy.
This figure shows the degree of HBcAg (A) and HBsAg (B) expression at baseline and after therapy in 51
patients treated with peginterferon alpha-2b (PEG-IFN) alone and 48 patients treated with PEG-IFN and
lamivudine combination therapy. There were no significant differences between the two treatment groups.
not significantly correlate with serum HBV DNA level (Spearman’s rho 0.13 for the monotherapy
group and ñ 0.26 for the combination therapy group, respectively, p=0.08 and p=0.36).
HBV immunohistochemistry and HBeAg loss
At the end of treatment HBeAg loss was observed in 28% of patients treated with PEG-IFN alone
and 50% of those with added lamivudine (p=0.02). There was a weak correlation between the
degree of HBcAg expression at baseline and HBeAg loss at week 52 among patients receiving
PEG-IFN monotherapy (Spearman's rho 0.25, p=0.05), but not in the combination therapy group
(Spearman's rho 0.11, p=0.47). Baseline degree of intrahepatic HBsAg expression did not correlate
with clearance of HBeAg from serum (Spearman's rho 0.16 for the entire group, p=0.11). Intrahepatic
HBsAg expression after therapy did correlate with clearance of HBeAg from serum (Spearman's
rho 0.36 for the entire group, p<0.001). HBeAg loss was observed in 16 of 21 patients (76%) who
cleared intrahepatic HBsAg and in 22 of 78 patients (28%) without clearance of HBsAg from the
liver (p<0.001).
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HBV immunohistochemistry and HBsAg loss
HBsAg loss was observed in 4% of patients treated with PEG-IFN alone and 8% of patients with
added lamivudine (p=0.43). Baseline degree of HBcAg and HBsAg expression in the liver did not
correlate with clearance of HBsAg from serum at week 52 (Spearman's  rho 0.03 and  ñ 0.15 for
the entire group, p=0.74 and p= 0.14). Intrahepatic HBsAg expression at week 52 significantly
correlated with loss of HBsAg from serum (Spearman's rho 0.40, p<0.001). HBsAg loss was
observed in 6 of 21 patients (29%) who cleared intrahepatic HBsAg and in none of 78 patients
(0%) without clearance of HBsAg from the liver (p<0.001).
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HBV genotypes and HBV immunohistochemistry
There were significant differences in immunohistochemical findings between the two most prevalent
HBV genotypes in our population (A and D). At baseline, HBcAg was expressed less extensively in
HBV genotype D than A infected patients (figure 2a). In contrast, HBV genotype D infected patients
had more HBsAg positive hepatocytes in the liver compared to patients with HBV genotype A
(figure 2b). HBcAg expression declined in HBV genotype A infected patients after therapy compared
to baseline (p=0.01 for the trend), but not in those with HBV genotype D (p=0.25 for the trend).
After therapy expression of HBcAg was significantly less extensive in HBV genotype D than A
infected patients (figure 2a). There was a decline in the proportion of HBsAg positive hepatocytes
among both HBV genotype A and D infected patients after therapy compared to baseline (p<0.04
for the trend). HBsAg expression was still less extensive expressed in HBV genotype A infected
patients compared to those with HBV genotype D after therapy (figure 2b), with absent intrahepatic
HBsAg in 42% and 0% of patients, respectively (p<0.001).
Figure 2: Degree of HBcAg and HBsAg expression at baseline and after therapy in genotype A and D
infected patients.
This figure shows the expression of HBcAg (A) and HBsAg (B) before and after treatment with peginterferon
alpha-2b alone or its combination with lamivudine in patients with HBV genotype A (n=31) of D (n=39).
Because of their limited numbers, patients with HBV genotypes B (n=9) and C (n=17) were not included.
HBcAg was more extensively expressed in hepatocytes of HBV genotype A than D infected patients (p<0.001
at baseline and after therapy), while for HBsAg expression it was the other way around (p<0.001 at baseline
and after therapy).
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DISCUSSION
This is first detailed report on HBV immunohistochemistry in patients treated with PEG-IFN. HBcAg
was not expressed in the hepatocytes of about half of these HBeAg-positive patients at baseline,
while the majority of patients had detectable HBsAg in the liver. Intrahepatic HBcAg expression
significantly declined after therapy compared to baseline in patients treated with PEG-IFN and
lamivudine therapy, but not in those receiving PEG-IFN monotherapy. Although not statistically
significant, clearance of intrahepatic HBsAg expression was observed twice as often in patients
receiving PEG-IFN and lamivudine combination therapy than in those receiving PEG-IFN alone.
This is important because clearance of HBsAg from the liver was strongly associated with loss of
HBeAg and HBsAg from serum.
A recent study in nucleoside analogue treated patients suggested that clearance of intrahepatic
HBsAg expression could not be achieved despite profound HBV DNA suppression.15 In 30 HBeAg
negative patients, serum HBV DNA and intrahepatic HBcAg expression significantly decreased
after five years of nucleoside analogue therapy compared to baseline. However, no significant
reduction in intrahepatic HBsAg expression was observed. Absence of HBsAg expression in
hepatocytes was observed in only three patients, all of whom cleared HBsAg from serum. Antiviral
agents that directly suppress the activity of the polymerase may thus not directly affect intrahepatic
HBsAg, while serum HBV DNA is generally promptly reduced.16 We found a higher rate of intrahepatic
HBsAg clearance in patients treated with PEG-IFN and lamivudine combination therapy than in
those treated with PEG-IFN alone (29% vs. 14%), although the difference was not significantly
different. We recently also found that patients treated with PEG-IFN and lamivudine seemed to
have a higher chance of HBsAg loss from serum compared to patients receiving PEG-IFN alone in
the long term.17 There may thus be an additive effect of lamivudine, although the immunomodulatory
effect of PEG-IFN seem crucial to achieve HBsAg clearance at all.
A shift of intracellular HBcAg from nucleus to cytoplasm has been described in the natural course
of HBeAg positive chronic hepatitis B. Chu et al. found that HBcAg was expressed at a relatively
higher level in the nucleus than in the cytoplasm during the immune tolerance phase, in which
there is little or no inflammatory activity in the liver. Pure nuclear HBcAg thus seems to reflect an
early phase of chronic HBV infection with little or mild host immune response.5 In the immune
clearance phase there was a shift to cytoplasmic HBcAg or negative HBcAg, which was frequently
accompanied by active hepatitis and a high HBeAg seroconversion rate.6 Hepatocytes with
cytoplasmic (or membranous) HBcAg have been stated to be possible targets for immune
hepatocytolysis,8 thereby resulting in more active hepatic inflammation. We found mixed nuclear
and cytoplasmic expression of HBcAg in the majority of patients at baseline, while most patients
were negative for HBcAg in the liver after PEG-IFN therapy. Pure nuclear expression was most
frequently observed in those positive for HBcAg after treatment with PEG-IFN. These findings thus
are in concordance with previous findings in similar patient groups.
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After HBeAg seroconversion, in the immune control phase, HBcAg is usually undetectable,5 although
loss of detectable HBcAg may also be associated with escape mutations occurring during periods
of cytotoxic T-cell clearance of virus-infected hepatocytes. The occurrence of these core gene
mutations is associated with the presence of precore stop-codon mutations, HBeAg-negative
chronic hepatitis B and active liver disease.18 We previously showed that precore and core-promoter
mutations occur more often in HBV genotype D than A infected patients treated with PEG-IFN.17
Our finding of lower HBcAg expression in hepatocytes of HBV genotype D infected patients is thus
in concordance with these findings. In addition, the greater reduction in intrahepatic HBsAg
expression in HBV genotype A than D infected patients is also in line with previously reported
serum HBsAg clearance rates in these HBV genotype.17, 19
In conclusion, we showed that PEG-IFN significantly reduced the proportion of hepatocytes stained
positive for HBcAg and HBsAg in patients with HBeAg positive chronic hepatitis B, although there
seemed to be a beneficial effect of added lamivudine in terms of intrahepatic HBsAg clearance.
Clearance of HBsAg from the liver is important because it was strongly associated with loss of
HBeAg and HBsAg from serum.
REFERENCES
Chu CM, Lin SM, Liaw YF. Hepatocyte expression of HBcAg and serum HBeAg in hepatitis B:
comparison of polyclonal and monoclonal antibodies during a trial of interferon. J Clin Pathol 1991;44:21-
24.
Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg,
viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of
hepatitis B virus. Hepatology 1983;3:656-662.
Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Jr., Lindsay K, Payne J, Dienstag JL, et al. A
randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment
of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295-301.
Ramakrishna B, Mukhopadhya A, Kurian G. Correlation of hepatocyte expression of hepatitis B viral
antigens with histological activity and viral titer in chronic hepatitis B virus infection: An
immunohistochemical study. J Gastroenterol Hepatol 2008.
Hsu HC, Su IJ, Lai MY, Chen DS, Chang MH, Chuang SM, Sung JL. Biologic and prognostic significance
of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus
infection. J Hepatol 1987;5:45-50.
Chu CM, Yeh CT, Chien RN, Sheen IS, Liaw YF. The degrees of hepatocyte nuclear but not cytoplasmic
expression of hepatitis B core antigen reflect the level of viral replication in chronic hepatitis B virus
infection. J Clin Microbiol 1997;35:102-105.
Ray MB, Desmet VJ, Bradburne AF, Desmyter J, Fevery J, De Groote J. Differential distribution of
hepatitis B surface antigen and hepatitis B core antigen in the liver of hepatitis B patients.
Gastroenterology 1976;71:462-469.
Chu CM, Liaw YF. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis
B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible
target for immune hepatocytolysis. Gastroenterology 1987;92:220-225.
Hsu HC, Lai MY, Su IJ, Chen DS, Chang MH, Yang PM, Wu CY, et al. Correlation of hepatocyte HBsAg
expression with virus replication and liver pathology. Hepatology 1988;8:749-754.
1.
2.
3.
4.
5.
6.
7.
8.
9.
153HBV immunohistochemistry in patients treated with PEG-IFN
Wee A, Yap I, Guan R. Hepatocyte hepatitis B surface antigen expression in chronic hepatitis B virus
carriers in Singapore: correlation with viral replication and liver pathology. J Gastroenterol Hepatol
1991;6:466-470.
Chu CM, Liaw YF. Membrane staining for hepatitis B surface antigen on hepatocytes: a sensitive and
specific marker of active viral replication in hepatitis B. J Clin Pathol 1995;48:470-473.
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, et al. Pegylated
interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a
randomised trial. Lancet 2005;365:123-129.
Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time
detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol
2000;38:2897-2901.
Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and
staging of chronic hepatitis. J Hepatol 1995;22:696-699.
Hadziyannis SJ, Costamena A, Katsikadelli E, Hadziyannis E. HBV surface and core protein expression
in the liver in chronic hepatitis B under long term antiviral therapy. Hepatology 2006;44:546A.
Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, et al. Serum hepatitis B surface
antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin
Gastroenterol Hepatol 2007;5:1462-1468.
Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, et al. Sustained HBeAg and
HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b.
Gastroenterology 2008;135:459-467.
Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004;24 Suppl 1:3-10.
Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with peg-
interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Am J Gastroenterol 2006;101:297-303.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.

Er
ik 
H.
C.
J. 
Bu
ste
r, 
Be
tti
na
 E
. H
an
se
n,
 T
in
g-
Ts
un
g 
Ch
an
g,
 R
ob
er
t G
.
 
G
ish
,
Ro
be
rt 
A.
 d
e 
M
an
, H
ar
ry
 L
.A
. J
an
ss
en
.
Su
bm
itt
ed
.
He
pa
tit
is
 B
 v
iru
s 
ge
no
ty
pe
 is
 a
n 
im
po
rta
n
t p
re
di
c-
to
r 
of
 s
us
ta
in
ed
 o
ff-
tre
at
m
en
t r
es
po
ns
e 
to
 b
ot
h
pe
gi
nt
er
fe
ro
n 
al
ph
a-
2b
 a
nd
 e
nt
ec
av
ir 
in
 H
Be
Ag
po
si
tiv
e 
ch
ro
ni
c 
he
pa
tit
is
 B
.
10
  156
Ch
ap
te
r 1
0
ABSTRACT
Background
Choice of initial antiviral therapy is becoming increasingly important in chronic hepatitis B. Knowledge
of the predictors of sustained off-treatment response may facilitate choice of therapy in individual
patients.
Methods
Grouped data from 354 patients treated with entecavir and 266 patients treated with peginterferon
alpha-2b (PEG-IFN alpha-2b) for one year were evaluated in this retrospective study. Sustained
virological response was defined as HBeAg loss and HBV DNA <7.0 x 105 copies/ml at the end of
treatment and at 6 months post-treatment. Predictors of response were identified by logistic
regression analysis.
Results
Sustained virological response was observed in 20% and 17% of patients treated with PEG-IFN
alpha-2b and entecavir, respectively. HBV genotype was a predictor of sustained virological response
to both PEG-IFN alpha-2b and entecavir (p=0.001 and p=0.03, respectively). In addition, baseline
necroinflammatory score predicted response to PEG-IFN alpha-2b (p=0.009), while baseline ALT
and HBV DNA were associated with sustained virological response after entecavir therapy (p=0.02
and p=0.02, respectively). Multivariate logistic regression analysis showed that PEG-IFN alpha-2b
resulted in higher rates of sustained virological response in genotype A and B infected patients
than entecavir. Response rates in genotype C infected patients were comparable, while in genotype
D infected patients sustained virological response rates were higher with entecavir.
Conclusion
HBV genotype is an important predictor of sustained response to both PEG-IFN alpha-2b and
entecavir. When aiming for sustained off-treatment response, determination of HBV genotype is
important in order to choose the optimal antiviral agent.
157HBV genotype is an important predictor of response to PEG-IFN and entecavir
INTRODUCTION
The introduction of nucleos(t)ide analogues in the 1990’s heralded a new era in the treatment of
chronic hepatitis B virus (HBV) infection. These drugs provided a safe, effective, and well-tolerated
alternative for interferon (IFN). Treatment with IFN-based therapy also significantly improved; the
addition of a polyethylenglycol (PEG) molecule to interferon allowed for a more convenient dosing
interval of once per week with response rates equal to or higher than those observed with standard
IFN.1 However, treatment with PEG-IFN is still associated with significant side-effects in a large
proportion of patients.2
A major advantage of IFN-based therapy in HBeAg positive chronic hepatitis B is the long-term
sustainability of response of about 80-90% among initial responders due to its immunomodulatory
effects.3-5 Antiviral potency of peginterferon (PEG-IFN) on the other hand is inferior to that of
nucleos(t)ide analogues. Nucleos(t)ide analogues directly target the HBV polymerase and treatment
with these drugs usually results in a rapid decline of serum HBV DNA levels. Although treatment
with nucleos(t)ide analogues profoundly suppresses serum HBV DNA levels and response can be
maintained over prolonged periods with ongoing therapy, response to lamivudine does not sustain
in a large proportion of patients after discontinuation of therapy. This implicates the necessity of
long-term, and maybe indefinite, nucleos(t)ide analogue treatment.6, 7
In a recent study of entecavir in HBeAg positive chronic hepatitis B 21% of patients, who had
HBeAg loss and HBV DNA <0.7MEq/ml at week 48, discontinued antiviral therapy. At 24 weeks
post-treatment, 82% of these patients had a sustained response.8, 9 A study investigating PEG-IFN
alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B showed
loss of HBeAg in 29% of patients at  the end of a one-year treatment course with sustained off-
treatment response in most patients.10
It is unknown whether the same baseline factors predict sustained response to both PEG-IFN and
entecavir. If differences would exist, this may help in choosing what treatment to start in an individual
patient.
METHODS
Patients
Data from 354 patients treated with entecavir in the BEHoLD AI463022 study,11 as well as data
from 266 patients treated with PEG-IFN alpha-2b (alone or in combination with lamivudine) in the
HBV99-01 study10 were evaluated in this retrospective analysis. The inclusion and exclusion criteria
for both studies have been described previously.10, 11 In short, patients were eligible for participating
in the BEHoLD study if they were 16 years or older, positive for hepatitis B surface antigen (HBsAg)
for at least 24 weeks, hepatitis B e antigen (HBeAg) positive, had HBV DNA >=3.0 MEq/ml (about
3.0 x 106 copies/ml]), serum ALT 1.3-10 x ULN and evidence of chronic hepatitis on a liver biopsy
specimen obtained within 52 weeks prior to randomization. Patients were eligible for participation
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in the HBV99-01 study if they were HBsAg positive for at least 6 months, hepatitis B e antigen
(HBeAg) positive on two occasions within 8 weeks prior to randomization, had elevated serum
ALT of >2-10 x the upper limit of normal (ULN) and had serum HBV DNA above 1.0 x 105 copies/ml.
Major exclusion criteria for both studies were: antiviral therapy with activity against HBV within 6
months prior to randomization, coinfection with hepatitis C virus (HCV), hepatitis delta virus (HDV)
or human immunodeficiency virus (HIV), or signs of decompensated liver disease.
Study design
A retrospective stratified analysis of grouped patient was performed. Sustained virological response
was defined as HBeAg loss and HBV DNA <7.0 x 105 copies/ml, according the definition of virological
response used in the BEHoLD study, both at the end of treatment and at six months post-treatment.
Data were stratified by HBV genotype in combination with one of the following baseline patient and
disease characteristics: ALT (<2 x ULN, 2-5 x ULN, >=5 x ULN), HBV DNA (<8 log10 copies/ml, 8-
9 log10 copies/ml, 9-10 log10 copies/ml, >=10 log10 copies/ml), previous antiviral treatment with
interferon alpha or lamivudine (yes, no), weight (<55 kg, 50-80 kg, >80 kg), BMI (<20 kg/m2, 20-25
kg/m2, 25-30 kg/m2, >=30 kg/m2), and necroinflammatory score (<3, 3-6, 6-9, >=9) and fibrosis
score (1-2, 3-4 or 5-6) according to the histological activity index.12
Statistics
Statistical analysis was performed using the SPSS 15.0 program (SPSS Inc. Chicago, IL).
Predictors of sustained virological response after treatment with PEG-IFN alpha-2b or entecavir
were investigated by univariate logistic regression analyses. A direct comparison of sustained
response rates to both therapies by Chi-square test could not be performed because the groups
were not comparable regarding baseline characteristics. Therefore, response rates after PEG-
IFN alpha-2b and entecavir therapy were compared by multivariate logistic regression analysis
using HBV genotype together with either baseline ALT, HBV DNA, previous antiviral treatment with
interferon alpha or lamivudine, weight, BMI, necroinflammatory score or fibrosis score, as well as
the type of antiviral therapy (PEG-IFN alpha-2b or entecavir) and the interactions between the
respective factors.
RESULTS
Baseline characteristics of patients treated with PEG-IFN alpha-2b and entecavir are shown in
table 1. Although inclusion and exclusion criteria of the two studies were quite similar, there were
significant differences in baseline weight, body mass index (BMI), ALT, HBV DNA, necroinflammatory
score, fibrosis score and HBV genotypes between the two patient groups. At the end of treatment,
virological response, defined as HBeAg loss and HBV DNA <7.0 x 105 copies/ml at the end of
treatment, was observed in 33.6% and 21.0% of patients treated with PEG-IFN alpha-2b and
entecavir, respectively. At 6 months post-treatment, these rates were 20.2% and 17.2%, respectively.
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Baseline ALT
Rates of sustained virological response with different baseline ALT levels are shown in figure 1 for
patients treated with PEG-IFN alpha-2b and entecavir separately. Among patients treated with
PEG-IFN alpha-2b, higher baseline ALT levels tended to be associated with a higher chance of
sustained virological response compared to lower baseline ALT levels (table 2, p=0.09). In entecavir
treated patients, sustained virological response rates significantly increased with increasing baseline
ALT levels (table 2, p=0.02).
Figure 1:
This figure shows the rate of
sustained virological response
(HBeAg loss and HBV DNA <7.0 x
105 copies/ml at six months post-
treatment) depending on baseline
ALT level in patients treated with
peginterferon alpha-2b or entecavir.
Baseline HBV DNA
Figure 2 shows the rates of sustained virological response after treatment with PEG-IFN alpha-2b
or entecavir depending on baseline serum HBV DNA. Although higher rates of sustained virological
response after PEG-IFN alpha-2b were observed with lower baseline HBV DNA levels, the
differences were not statistically significant (table 2, p=0.24). Lower HBV DNA levels were associated
with a higher chance of sustained virological response to entecavir (table 2, p=0.02).
Figure 2:
This figure shows the rate of
sustained virological response
(HBeAg loss and HBV DNA <7.0 x
105 copies/ml at six months post-
treatment) depending on baseline
HBV DNA level in patients treated
with peginterferon alpha-2b or
entecavir.
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HBV genotype
Sustained virological response rates were different across genotypes in both PEG-IFN alpha-2b
and entecavir treated patients (figure 3). Genotype A infected patients had a higher chance of
achieving sustained virological response after treatment with PEG-IFN alpha-2b compared to those
with genotype C or D infection (table 2, p=0.001). In entecavir treated patients, patients with genotype
B had a lower chance of achieving sustained virological response compared to those with genotype
A, C or D (table 2, p=0.03). All other comparisons between the different genotypes were not
statistically significant in both PEG-IFN alpha-2b and entecavir treated patients.
Baseline liver histology
Figure 4 shows the rate of sustained virological response depending on baseline necroinflammatory
score. In patients treated with PEG-IFN alpha-2b, high baseline necroinflammatory scores were
asociated with higher rates of sustained virological response compared to low necroinflammatory
activity (table 2, p=0.009). There was no statistically significant difference in sustained virological
response rates depending on baseline necroinflammation in entecavir treated patients (table 2,
Figure 3:
This figure shows the rate of
sustained virological response
(HBeAg loss and HBV DNA <7.0 x
105 copies/ml at six months post-
treatment) depending on HBV
genotype in patients treated with
peginterferon alpha-2b or entecavir.
Figure 4:
This figure shows the rate of
sustained virological response
(HBeAg loss and HBV DNA <7.0 x
105 copies/ml at six months post-
treatment) depending on baseline
necroinflammatory score in patients
treated with peginterferon alpha-2b
or entecavir.
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p=0.14). Liver fibrosis stage did not influence the chance of achieving sustained virological response
to either antiviral drug, with sustained virological response in 20% and 17%, 24% and 25%, and
21% and 24% of patients with Ishak fibrosis score 1-2, 3-4, and 5-6 treated with PEG-IFN alpha-2b
or entecavir, respectively (p=0.76 and 0.24 for PEG-IFN alpha-2b and entecavir, respectively).
Other baseline factors
Baseline weight, body mass index, and previous treatment with interferon or lamivudine were not
associated with sustained virological response rates in patients treated with PEG-IFN alpha-2b
(table 2, p>0.16), nor in those receiving entecavir (table 2, p>0.14).
Comparison of sustained virological response rates after PEG-IFN alpha-2b and entecavir
Multivariable logistic regression analyses including the type of antiviral therapy (PEG-IFN alpha-2b
or entecavir) and HBV genotype plus either ALT, HBV DNA or necroinflammation, and the interaction
between these factors showed that the only significant interaction term was that of HBV genotype
and antiviral therapy. Odds ratios for the chance of achieving sustained virological response after
treatment with PEG-IFN alpha-2b compared to entecavir in the different genotypes after correction
for ALT, HBV DNA or necroinflammation are shown in table 3.
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DISCUSSION
This is the first study investigating predictors of sustained response to both PEG-IFN and entecavir.
We found that HBV genotype was an important predictor of sustained virological response (HBeAg
loss and HBV DNA <7.0 x 105 copies/ml at 6 months post-treatment) to treatment with both drugs.
In addition, baseline necroinflammatory score predicted response to PEG-IFN alpha-2b and baseline
ALT and HBV DNA level were significantly associated with sustained virological response after
entecavir therapy.
The inclusion criteria of the two studies involved were quite similar. Still, the baseline characteristics
of the two patient groups were different. A direct comparison of response rates in two treatment
groups and in subgroups was therefore not possible. Ideally, multivariate logistic regression analysis
including all baseline characteristics and type of antiviral treatment would have been performed to
correct for differences in baseline factors. However, this was not possible because individual
patient data from the entecavir treated patients were unfortunately not made available to us. We
therefore performed logistic regression analysis with grouped patient data.
It is well known that HBV genotype is associated with response to IFN-based therapy, with the
highest response rates in genotype A infected patients.10, 13, 14  Although one study showed a higher
rate of HBeAg seroconversion in genotype B than genotype C infected lamivudine treated patients,
15
 other studies did not find such a relation between HBV genotype and response to either lamivudine,
adefovir or entecavir.16-18 It should be noted that other definitions of response to therapy were used
in these studies than the endpoint we used in this study. Off-treatment sustained response is
rarely used as an endpoint of nucleos(t)ide analogue therapy since prolonged treatment regimes
are generally used. We found a significant interaction between HBV genotype and type of antiviral
therapy on multivariate logistic regression analysis, indicating that the chance of sustained response
to PEG-IFN alpha-2b or entecavir was different across genotypes. Genotype A and B infected
patients had a higher likelihood of sustained virological response to PEG-IFN alpha-2b than
entecavir. Patients infected with genotype C responded equally to PEG-IFN alpha-2b and entecavir,
while genotype D infected patients had a higher chance of achieving sustained virological response
with entecavir than PEG-IFN alpha-2b.
One may question whether the long-term sustainability of response to PEG-IFN alpha-2b and
entecavir is comparable. A recent study investigating long-term outcome after treatment with  PEG-
IFN alpha-2b showed that HBeAg loss was sustained in 81% of initial responders after a mean
period of 3 years.19 The long-term off-treatment sustainability of entecavir-induced HBeAg loss is
however still unknown. It has already been shown that the long-term sustainability of HBeAg loss
after IFN therapy was significantly higher than of HBeAg loss occurring during lamivudine therapy,
with HBeAg relapse in about 40% of lamivudine treated and 20% of IFN treated patients after one
year.4 However, extending lamivudine therapy for several months after HBeAg seroconversion
significantly increased long-term sustainability of response compared to stopping lamivudine therapy
shortly after HBeAg seroconversion.15, 20 Therefore, in a recent study comparing telbivudine and
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lamivudine for the treatment of HBeAg positive chronic hepatitis B, treatment could be discontinued
only if HBeAg seroconversion had been achieved and maintained for at least six months.21 In that
study, 86% of patients with telbivudine induced HBeAg loss were still HBeAg negative at one year
post-treatment.22 These findings suggest that long-term sustained response can be achieved with
nucleos(t)ide analogues in HBeAg positive patients, given that an treatment is continued for several
months after HBeAg loss. Investigating treatment strategies aimed at sustained off-treatment
response to either PEG-IFN or nucleos(t)ide analogues is in our opinion of particular interest because
many young HBV infected patients have an indication for antiviral therapy and a significant proportion
of them may otherwise unnecessarily receive indefinite nucleos(t)ide analogue maintenance therapy.
We conclude that HBV genotype is an important predictor of sustained response after both PEG-
IFN alpha-2b and entecavir. Since response to PEG-IFN alpha-2b and entecavir was significantly
different across genotypes we recommend to determine HBV genotype prior to antiviral therapy in
all patients in whom inducing sustained off-treatment response is pursued. Knowledge of the HBV
genotype can then facilitate the choice of optimal antiviral therapy in individual patients. The results
of this study warrant a head-to-head comparison of sustained virological response after treatment
with PEG-IFN and one of the newest, potent, nucleos(t)ide analogues.
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SUMMARY
Hepatitis B virus (HBV) infected health care workers (HCWs) can infect patients undergoing expo-
sure prone procedures. Until now reviews have focussed on the problem of the HBeAg positive
HCWs. After transmission of HBV by HBeAg negative surgeons, the focus of Public Health policy
in the UK and the Netherlands has changed from HBeAg status to serum HBV DNA level.
Viral load and the volume of blood transmitted determine the transmission risk of HBV. We have
estimated the number of infectious particles transmitted by needlesticks, in comparison with those
attributed in maternal-fetal transfusion. The blood-volume transmitted by needlestick is roughly 1-
30% of that of delivery. As vertical transmission with maternal HBV DNA levels below 107 copies/ml
is rarely documented, HBV transmission by needlesticks is according to our assumptions unlikely
to occur with HBV DNA levels below 107 copies/ml.
Sera of transmitting HCWs contained HBV DNA levels between 5.0 x 109 and 6.35 x 104 copies/ml,
interpretation of these levels is hampered as the sera were taken at least 3 months after transmis-
sion. To prevent both loss of expertise and nosocomial transfer, highly viremic HCWs can be
offered antiviral therapy. Lamivudine and alpha-interferon can now be complemented with adefovir,
tenofovir and entecavir to provide effective new solutions for chronic HBV infected HCWs.
INTRODUCTION
Hepatitis B virus (HBV) is known to have been transmitted by infected health care workers (HCW)
to patients undergoing exposure prone procedures (EPP). Worldwide 45 HCW, who transmitted
HBV to their patients, have been identified since 1970.1-8 These 45 cases of doctor-to-patient
transmission resulted in 437 hepatitis B infected patients.
The CDC recommendation states that HCWs who are infected with HBV should not perform
exposure-prone procedures unless they have sought counsel from an expert review panel and
have been advised under what circumstances, if any, they may continue to perform these proce-
dures. Such circumstances would include notifying prospective patients of the HCW's seroposi-
tivity before they undergo EPPs.9 Until 1997 all described cases of HBV transmission to patients
involved hepatitis B e-antigen (HBeAg) positive HCWs. Therefore, to prevent patients from being
infected, Public Health measures focussed on excluding HBeAg positive HCWs from performing
EPPs.
Transmission by HBeAg negative surgeons was first described in 1997.10 All described cases of
HBeAg negative HCWs, who infected patients, involved surgeons bearing precore mutants.6-8,11
HBV carriers with this variant form of HBV do not produce HBeAg. After the identification of these
transmitting HBeAg negative HCWs a more direct measure of infectivity, based on HBV DNA
levels, was required.
The 2000 NHS Health Service Circular defines criteria necessary for the conduct of exposure
prone procedures by HBV carriers whose serum does not contain HBeAg. For a HBeAg negative
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HCW to be permitted to perform EPP their HBV DNA level must be below 103 copies/ml. The UK
and Eire exclude all HBeAg positive HCW.12,13 In the Netherlands a maximum HBV DNA level of
105 copies/ml is used to allow for the conduct of EPPs, irrespective of HBeAg status.14 In the US
exclusion from performing EPPs is still based only on the presence of HBeAg.15
In this paper we review doctor-to-patient transmission of HBV with main focus on quantitative HBV
DNA levels.
DOCTOR TO PATIENT TRANSMISSION OF HEPATITIS B VIRUS
Since the early 1970s HBV infected HCWs have been identified to be the source of infection for
patients who underwent surgical procedures. Retrospective investigations were performed to iden-
tify all possibly infected patients of HBV infected HCWs. Hasselhorn and Hofmann reported 40
cases of hepatitis B transmission by health care workers.6 We found that at least five other cases
of HBV transmission have been described, which are summarised here, pointing to a more wide-
spread problem:
 11 patients infected by a nurse3
 7 infected patients and 4 cases of secondary transmission by a cardiac surgeon5
 6 dental patients infected by a HBeAg positive dentist4
 4 patients infected by a HBeAg positive oral surgeon1
 2 patients infected by a HBeAg negative cardiothoracic surgeon bearing a precore mutant7
In our registry 45 described incidents of HBV transmission from HCW to patients resulted in 437
infected patients. The risk of transmission is proven and real, but still small. For example, in the
Netherlands with a compulsory reporting of viral hepatitis, 3 cases of doctor to patient transmis-
sion have been described since the 1970s and about 500,000 surgical procedures are performed
each year.
RISK OF TRANSMISSION OF HBV
The risk for patients to become infected during surgical procedures depends on several factors
(table 1). Most infections occur during high-risk procedures. Characteristics of procedures asso-
ciated with higher risk of transmission include: blind digital palpation of a needle tip,16-18 digital
guidance or handling of the needle tip while suturing,18 simultaneous presence of fingers and
instrument in the operating area19 and interrupted vision during a surgical procedure.20
Although various routes of transmission of HBV have been described, most HBV infections are
caused by contact with infected blood. Sharp injuries with needles or other sharp devices can
occur during the treatment of patients. Percutaneous injuries occur in 6.9% of operative proce-
dures, in 32% of the observed injuries to surgeons the sharp object recontacted the patient's open
wound. The risk for contact between the HCW's and patient's blood is therefore 2.21%.21 A com-
parable risk for blood contact of 2.02% during operations was found by Tokars et al.22
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The amount of infected blood transmitted affects the risk of transmission .21,23 The volume of blood
inoculated in a needlestick injury from a suture needle without the use of gloves varies from 11 nl
(0.33mm needle, 2mm penetration) to 366 nl (1.12mm needle, 5mm penetration). The volume of
blood inoculated in a needlestick with a phlebotomy needle is higher and varies between 133 nl
(0.71mm needle, 2 mm penetration) and 683 nl (1.12mm needle, 5 mm penetration).24 The vol-
ume of blood increases significantly with increasing depth of penetration, increasing needle diam-
eter and the use of a phlebotomy needle instead of a suturing needle.24 Napoli found the mean
volume of blood inoculated using a 0.71 mm (22 gauge) phlebotomy needle to be on the order of 1
μl.25 About 75% of sharp injuries is related to suturing.21-23 Injuries with solid-bore needles (suture
needles) carry a lower risk of transmission than hollow-bore, blood-filled needles.26 Double glov-
ing is effective in reducing the risk of inner glove puncture and decreases the volume of blood
transmitted by suture needles.24,27 During delivery infected maternal blood can be transmitted to
the unborn child. Maternal-fetal transfusion during delivery with blood volumes greater than 1 μl is
infrequent.28
The number of HBV particles transmitted by a needlestick and during delivery depends on the viral
load and the volume of blood transmitted. We have estimated the number of infectious HBV par-
ticles transmitted by maternal-fetal transfusion and needlesticks (table 2). Because HBV DNA
levels are measured in serum, a factor of 0.64 has been used to calculate the volume of serum in
the blood transmitted (assuming a hematocrite value of 0.36; the lower limit of normal in women).
Multiplying the serum volume by the HBV DNA concentration gives an estimate of the number of
viral particles in the serum volume. Heermann et al. stated that almost 10% of detected HBV
particles is infectious.29 Therefore, the estimated number of viral particles in the serum volume
has been devided by ten. The number of infectious particles transmitted during delivery and by
needlesticks with HBV DNA levels ranging from 103 to 109 copies/ml is shown in table 2.
IMPLICATION OF HBEAG STATUS
HBeAg is considered a marker for viral replication and infectivity. High levels of HBV DNA usually
correlate with the presence of HBeAg,30 serum of HBeAg positive persons is likely to contain up to
.noissimsnartsurivBsititapehfoksirehthtiwdetaicossasrotcaF:1elbaT
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109 HBV particles per ml of serum.23,27 The presence of anti-HBe is thought to indicate a low level
or lack of viral replication and often the absence of virus in the blood.31 However, in HBV carriers
with precore mutants HBeAg is not expressed despite continuing viral replication. The most com-
mon mutation, a G-to-A transition at nucleotide 1896 of codon 28 introduces a stop-codon, pre-
venting expression of hepatitis B e-antigen. About half of all HBeAg negative, anti-HBe positive
virus carriers carry a precore mutant. These mutants can be associated with highly productive
infection in HBeAg negative HBV carriers.11,12,30,31
Martinot-Peignoux et al. performed a study to quantify HBV DNA levels in inactive HBsAg carriers
using the Cobas Amplicor HBV Monitor (Roche) with a sensitivity of 200 copies/ml.32 The mean
HBV DNA concentration in this group of patients was found to be 1300 copies/ml and 98% of sera
of inactive HBeAg negative carriers contained HBV DNA levels below 105 copies/ml. Tedder et al.
found evidence for fluctuations in HBV DNA levels in HBeAg negative HBV carriers. The variations
in HBV DNA level of several orders of magnitude occurred over relative short time periods and
indicate a dynamic host-parasite relationship.12
HBeAg / anti-HBe status is often used as a marker of infectivity. However, serum HBeAg is at best
an indirect measure of hepatitis B viremia because of possible mutations in the precore region.
Measurement of both HBV DNA level and HBeAg status gives a more reliable estimate of infectiv-
ity.30
HBV DNA CONCENTRATION AND TRANSMISSION RATE
The infection risk after exposure to HBV infected blood depends on the viral load. Although trans-
mission of HBV from health care workers to patients has repeatedly been described since 1970,
the viral load of the HCW involved has only been determined in five investigations (table 3). Sera of
transmitting surgeons were found to contain HBV DNA levels between 5.0 x 109 and 6.35 x 104
copies/ml. The lowest measured HBV DNA level in serum from a transmitting surgeon was 4.0 x
104 copies/ml in a sample taken at least 3 months after transmission.11
The proportion of patients infected with HBV after treatment by an infected HCW varies between
0.5 % and 13.1% in different investigations.6 The study performed by Spijkerman et al. describes a
retrospective analysis to identify infected patients.33 All patients operated on by the surgeon, sexual
partners and household contacts of patients with evidence of HBV were offered serological testing
for anti-HBc and HBsAg after the incubation period. Cases were considered confirmed cases if
the patients' sera patients contained HBV markers and the same HBV DNA sequence as the
surgeon. Probable cases were positive for anti-HBc and anti-HBs and provided clinical evidence
of HBV infection within six months after surgery. Possible cases were positive for anti-HBc and
anti-HBs and provided no epidemiological evidence of other sources of HBV infection. Using these
definitions 8 confirmed cases, 2 probable cases and 18 possible cases were identified among
1564 tested patients. The proportion of infected patients (transmission rate) lies between 0.5%
(confirmed cases only) and 1.8% (all cases). Because many different calculations and definitions
175Doctor to patient transmission of HBV - Implications of HBV DNA levels
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have been used in the studies of doctor-patient transmissions the transmission rates were recal-
culated using the definitions stated by Spijkerman et al.33
The highest transmission rate is found by Harpaz et al., in this study 19 of 144 susceptible patients
operated on were found to be infected by a surgeon (13.2%).17 Sequence analysis confirmed
infection in 9 cases. The total number of tested patients was actually 170, therefore the infection
rate varies between 5.3% and 11.2%. In the study performed by Welch et al. a transmission rate of
8.9% was found.19 The transmission rate is based on 22 infected patients of 247 tested patients.
In six patients with presence of HBsAg subtyping confirmed infection by the surgeon, resulting in a
transmission rate between 2.4% and 8.9%. Prentice found that a surgical trainee infected 6.1% of
patients treated.34 Two hundred eighty patients thought to be at risk were tested, 17 were found to
have acquired HBV after the operation and 9 patients had the same HBV subtype as the surgeon.
The transmission rate in study varies between 3.2% and 6.1%. The actual rate is probably lower
because patients undergoing procedures with minimal risk of transmission were excluded from
the study. Hadler found that 6 of 764 patients of a HBV infected dentist had signs of HBV infection.4
The proportion of infected patients lies between 0.3% and 0.8%. In two patients HBsAg subtyping
could be performed and was found to be the same as the surgeon. In the studies performed by
Molyneaux, Sundkvist, Haerem and Lettau all patients were found to have the same subtype as
their surgeons.5,7,8,18
DISCUSSION
Public Health policy to prevent transmission of HBV to patients in different countries was based on
serum HBeAg status. After incidents of transmission by HBeAg negative surgeons a more reliable
estimate of non-infectivity was needed. Serum HBV DNA level may be more reliable to estimate
non-infectivity than anti-HBe status alone. Current Public Health policy in the Netherlands does not
allow the conduct of EPPs by HCWs with HBV DNA levels above 105 copies/ml, irrespective of
HBeAg status.14 The use of this HBV DNA level of 105 copies/ml as a cut-off minimises the risk of
transmission and allows most high-educated HBV infected HCWs to continue practice. Setting
the cut off below this level would exclude the majority of HBeAg negative HCWs from performing
EPPs in the Netherlands. The UK and Eire exclude all HBeAg positive HCW and a HBV DNA cut
off level of 103 copies/ml is used for HBeAg negative HCWs.13 In the US excluding HCWs from
performing EPPs is based on the presence of HBeAg only.15
Transmission of HBV is not likely to occur with HBV DNA levels below 107 copies/ml according to
vertical transmission studies. No cases of mother to child transmission were observed with ma-
ternal HBV DNA levels below 6,0 x 105 copies/ml, whereas 25% of children from women with HBV
DNA levels above 107 copies/ml were infected.35 The maximum HBV DNA level of 105 copies/ml in
the Netherlands is based on 107 copies/ml, below which vertical transmission is not likely to occur.
A safety margin of 2 log is used to account for natural fluctuations in viral load and variations in the
assay used for quantifying HBV DNA. In the UK the lower cut off level of 103 copies/ml is based on
177Doctor to patient transmission of HBV - Implications of HBV DNA levels
a safety margin of 3 log as the viral load is then unlikely to rise above 106 copies/ml.
Most percutaneous injuries during surgical procedures involve suture needles. As can be seen in
table 2 the estimated number of particles transmitted with suture needles is less than the number
transmitted by maternal-fetal transfusion. HBV transmission by needlesticks is according to our
assumptions unlikely to occur with HBV DNA levels below 107 copies/ml.
Recent investigations of transmissions of HBV to patients involved determining HBV DNA levels of
the HCWs. Transmission rate does not seem to depend on serum HBV DNA level only. Serum of
the surgeon described by Harpaz et al. contained 1.0 x 109 copies/ml, associated with a maxi-
mum transmission rate of 11.2%.17 The surgeon described by Spijkerman et al. had a viral load of
5.0 x 109 copies/ml and infected 1.8% of his patients.33 Although these surgeons were both HBeAg
positive and had comparable HBV DNA levels the transmission rates vary greatly. A relation be-
tween HBV DNA level and transmission rate was not found in the HBeAg positive HCWs. A pos-
sible explanation could be that the surgeon described by Harpaz et al., as a thoracic surgeon,
performed more high risk procedures as the general surgeon described by Spijkerman et al.
The lowest serum HBV DNA level in a transmitting surgeon was found to be 4.0 x 104 copies/ml.11
This rises the question which HBV DNA level should be used to allow for the conduct of exposure
prone procedures by HBV infected HCWs. However, in our opinion Public Health policy should not
be based on the measurements of HBV DNA levels in these HCWs because all samples were
taken at least 3 months after the actual transmission occurred. As described by Tedder et al.,
variations in HBV DNA levels in HBeAg negative carriers occur over relative short periods of time.12
Therefore, HBV DNA levels might actually have been higher at the time of transmission.
Doctor to patient transmission is a complex issue due to legal and ethical factors. These factors
include the hospital's policy, federal discrimination laws and issues of informed consent and dis-
closure of HBV infection. Restriction of infected HCWs is also complicated by the definition of
disability. A surgeon might be restricted in practice but possibly not qualify for disability insurance
compensation.36
HCWs not allowed to perform EPPs due to high HBV DNA levels can be offered antiviral therapy to
prevent both exclusion from practice and transmission to patients. In most countries the regis-
tered treatment for HBV consists of alpha-interferon or lamivudine. In an experimental setting
lamivudine is sometimes combined with interferon to accomplish higher HBeAg seroconversion
rates, generally associated with low HBV DNA levels. Viral resistance to lamivudine with emer-
gence of YMDD mutants in the c-region of the HBV polymerase gene during long-term lamivudine
therapy is well described.37,38 After 1 year in 15-30% and in up to 50% after 3 years of patients
treated with lamivudine monotherapy a resistant virus emerges.39 Recently new nucleoside ana-
logues tenofovir disoproxil fumarate,40 adefovir dipivoxil41,42 and entecavir43,44 have shown to be
effective in suppressing both wild-type and YMDD-mutant HBV replication. Although these antiviral
drugs have not yet been registered for the treatment of HBV in most countries, they can provide
potential new solutions for the treatment of chronic hepatitis B infected health care workers.
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SUMMARY
To prevent transmission of hepatitis B virus (HBV) from health care workers (HCWs) to patients,
highly viremic HCWs are often advised to restrict performing exposure prone procedures (EPPs).
To prevent loss of highly qualified medical personnel and simultaneously minimize transmission
risk to patients, we offered highly viremic HCWs antiviral therapy and evaluated the effects of this
strategy. Eighteen chronic HBV infected HCWs have been monitored every 3-6 months for a
median period of 5.6 years (range 1.1-12.5 years). Antiviral therapy was offered if HBV DNA was
above 105 copies/ml and EPPs were performed or active liver disease was present. Median HBV
DNA levels, the percentage of days with HBV DNA above 103, 104 and 105 copies/ml, and reduction
of HBV DNA during antiviral treatment have been analysed for HBeAg-positive and HBeAg-nega-
tive HCWs separately. Prolonged viral suppression was achieved in both HBeAg-positive, as well
as HBeAg-negative HCWs. In HBeAg-negative HCWs treatment with interferon or lamivudine main-
tained HBV DNA levels below 105 copies/ml. For HBeAg-positive HCWs continuous treatment with
tenofovir or entecavir was essential for reaching low viremia persistently. In 2004 median HBV
DNA levels in both HBeAg-negative and HBeAg-positive HCWs were below 103 copies/ml and all
HCWs executed their professional work full-range. For both HBeAg-positive and HBeAg-negative
HCWs, antiviral treatment is effective in persistent suppression of virus levels below 105 copies/
ml. This observation supports antiviral therapy as a viable management option instead of work
restriction, with the provision of regular expert monitoring including quantification of HBV DNA.
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INTRODUCTION
Transmission of hepatitis B virus (HBV) from infected health care workers (HCW) to patients has
repeatedly been reported in the past 30 years. Since the 1970s at least 45 of such cases have
been described, altogether resulting in 437 infected patients.1 To prevent transmission of HBV
from HCWs to patients, infected HCWs are often restricted in performing exposure prone proce-
dures (EPP). The CDC defined exposure prone procedures to include "digital palpation of a needle
tip in a body cavity or the simultaneous presence of the HCWs fingers and a needle or other sharp
object in a poorly visualized anatomic site".2
In 1991, the CDC stated that HCWs who are infected with HIV or HBeAg-positive HBV should not
perform exposure-prone procedures unless they have sought counsel from an expert review panel.2
In 2003, a European consensus panel proposed that HBsAg-positive HCWs undergo annual HBV
DNA testing and that those with HBV DNA levels above 104 copies/ml are restricted, as this would
provide a balance between risk of transmission and loss of specialist HCWs.3
The transmission risk of HBV is determined by the number of infectious particles transmitted and
thus the HCW's serum HBV DNA level and the volume of infectious blood transmitted. Transmis-
sion is rarely documented with HBV DNA levels below 105 copies/ml, according to several studies
on vertical transmission.4-6 Only one case of transmission of HBV by a HCW with a HBV DNA level
below 105 copies/ml has been described; in that case, interpretation is difficult because the sample
was taken more than three months after the actual transmission occurred.7 The fact that the level
of viremia is an important factor for the risk of transmission leads to the concept that suppression
of viremia by antiviral therapy may almost completely reduce the risk of transmission, as has been
proven in the setting of mother-to-infant transmission both for HIV and HBV.8,9
Punitive policies may provide disincentives for HCWs to determine their virus status. Gostin ad-
dressed this topic in 2000 and suggested a new policy, focused on management of the workplace
environment, injury prevention and antiviral therapy for infected HCWs as this would achieve pa-
tient safety without discrimination and invasion of HCW privacy.10 At that time, registered treatment
of HBV consisted of interferon (IFN) and lamivudine. Three new nucleos(t)ide analogues provide
increased potential for prolonged effective treatment of chronic HBV infected HCWs. Adefovir
dipivoxil, entecavir and tenofovir have activity against both wild-type and lamivudine resistant HBV.11-
13
 The former two have recently been licensed for the treatment of chronic hepatitis B.
In this paper we analyse the effectiveness of current antiviral treatment in suppressing viral repli-
cation in HBV infected HCWs and provide evidence supporting the concept of antiviral therapy as
a feasible option that allows continuation of a full range of work without jeopardizing patient safety.
METHODS
Study participants, treatment and monitoring
All eighteen chronic HBV infected HCWs monitored in the Erasmus MC University Medical Center
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Rotterdam, The Netherlands between 1994 and 2004 were included in this study; ten were HBeAg-
positive and eight HBeAg-negative at inclusion. They were tested at least every 3 to 6 months for
serum ALT, HBV DNA, HBeAg, anti-HBe, HBsAg and anti-HBs.
HCWs were offered antiviral therapy if they had serum HBV DNA levels above 105 copies/ml and
performed EPPs or had elevated serum ALT above twice the upper limit of normal.14 Patients
were initially treated with (pegylated)-IFN (various treatment regimes) and/or lamivudine (100mg
daily). In case of non-response, relapse or resistance the new nucleos(t)ide analogues adefovir
(10mg daily), entecavir (0.5-1mg daily) and tenofovir (245mg daily) were used depending on avail-
ability in the Netherlands. For patients with antiviral resistance sequential nucleos(t)ide analogue
monotherapy with an overlap period was used.
Median HBV DNA levels, the percentage of days with HBV DNA levels above various cut-off levels
and speed of reduction of HBV DNA levels during antiviral treatment have been analysed for HBeAg-
positive and HBeAg-negative HCWs separately. Transition in HBV DNA level was assumed to
occur halfway between two samples.
HBV DNA measurement
For the accurate measurement of HBV DNA in serum over a ten year period several assays were
used including the commercially available assays, Digene Hybrid Capture II microplate assay
(Digene Diagnostics; dynamic range from 1.4 x 105 - 1.7 x 109 copies/ml) and HBV Monitor assay
(Roche Diagnostics; dynamic range from 400 - 4.0 x 107 copies/ml), as well as an in-house devel-
oped HBV DNA TaqMan assay (dynamic range 373 - 1010 copies/ml).15 All assays were calibrated
using EUROHEP HBV DNA standards, and yearly validated by participation in a quality control
program.16,17
Mutations in the polymerase gene were detected using a line probe assay (INNO-LiPA, Innogenetics,
Ghent, Belgium).18 Where the INNO-LiPA assay was indeterminate a sequence analysis was used.19
Statistical analysis
Statistical analysis was performed using the functions of the SPSS 11.5 software. Statistical analysis
of differences between groups was performed with the Mann-Whitney U-test or Student's t-test,
where appropriate. A p-value of <0.05 was considered significant.
RESULTS
Baseline characteristics of the HBV infected HCWs are shown in table 1. Median HBV DNA level at
inclusion was significantly higher for HBeAg-positive HCWs compared to HBeAg-negative HCWs
(7.5 x 108 and 1.9 x 104 copies/ml, p<0.001). The HCWs were monitored for a median period of 5.6
years (range 1.1-12.5 years). At the end of follow-up 9 of 10 HBeAg-positive HCWs and 4 of 8
HBeAg-negative HCWs had been treated with antiviral drugs.
From 1998 - 2003 median serum HBV DNA remained above 105 copies/ml in HBeAg-positive
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HCWs. In 2004 median serum HBV DNA for HBeAg-positive HCWs was below 103 copies/ml.
Only one untreated HBeAg-positive HCW continuously had HBV DNA above 105 copies/ml, this
patient received no treatment since ALT was normal and EPPs were not performed. One HCW
showed a temporary rise in HBV DNA from 1.5 x 103 to 6.8 x 105 copies/ml after switching from
experimental lamivudine-tenofovir combination therapy to licensed adefovir monotherapy. In HBeAg-
negative HCWs median serum HBV DNA was continuously below 105 copies/ml, and below 104
copies/ml since 2001. In 2004 a median HBV DNA level below 103 copies/ml was observed (range
<373 - 2.2 x 104 copies/ml).
The percentage of days HCWs had HBV DNA levels above 103, 104, and 105 copies/ml is given in
figure 1 for HBeAg-positive and HBeAg-negative HCWs separately. In HBeAg-positive HCWs con-
tinuous effective viral suppression was not observed in IFN-alfa and/or lamivudine treated HCWs.
A decline in percentage of days with high serum HBV DNA was observed with the use adefovir,
entecavir and tenofovir. Almost all HBeAg-negative HCWs could effectively be treated with lamivudine
and/or  IFN-alfa, non-responders with individually tailored nucleos(t)ide analogue treatment.
Furthermore, we analyzed the time required for serum HBV DNA to reach levels below the maxi-
mum level described in public health guidelines. Figure 2 shows the percentage of HBeAg-positive
HCWs with HBV DNA levels below 103, 104 and 105 copies/ml after one, three, six and 12 months
of antiviral treatment. HBV DNA levels were below 105 copies/ml in all treated HBeAg-positive
HCWs after 12 months of adefovir, tenofovir or entecavir treatment. In all HBeAg-negative HCWs
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HBV DNA levels below 103 copies/ml were observed 6 months after starting lamivudine and/or IFN
therapy and as soon as 1 month after starting treatment with adefovir, entecavir or tenofovir.
Figure 1: Percentage of days with HBV
DNA levels above various cut-off lev-
els.
In HBeAg-positive HCWs (n=10; A) con-
tinuous effective viral suppression was
not observed with IFN and/or lamivudine
treatment from 1997-2002. In 6
lamivudine treated HBeAg-positive
HCWs a mutation in the YMDD motif
had occurred. With the successive avail-
ability of tenofovir, adefovir and entecavir
from 2002 onwards a decline in percent-
age of days with high serum HBV DNA
was observed in 2003 and 2004.
Almost all HBeAg-negative HCWs (n=8;
B) could effectively be treated with
lamivudine and/or IFN from 1998-2002.
Lamivudine resistance has not been
found in any of these HBeAg-negative
HCWs. Since the start of individually
tailored nucleos(t)ide analogue treat-
ment, that was continuous since 2003,
HBV DNA levels above 105 copies/ml
have not been observed.
DISCUSSION
Prolonged antiviral treatment in HBV infected HCWs has rarely been documented.20,21 This study
documents in small number of HCWs that both HBeAg-negative, as well as HBeAg-positive HCWs
can effectively maintain HBV DNA levels below 105 copies/ml for prolonged periods. This requires
an arsenal of antiviral drugs, which fortunately is readily available since 2004. In this patient popu-
lation compliance with antiviral medication was excellent, be it in a setting of HBV DNA monitoring
every 3-6 months. Our observations may give further support to solving the HBV infected HCW
problem in a new way.
Although the number of HCWs studied is small, the uniformity of the findings at several time
periods point to confidence in the reliability of the observations. Even with this small number of
patients, many foreseeable complications, like resistance to lamivudine, adefovir or entecavir,
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were observed and quickly amended. One of the HCWs is now receiving antiviral medication for 9
years with prolonged control of HBV DNA suppression.
In 2003, an expert panel advised referral of all HBV infected HCWs to a hepatologist for specialist
advice on antiviral treatment.3 In order to return to performing EPPs, infected HCWs receiving
treatment should have HBV DNA levels below the maximum cut-off level according to local public
health policy, and should be retested every 3 months while receiving antiviral therapy. A maximum
HBV DNA level of 104 copies/ml was proposed. In HCWs receiving antiviral therapy reduction of
HBV DNA to levels below 104 copies/ml is now feasible (figure 1).
We used a maximum level of 105 copies/ml, as currently used in The Netherlands, as indication
for antiviral therapy.14 Based on data of studies on vertical transmission and the virtual absence of
reports on HBV transmission by HCWs with HBV DNA levels below 105 copies/ml, doctor to pa-
tient transmission of HBV seems unlikely to occur with serum HBV DNA below this level.4,6,7 Gerlich
estimated a risk below 1:100,000 that one case of HBV transmission caused by viremia below 105
copies/ml occurs in a period of 15 years.22
We remain reluctant to initiate antiviral therapy in individuals with repeated HBV DNA between 103
and 105 copies/ml. Regular quantification of HBV DNA is required to account for naturally occur-
ring fluctuations in serum HBV DNA in these untreated patients.23 Further data with validated HBV
DNA assays are needed to guide public health measures on this topic. Use of standardised as-
says for quantification of HBV DNA is essential when using HBV DNA in the decision process of
work restriction.
It is still a question of debate whether to strive for a zero-risk strategy or whether a strategy aimed
at reducing the risk of transmission to a level comparable to other accepted risks associated with
surgical procedures, such as anaesthesia or wound infection, can be chosen. Acceptance of
antiviral therapy as a management option for HCWs by public health policies may result in in-
creased willingness of HCWs to undergo voluntary testing. This would increase infections to be
detected and treated, and thereby decrease risks to patients.24
Figure 2: Percentage of HBeAg-positive
HCWs with confirmed HBV DNA below
various cut-off levels after starting antivi-
ral treatment.
Four of 9 HBeAg-positive HCWs (44%)
treated with standard IFN and/or lamivudine
therapy had serum HBV DNA levels below
105 copies/ml 12 months after starting treat-
ment. Four of 6 HBeAg-positive HCWs (75%)
treated with adefovir, entecavir or tenofovir
had serum HBV DNA below 104 copies/ml
after 6 months of treatment, all of them had
HBV DNA below this level 12 months after
starting treatment with these drugs.Months after starting antiviral therapy
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This study shows promising results for maintaining persistent minimal risk viremia in both HBeAg-
positive, as well as HBeAg-negative HCWs with the use of antiviral drugs. Based on these data we
suggest general application of prolonged antiviral therapy as a new management option for chronic
HBV infected HCWs with high viremia, with the provision of regular expert monitoring including
quantification of HBV DNA.
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INTRODUCTION
Hepatitis B virus (HBV) infection is still an important health problem, it is estimated that about one-
third of world's population has evidence of infection with HBV and that 400 million people are chroni-
cally infected.1, 2 Without antiviral therapy, ongoing hepatic inflammation will lead to progression of
liver disease and eventually to the development of decompensated cirrhosis and hepatocellular
carcinoma (HCC) in 25-40% of patients.3 It is estimated that over 500,000 people die annually due
to HBV associated liver disease, largely due to complications of cirrhosis and/or HCC.4 With the
availability of multiple new antiviral agents the treatment of chronic hepatitis B has become more
effective and a large proportion of future deaths could potentially be prevented.
ANTIVIRAL THERAPY FOR HBEAG POSITIVE CHRONIC HEPATITIS B
In hepatitis B e antigen (HBeAg) positive patients with high serum HBV DNA levels (>1.0 x 105
copies/ml) and elevated ALT levels, antiviral therapy can be postponed for 3-6 months to await
spontaneous HBeAg seroconversion. Among 3,063 Chinese patients, spontaneous HBeAg
seroconversion occurred in 46% of those with peak ALT levels over five times the upper limit of
normal (ULN) within three months.5 HBeAg positive patients with elevated ALT levels for longer
periods should be considered for antiviral therapy. In addition, antiviral therapy can also be consid-
ered in those with histological evidence of significant hepatic necroinflammation and/or significant
liver fibrosis. In HBeAg positive patients, successful antiviral treatment with loss of HBeAg, decline
in serum HBV DNA and normalization of ALT is associated with favorable long-term outcome,
independent of the antiviral drug used. The practicing clinician is currently faced with a number of
treatment options for chronic hepatitis B, including two formulations of IFN (standard IFN and
pegylated IFN) and five nucleos(t)ide analogues (lamivudine, adefovir, entecavir, telbivudine and
tenofovir). As a result, the complexity of decision-making has increased and the question arises
whether a finite course of pegylated IFN (PEG-IFN) or nucleos(t)ide analogue therapy, with the
possibility of long-term maintenance therapy, is better as first-line therapy.
FACTORS INFLUENCING THE CHOICE OF ANTIVIRAL THERAPY
The added complexity of treating chronic hepatitis B has led to the development of national and
international guidelines for the treatment of chronic HBV infection in the past few years.4, 6-9 Most of
these guidelines do however not provide specific recommendations as to whether PEG-IFN or
nucleos(t)ide analogues should be used as preferred first-line therapy, because both approaches
have proved effective, and both have advantages and limitations (Table 1). In addition, numerous
other factors including serum HBV DNA and ALT levels, HBeAg status, HBV genotype, the severity
of liver disease and the patient's preference play an important role when deciding on which drug to
start in an individual patient. Ideally, antiviral therapy should be directed toward achieving the high-
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est rate of viral clearance with the shortest duration of treatment.
SIDE EFFECTS OF TREATMENT
PEG-IFN therapy is often complicated by the occurrence of side-effects such as flu-like symp-
toms, myelosuppression and depression.10 Nucleos(t)ide analogues are very well tolerated by com-
parison. Because of presumed lack of efficacy and fear for hepatic flares and other toxicity of PEG-
IFN, it is often not given to HBV infected patients with advanced fibrosis or cirrhosis. It is well known
that IFN-based therapy can induce severe complications of bacterial infection and exacerbation of
liver disease in patients with Child's class B or C cirrhosis.11,12 Although we found that patients with
advanced fibrosis more often required dose adjustment and more often prematurely discontinued
PEG-IFN alpha-2b therapy, response rates were comparable to those observed in patients without
advanced fibrosis (Chapter 3).
Retinopathy is a relatively rare adverse reaction which can be observed during PEG-IFN therapy. In
chronic hepatitis C virus infected patients retinopathy is probably more common, it was observed
in 24% of patients who underwent routine fundoscopic examination.13 We found retinopathy in only
one of 24 (4%) chronic hepatitis B patients during treatment with PEG-IFN alpha-2b (Chapter 4).
Routine screening for retinopathy seems therefore not necessary in chronic hepatitis B patients
undergoing PEG-IFN therapy in the absence of risk factors for retinopathy such as diabetes melli-
tus and hypertension.
SUSTAINED RESPONSE TO PEG-IFN
Of currently licensed drugs for the treatment of chronic hepatitis B, PEG-IFN seems to results in
the highest rate of sustained off-treatment response after a one-year course of therapy.14-17 At the
end of treatment, HBeAg loss was observed in 29% of patients treated with PEG-IFN alpha-2b
alone and in 44% of patients treated with combination therapy with lamivudine.15 Relapse occurred
in 13% and 39% of these patients within 6 months post-treatment (Chapter 5). Post-treatment
HBeAg loss was observed in 9% of patients, resulting in an overall HBeAg loss rate of 36% at six
months after discontinuation of PEG-IFN. After an additional mean 3.0 years of follow-up, 37% of
patients treated with PEG-IFN alpha-2b were HBeAg negative and clearance of HBsAg from serum
was observed in 11% (Chapter 7). Among patients who were HBeAg negative at six months post-
treatment (initial responders), the HBsAg clearance rate was 30%. It is well known that the rate of
HBsAg loss increases during prolonged follow-up to 12-65% of virological responders.18-26 We
showed that PEG-IFN significantly reduced the proportion of hepatocytes stained positive for HBcAg
and HBsAg in patients with HBeAg positive chronic hepatitis B, although there seemed to be a
beneficial effect of added lamivudine in terms of intrahepatic HBsAg clearance. Clearance of HBsAg
from the liver is important because it was strongly associated with loss of HBeAg and HBsAg from
serum (Chapter 9). In addition we found that HBsAg loss particularly occurred in patients who
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cleared HBeAg from serum within 32 weeks of PEG-IFN alpha-2b therapy (Chapter 8). Since early
HBeAg loss and long-term HBsAg loss may be associated with more profound viral suppression
during the first weeks of therapy in patients with added lamivudine, adding a nucleos(t)ide analogue
to PEG-IFN therapy might increase HBsAg loss rates in the long-term.
PREDICTORS OF RESPONSE TO PEG-IFN
Most studies investigating IFN-based therapy in HBeAg-positive chronic hepatitis B found that high
baseline ALT, low baseline HBV DNA and HBV genotype A or B infection were associated with a
higher chance of response to IFN-based therapy.15,27-29 In addition to these factors, we identified
sex, age and previous IFN therapy as predictors of response to PEG-IFN (Chapter 2). We found
that the influence of sex, age, HBV DNA and previous IFN therapy was significantly different across
HBV genotypes. Based on these findings we developed a practical tool to calculate the predicted
probability of sustained response to PEG-IFN in individual HBeAg-positive patients. This treatment
index can be easily used in clinical practice to select the optimal candidates for PEG-IFN therapy.
Based on our finding we recommend to consider PEG-IFN therapy in all genotype A infected pa-
tients, except for those with both low ALT (<2 x ULN) and high HBV DNA levels (>=9log10 copies/
ml). In addition, genotype B and C infected patients with both favorable ALT (>=2 x ULN) and HBV
DNA (<9log10 copies/ml) values are good candidates for PEG-IFN therapy. Genotype D infected
patients are generally not candidates for treatment with PEG-IFN, because they have a low likeli-
hood of sustained response irrespective of ALT and HBV DNA levels.
SUSTAINED RESPONSE TO NUCLEOS(T)IDE ANALOGUES
Although treatment with nucleos(t)ide analogues profoundly suppresses serum HBV DNA levels
and response can be maintained over prolonged periods with ongoing therapy, response to
lamivudine was less sustainable after discontinuation of therapy compared to IFN.30 We found
combined response of HBeAg loss and HBV DNA <7.0 x 105 copies/ml in 34% of patients treated
with PEG-IFN alpha-2b and 21% of patients treated with entecavir at the end of a one-year course
(Chapter 10). At 6 months post-treatment, these rates were 20% and 17%, respectively. Predictors
of sustained response after entecavir therapy include high baseline ALT, low baseline HBV DNA,
high baseline necroinflammatory score and infection with HBV genotype A or D (Chapter 10).
Relapse after discontinuation of therapy poses a risk for hepatitis flares. Flares are a well known
and potentially dangerous phenomenon after discontinuation nucleos(t)ide analogues and in pa-
tients developing antiviral resistance, particularly in case of advanced liver disease.31,32 We how-
ever found that severe flares also occur frequently after discontinuation of PEG-IFN therapy, with a
rise in ALT above 10 x ULN in 14% of PEG-IFN treated patients (Chapter 6). In order to reduce the
risk of relapse, nucleos(t)ide analogue therapy can be extended for several months after HBeAg
seroconversion as this significantly reduces relapse rates.33,34 HBeAg seroconversion was sus-
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tained in 86% of patients treated with telbivudine or lamivudine who discontinued therapy after at
least six months of maintenance therapy.35,36 These findings suggest that sustained off-treatment
response can be achieved with nucleos(t)ide analogues, given that treatment is continued for sev-
eral months after HBeAg loss.
THE IMPORTANCE OF HBV GENOTYPE
It is well known that HBV genotype is associated with response to IFN-based therapy, with the
highest response rates in genotype A infected patients.15,37,38 We found that HBV genotype also
was a strong predictor of long-term sustainability of response to PEG-IFN alpha-2b, with signifi-
cantly higher rates of HBeAg negativity in genotype A infected initial responders compared to those
with genotype-non-A (96% vs. 71%, p=0.02), as well as HBsAg loss (58% vs. 11%, p<0.001) after
a mean of 3.5 years of follow-up (Chapter 7). Although a higher rate of lamivudine-induced HBeAg
seroconversion has been reported in genotype B as compared to genotype C infected patients,33
other studies did not find such a relation between HBV genotype and on-treatment response to
either lamivudine, adefovir or entecavir.39-41 We did however find an association of HBV genotype
with sustained off-treatment response to entecavir (Chapter 10). In addition, we found that the
chance of sustained response to either PEG-IFN alpha-2b or entecavir was significantly different
across genotypes. Genotype A and B infected patients had a higher chance of sustained response
to PEG-IFN alpha-2b than entecavir. Patients infected with genotype C responded equally to PEG-
IFN alpha-2b and entecavir, while genotype D infected patients had a higher chance of sustained
response to entecavir than PEG-IFN alpha-2b. HBV genotype can thus guide the choice of therapy
in HBeAg positive chronic hepatitis B.
MAINTAINED VIRAL SUPPRESSION WITH NUCLEOS(T)IDE ANALOGUE THERAPY
Because of the modest rates of sustained response, long-term, and possibly indefinite, nucleos(t)ide
analogue treatment seems necessary in a large proportion of patients.42,43 The excellent tolerability
of nucleoside analogs has made it relatively easy to use them for prolonged periods in order to
maintain viral suppression. This strategy proved effective in reducing disease progression and the
development of hepatocellular carcinoma in patients with advanced fibrosis.44 A drawback how-
ever is the risk of developing antiviral resistance in the long-term, particularly when using drugs
with a low genetic barrier and/or low potency.45 In chronic HBV infected health care workers (HCWs)
who perform exposure prone procedures there is even more at stake. According to a European
expert panel, HBV infected HCWs should have HBV DNA levels below 1.0 x 104 copies/ml in order
to be allowed to continue the full range of work.46 Those receiving antiviral treatment should be
retested every three instead of six months while receiving therapy. Based on data of studies on
vertical transmission and the virtual absence of reports on HBV transmission by HCWs with HBV
DNA levels below 1.0 x 105 copies/ml, doctor to patient transmission of HBV seems highly unlikely
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to occur with serum HBV DNA below this level (Chapter 11). We showed that both HBeAg positive
and HBeAg negative HCWs can now effectively maintain HBV DNA levels below this level for pro-
longed periods (Chapter 12). This requires an arsenal of antiviral agents, which fortunately is readily
available.
CONCLUSION
In conclusion, choice of antiviral therapy has become more important and more complex at the
same time in the past decade. Both treatment with PEG-IFN therapy and nucleos(t)ide analogue
therapy have proven effective and can improve long-term outcome. Since HBV genotype has such
great influence on choice of antiviral therapy in HBeAg positive chronic hepatitis B, determination of
HBV genotype is essential in all patients in whom sustained off-treatment response is pursued. In
general, PEG-IFN therapy is recommended in all HBV genotype A infected HBeAg positive patients,
while nucleos(t)ide analogue therapy is preferred in those with HBV genotype D. In patients harbouring
the HBV genotype B and C, the pros and cons of the available drugs as well as patient-specific
characteristics should be carefully balanced.
REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging
prevention and control measures. J Viral Hepat 2004;11:97-107.
Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005;25 Suppl 1:3-8.
de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo
A, Rodes J, Rosenberg W, Valla D. EASL International Consensus Conference on Hepatitis B. 13-14
September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39:S3-25.
Yuen MF, Yuan HJ, Hui CK, Wong DK, Wong WM, Chan AO, Wong BC, Lai CL. A large population
study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection:
implications for antiviral therapy. Gut 2003;52:416-9.
Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S,
Schirmacher P, Fleig WE, Manns MP. The German guideline for the management of hepatitis B virus
infection: short version. J Viral Hepat 2008;15 Suppl 1:1-21.
Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific
consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008:DOI
10.1007/s12072-008-9080-3.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke
Bakker C, Reesink HW, Janssen HL. Treatment of chronic hepatitis B virus infection - Dutch national
guidelines. Neth J Med 2008;66:292-306.
van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM,
Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL. The safety of pegylated interferon alpha-
2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinu-
ation. Aliment Pharmacol Ther 2005;21:1163-71.
Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent
197Immunomodulation or Viral Suppression
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
cirrhosis due to chronic hepatitis B. Gastroenterology 1993;104:1116-21.
Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, Schiff E, Bodicky C, Miller B,
Denham C, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic
infection with hepatitis B virus. Gastroenterology 1995;109:908-16.
d'Alteroche L, Majzoub S, Lecuyer AI, Delplace MP, Bacq Y. Ophthalmologic side effects during alpha-
interferon therapy for viral hepatitis. J Hepatol 2006;44:56-61.
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J,
Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for
HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken
G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated interferon alfa-2b alone or
in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet
2005;365:123-9.
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC,
Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the
combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95.
Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS,
Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic
hepatitis B. N Engl J Med 2003;348:808-16.
Carreno V, Castillo I, Molina J, Porres JC, Bartolome J. Long-term follow-up of hepatitis B chronic carriers
who responded to interferon therapy. J Hepatol 1992;15:102-6.
Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-
positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on
Viral Hepatitis (EUROHEP). Hepatology 1997;26:1338-42.
Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of
chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-34.
Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-
Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive
Team on Anti-Viral Treatment. J Viral Hepat 1998;5:389-97.
Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of
patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-7.
Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in
patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5.
Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with
interferon alfa. Gastroenterology 1993;105:1833-8.
Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up
of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-
7.
Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US,
Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg loss
after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b. Gastroenterology
2008;135:459-467.
Cooksley G, Lau GKK, Liaw YF, Marcellin P, Chow WC, Thongsawat S, Gane E, Fried MW, Zahm FE.
Effects of genotype and other baseline factors on response to peginterferon alfa-2a (40 kDa) (Pegasys®)
in HBeAg-positive chronic hepatitis B: results from a large, randomised study. J Hepatol 2005;42:S30.
Bonino F, Lau GKK, Marcellin P, Hadziyannis S, Kitis G, Jin R, Yao GB, Piratvisuth T, Germanidis G,
Yurdaydin C, Diago M, Gurel S, Lai MY, McCloud P, Brunetto MR, Farci P. The first detailed analysis of
predictors of response in HBeAg-negative chronic hepatitis B: data from a multicenter, randomized,
  198
Su
m
m
ar
y 
an
d 
Di
sc
us
sio
n
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
partially double-blind study of peginterferon-alfa-2a (4-KD) (Pegasys®) alone or in combination with
lamivudine vs lamivudine alone. Hepatology 2004;40:A1142.
Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 2003;39
Suppl 1:S99-105.
van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen
HL, de Man RA, Schalm SW. Durability of HBeAg seroconversion following antiviral therapy for chronic
hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine ami-
notransferase. Gut 2003;52:420-4.
Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepa-
titis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-9.
Janssen HL, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, Hadziyannis S. Fatal hepatic decom-
pensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep). BMJ
1993;306:107-8.
Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine
therapy. Hepatology 2003;38:1267-73.
Ryu SH, Chung YH, Choi MH, Kim JA, Shin JW, Jang MK, Park NH, Lee HC, Lee YS, Suh DJ. Long-
term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective
study. J Hepatol 2003;39:614-9.
Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej
N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown
NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88.
Poynard T, Hou JL, Chutaputti A, Manns M, Naoumov N. Sustained durability of HBeAg seroconversion
in chronic hepatitis B patients after treatment with telbivudine. J Hepatol 2008;48:S263-S264.
Hadziyannis S, Lau GKK, Marcellin P, Piratvisuth T, Cooksley G, Bonino F, Chutaputti A, Diago M, Jin
R, Pluck N. Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with
peginterferon alpha-2a (40kDa) (Pegasys®). J Hepatol 2005;42:S178.
Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon
therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-30.
Buti M, Cotrina M, Valdes A, Jardi R, Rodriguez-Frias F, Esteban R. Is hepatitis B virus subtype testing
useful in predicting virological response and resistance to lamivudine? J Hepatol 2002;36:445-6.
Lurie Y, Manns MP, Gish RG, Chang TT, Yurdaydin C, Lai CL, Shouval D, Brown Jr. RS, Apelian D,
Fernandes L, Klesczewski KS, Cross A, Wilber R. The efficacy of entecavir is similar regardless of
disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients
with chronic hepatitis B. J Hepatol 2005;42:184.
Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AO, Wang BC, Lai CL. Hepatitis B
virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003;8:531-4.
Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S,
Schiff E. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology
2003;37:748-55.
Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine
therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6.
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON,
Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver dis-
ease. N Engl J Med 2004;351:1521-31.
Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M,
Kuiken C. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommenda-
tions for management. Hepatology 2007;46:254-65.
Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H, Holzmann H, de Schryver A, Reynders D,
199Immunomodulation or Viral Suppression
Connell J, Gerlich WH, Marinho RT, Tsantoulas D, Rigopoulou E, Rosenheim M, Valla D, Puro V, Struwe
J, Tedder R, Aitken C, Alter M, Schalm SW, Carman WF. Hepatitis B virus (HBV) and hepatitis C virus
(HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and
HCV from HCW to patients. J Clin Virol 2003;27:213-30.

Sa
m
en
va
tti
ng
 e
n 
di
sc
us
si
e
Be
we
rk
in
g 
va
n:
 T
he
 N
et
he
rla
nd
s 
Jo
ur
na
l o
f M
ed
ici
ne
 
20
06
; 6
4(6
):1
75
-18
5.
An
tiv
ira
l b
eh
an
de
lin
g 
bij
 ch
ron
isc
he
 he
pa
titi
s B
 vi
rus
 in
fec
tie
: Im
mu
un
-
m
od
ul
at
ie
 o
f v
ira
le
 s
up
pr
es
sie
?
  202
Sa
m
en
va
ttin
g 
en
 d
isc
us
sie
INLEIDING
Hepatitis B virus (HBV) infectie is nog steeds een belangrijk gezondheidsprobleem, naar schatting
zijn er aanwijzingen voor contact met HBV bij eenderde van de wereldbevolking. Het aantal mensen
met chronische HBV infectie wordt geschat op 400 miljoen.1, 2 Indien onbehandeld zal persisterende
onsteking van de lever leiden tot progressive van fibrose en uiteindelijk tot gedecompenseerde
cirrose en hepatocellulair carcinoom (HCC) bij 25-40% van de patiënten.3 Naar schatting sterven
er wereldwijd elk jaar 500.000 personen aan de gevolgen van HBV geassocieerde leverziekte,
voornamelijk door de complicaties van levercirrose en HCC.4 Met de beschikbaarheid van meerdere
nieuwe antivirale middelen is de behandeling van chronische hepatitis B effectiever geworden en
kan er in potentie een aanzienlijke reductie in sterfte aan deze chronische leverziekte bereikt worde..
ANTIVIRALE THERAPIE VOOR HBEAG POSITIEVE CHRONISCHE HEPATITIS B
Er is een indicatie voor antivirale behandeling bij hepatitis B e antigen (HBeAg) positieve patiënten
met hoog HBV DNA (>1.0 x 105 kopieën/ml) en verhoogd alanine aminotransferase (ALAT). Wel
kan behandeling 3-6 maanden worden uitgesteld om eventuele spontane HBeAg seroconversie af
te wachten. Spontane HBeAg seroconversie trad binnen drie maanden op bij 46% van 3063 Chinese
patiënten met ALAT waarden boven vijf maal de bovenwaarde van normaal.5 Indien er geen spontane
HBeAg seroconversie is opgetreden na deze periode komt de patiënt in aanmerking voor
behandeling. Daarnaast kan behandeling overwogen worden indien er bij histologisch onderzoek
aanwijzingen zijn voor significante necroinflammatie of fibrose. Bij HBeAg positieve patiënten is
succesvolle antivirale behandeling met verlies van HBeAg, daling van HBV DNA en normalisatie
van ALAT geassocieerd met verbeterde uitkomst op lange termijn. Dit is onafhankelijk van het
gebruikte antivirale medicijn. Behandelaars hebben op dit moment keuze uit een tweetal vormen
van IFN (standaard IFN en gepegyleerd IFN [PEG-IFN]) en een vijftal nucleos(t)ide analogen
(lamivudine, adefovir, entecavir, telbivudine en tenofovir). Met de beschikbaarheid van nieuwe
antivirale middelen is de keuze van optimale behandeling complexer geworden. Indien een patiënt
in aanmerking komt voor behandeling dient er allereerst een keuze gemaakt te worden tussen
behandeling met PEG-IFN met een vaste behandelduur of langdurige behandeling met een
nucleos(t)ide analog.
FACTOREN DIE DE KEUZE VAN BEHANDELING BEINVLOEDEN
De toegenomen complexiteit van behandeling van chronische hepatitis B heeft geleid tot de
ontwikkeling van meerdere nationale en internationale richtlijnen in de afgelopen jaren.4, 6-9 De
meeste van de richtlijnen geven echter geen specifieke aanbevelingen betreffende de keuze tussen
PEG-IFN of een nucleos(t)ide analoog als eerstelijns behandeling. Beide strategieën zijn effectief
gebleken en hebben ieder hun voor- en nadelen (tabel 1). Daarnaast spelen factoren als HBV
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DNA, ALAT, HBeAg status, HBV genotype, ernst van leverziekte en de voorkeur van de patiënt een
belangrijke rol bij de keuze van antivirale behandeling in een individuele patiënt. Optimale antvirale
behandeling is geassocieerd met de hoogste kans op klaring van het virus met een beperkte
behandelduur.
BIJWERKINGEN VAN DE BEHANDELING
Behandeling met PEG-IFN gaat vaak gepaard met bijwerkingen als griep-achtige klachten,
myelosuppressie en depressive.10 Nucleos(t)ide analogen worden daarentegen zeer goed
verdragen. PEG-IFN wordt vaak niet gegeven aan patiënten met gevorderde fibrose of cirrose in
verband met de veronderstelde verminderde effectiviteit en het verhoogde risico op acute
exacerbatie van ontstekingsactiviteit. Het is bekend dat behandeling met IFN ernstige compllicaties
als bacteriële infectie en decompensatie kan geven bij patiënten met Child B of C levercirrose.11, 12
Hoewel we inderdaad vonden dosisreductie en vroegtijdig staken van PEG-IFN behandeling vaker
nodig waren bij patiënten met dan zonder gevorderde cirrose, waren de responspercentages
vergelijkbaar in beide groepen (Hoofdstuk 3).
Retinopathie is een relatief zeldzame afwijkinng die kan worden gezien tijdens PEG-IFN behandeling.
Bij patiënten met chronische hepattis C virus infectie retinopathie waarschijnlijk vaker voor, het
werd gezien bij 24% van patiënten die behandeld werden met PEG-IFN en een fundoscopie
ondergingen.13 Wij vonden slecht bij één van de 24 (4%) met chronische hepatitis B aanwijzingen
voor retinopathie tijdens behandeling met PEG-IFN. (Hoofdstuk 4). Routinematige screening op
retinopathie voorafgaand aan en tijdens PEG-IFN lijkt daarom niet noodzakelijk bij patiënten met
chronische hepatitis B bij afwezigheid van andere risicofactoren voor retinopathie als diabetes
mellitus en hypertensie.
BLIJVENDE RESPONS OP PEG-IFN
Eén jaar na het staken van de behandeling lijkt PEG-IFN te resulteren in de hoogste kans op
blijvende respons in vergelijking met de overige beschikbare antivirale middelen voor de behandeling
van chronische hepatitis B.14-17 Aan het einde van de behandeling werd HBeAg verlies gezien bij
29% van de patiënten die behandeld werden met alleen PEG-IFN alpha-2b en bij 44% van de
patiënten die hierbij ook lamivudine kregen.15 Verlies van de behaalde response trad op bij 13% en
39% van deze patiënten binnen 6 maanden na behandeling (Hoofdstuk 5). Bij 9% van de patiënten
trad HBeAg verlies pas op nadat de behandeling reeds gestaakt was, hiermee komt 6 maanden
na behandeling het responspercentage op 36%. Na gemiddeld 3 jaar was 37% van de patiënten
die behandeld waren met PEG-IFN á-2b HBeAg negatief en was 11% ook HBsAg negatief (Hoofdstuk
7). Het percentage HBsAg verlies was 30% onder patiënten die 6 maanden na behandeling HBeAg
negatief waren (initiële responders). Het is bekend dat het percentage HBsAg verlies toeneemt bij
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een langere follow-up duur. Dit neemt op de lange termijn toe toe tot 12-65% van de patiënten met
virologische respons.18-26
We vonden dat het percentage hepatocyten dat positief was voor HBcAg en HBsAg significant
verminderd was na PEG-IFN behandeling in vergelijking met voorafgaand aan behandeling. Er
leek een gunstig effect te zijn van het toegevoegen van lamivudine. Verdwijnen van HBsAg expressie
in de lever is belangrijk omdat het sterk geassocieerd is met klaring van HBeAg en HBsAg uit het
serum (Hoofdstuk 9). Daarnaast bleek HBsAg verlies voornamelijk op te treden bij patiënten die
binnen 32 weken na aanvang van PEG-IFN behandeling HBeAg negatief waren geworden (Hoofdstuk
8). Een sterke daling van de virusconcentratie tijdens de eerste maanden van behandeling, wat
met name bereikt werd in patiënten met toegevoegde lamivudine, leek geassocieerd met een
hogere kans op vroeg HBeAg verlies en HBsAg verlies op lange termijn (Hoofdstuk 9).
VOORSPELLERS VAN RESPONS OP PEG-IFN
De meeste studies met IFN voor HBeAg positieve chronische hepatitis B hebben gevonden dat
hoog ALAT, laag HBV DNA en HBV genotype A of B zijn geasscocieerd met een hogere kans op
respons.15, 27-29 Naast deze factoren vonden wij ook dat geslacht, leeftijd en voorgaande behandeling
met IFN voorspellers van respons op PEG-IFN waren (Hoofdstuk 2). Wel bleek de invloed van
geslacht, leeftijd, HBV DNA en voorgaande IFN behandeling significant verschillend tussen de
HBV genotypes. Op basis van deze bevindingen hebben we een practisch hulpmiddel opgesteld
om de voorspelde kans op respons op PEG-IFN voor HBeAg positieve patiënten te berekenen.
Deze behandelindex kan in de klinische praktijk het selecteren van optimale HBeAg positieve
kandidaten voor PEG-IFN behandeling vereenvoudigen. Op basis van het model zouden we PEG-
IFN willen aanbevelen voor genotype A patiënten met hoog ALAT (>=2 x ULN) of laag HBV DNA
(<9log10 kopieën/ml) en voor genotype B of C patiënten met hoog ALAT en laag HBV DNA. Patiënten
met genotype D hebben in het algemeen een lage kans op respons op PEG-IFN en zijn daarom
meestal geen goede kandidaten voor behandeling met PEG-IFN, onafhankelijk van HBV DNA en
ALAT concentraties.
BLIJVENDE RESPONS NA BEHANDELING MET NUCLEOS(T)IDE ANALOGEN
Behandeling met nucleos(t)ide analogen resulteert in een sterke daling van de serum HBV DNA
concentratie, wat behouden kan worden middles langdurige onderhoudsbehandeling. Het
percentage blijvende respons na een jaar behandeling met lamivudine was echter lager dan met
IFN.30 Wij vonden dat gecombineerde respons van HBeAg verlies en HBV DNA <7.0 x 105 kopieën/
ml na één jaar behandeling was opgetreden bij 34% van de patiënten behandeld met PEG-IFN (en
lamivudine) en bij 21% van degenen met entercavir behandeling (Hoofdstuk 10). Zes maanden na
behandeling waren de percentages blijvende respons vergelijkbaar, namelijk 20% en 17%.
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Voorspellers van blijvende respons op entecavir zijn hoog ALAT, laag HBV DNA, hoge
necroinflammatiescore en infectie met HBV genotype A of D (Hoofdstuk 10).
Verlies van respons na het staken van behandeling geeft een risico op acute verergering van de
hepatitis (flare). Flares kunnen met name optreden in patiënten die stoppen met nucleos(t)ide
analogen of antitivrale resistentie ontwikkelen, ze zijn met name berucht in patiënten met gevorderde
leverziekte.31, 32 Wij vonden dat ernstige flares ook optreden na het stoppen van behandeling met
PEG-IFN, de ALAT concentratie steeg tot boven de 10 maal de bovenwaarde van normaal bij 14%
van de met PEG-IFN behandelde patiënten (Hoofdstuk 6).
Bij nucleos(t)ide analog behandeling kan het risico op verlies van respons worden gereduceerd
door de behandeling tenminste enkele maanden te continueren na het optreden van HBeAg
seroconversie.33, 34 Bij patiënten die volgens dit principe behandeld werden met lamivudine of
telbivudine was HBeAg seroconversie 6 maanden na behandeling blijvend bij 86% van de
patiënten.35, 36 Deze bevindingen suggereren dat blijvende respons bij HBeAg positieve patiënten
ook kan worden bereikt met nucleos(t)ide analogen mits er gedurende enkele maanden
zogenaamde consolidatiebehandeling wordt gegeven.
HET BELANG VAN HBV GENOTYPE
Het is al geruime tijd bekend dat patiënten met HBV genotype A de hoogste kans op respons
hebben op behandeling met IFN.15, 37, 38 We vonden dat HBV genotype ook een sterke voorspeller
is van blijvende respons op lange termijn (gemiddeld 3,5 jaar na behandeling). HBeAg negatitiviteit
werd significant vaker gezien bij patiënten met genotype A dan in degenen met een ander genotype
(96% vs. 71%, p=0.02), net als HBsAg verlies (58% vs. 11%, p<0.001) (Hoofdstuk 7). Met lamivudine
is er is een hogere kans op HBeAg seroconversie gerapporteerd in genotype B dan genotype C,33
al hebben andere studies dit niet kunnen bevestigen zowel lamivudine, adefovir en entecavir.39-41
Wij vonden echter wel een relatie tussen genotype en blijvende respons na behandeling met
entecavir (Hoofdstuk 10). Verder bleken er significante verschillen te zijn in de kans op blijvende
respons op behandeling met PEG-IFN of entecavir tussen de verschillende genotypes. Zo hadden
patiënten met genotype A of B een hogere kans op blijvende respons met PEG-IFN, terwijl genotype
D patiënten een hogere kans op blijvende respons met entecavir hadden. Bij patiënten met genotype
C werden geen verschillen in blijvende respons gezien. HBV genotype kan dus de keuze van
optiamel antivirale behandeling vereenvoudigen.
LANGDURIGE VIRALE SUPPRESSIE MET NUCLEOS(T)IDE ANALOGEN
Door de beperkte kans op blijvende respons moet behandeling met nucleos(t)ide analogen meestal
langdurig en wellicht levenslang gegeven worden in een groot deel van de patiënten.42, 43 De
voortrefffelijk verdraaglijkheid van deze middelen is het relatief makkelijk ze voor langere tijd te
gebruiken om zo optimale virale suppressie te behouden. Deze strategie is effectief gebleken bij
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patiënten met gevordere fibrose, waarbij ere en verlaagde kans op ziekte progressive en HCC
was.44 Een nadeel van langdurige behandeling met nucleos(t)ide analogen is echter het ontwikkelen
van antivirale resistentie, voornamelijk bij gebruik van middelen met een lage genetische barrière
of weinig potente middelen.45
Bij gezondheidszorgwerkers met chronische hepatitis B staat er zelfs nog meer op het spel.
Volgens een panel van Europese experts op dit gebied moeten gezondheidszorgwerkers met
HBV infectie een HBV DNA concentratie hebben van minder dan 1.0 x 104 kopieën/ml om het
verrichten van invasieve ingrepen te mogen voortzetten.46 Indien zij antivirale behandeling krijgen
moeten er elke 3 maanden bepaling van de HBV DNA concentratie plaatsvinden, anders volstaat
eenmaal per 6 maanden. Op basis van onderzoek naar moerder-kind transmissie en de afwezigheid
van gedocumenteerde casus van transmissie bij een HBV DNA lager dan 1.0 x 105 kopieën/ml lijkt
overdracht van behandelaar naar patiënt erg onwaarschijnlijk bij een HBV DNA concentratie onder
dit niveau (Hoofdstuk 11). We toonden aan dat het bij zowel HBeAg positieve als HBeAg negatieve
gezondheidszorgwerkers mogelijk is de HBV DNA concentratie langdurig onder dit niveau te houden
met de huidige nucleos(t)ide analogen (Hoofdstuk 12).
CONCLUSIE
Concluderend in het kiezen van de optimale behandelstrategie belangrijker maar tegelijk ook
complexer geworden in de afgelopen 10 jaar. Zowel behandeling met PEG-IFN als met nucleos(t)ide
analogen is effectief kan waarschijnlijk de uitkomst op lange termijn gunstig beïnvloeden. Omdat
HBV genotype zo’n belangrijke invloed heeft op de keuze van behandeling is het van belang om het
genotype bepalen bij alle patiënten bij wie gestreefd wordt naar blijvende respons. In het algemeen
heeft PEG-IFN de voorkeur bij genotype A patiënten, terwijl bij patiënten met genotype D betere
resultaten behaalt worden met nucleos(t)ide analogen. Bij patiënten met genotype B en C kunnen
niet zonder meer aanbevelingen gedaan worden en moeten nog meer ook andere factoren alsmede
de  voor- en nadelen van beide strategieën nauwkeurig worden afgewogen voor een individuele
patiënt.
REFERENTIES
1.
2.
3.
4.
5.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging
prevention and control measures. J Viral Hepat 2004;11:97-107.
Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005;25 Suppl 1:3-8.
de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo
A, Rodes J, Rosenberg W, Valla D. EASL International Consensus Conference on Hepatitis B. 13-14
September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003;39:S3-25.
Yuen MF, Yuan HJ, Hui CK, Wong DK, Wong WM, Chan AO, Wong BC, Lai CL. A large population
study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection:
implications for antiviral therapy. Gut 2003;52:416-9.
207Immuunmodulatie of virale suppressie
Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S,
Schirmacher P, Fleig WE, Manns MP. The German guideline for the management of hepatitis B virus
infection: short version. J Viral Hepat 2008;15 Suppl 1:1-21.
Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific
consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008:DOI
10.1007/s12072-008-9080-3.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539.
Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke
Bakker C, Reesink HW, Janssen HL. Treatment of chronic hepatitis B virus infection - Dutch national
guidelines. Neth J Med 2008;66:292-306.
van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM,
Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL. The safety of pegylated interferon alpha-
2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinu-
ation. Aliment Pharmacol Ther 2005;21:1163-71.
Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent
cirrhosis due to chronic hepatitis B. Gastroenterology 1993;104:1116-21.
Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, Schiff E, Bodicky C, Miller B,
Denham C, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic
infection with hepatitis B virus. Gastroenterology 1995;109:908-16.
d'Alteroche L, Majzoub S, Lecuyer AI, Delplace MP, Bacq Y. Ophthalmologic side effects during alpha-
interferon therapy for viral hepatitis. J Hepatol 2006;44:56-61.
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J,
Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for
HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM,
Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated interferon alfa-2b
alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
Lancet 2005;365:123-9.
Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC,
Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the
combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95.
Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS,
Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic
hepatitis B. N Engl J Med 2003;348:808-16.
Carreno V, Castillo I, Molina J, Porres JC, Bartolome J. Long-term follow-up of hepatitis B chronic
carriers who responded to interferon therapy. J Hepatol 1992;15:102-6.
Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e
antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted
Action on Viral Hepatitis (EUROHEP). Hepatology 1997;26:1338-42.
Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of
chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-34.
Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The
Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP).
Executive Team on Anti-Viral Treatment. J Viral Hepat 1998;5:389-97.
Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of
patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-7.
Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in
patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
  208
Sa
m
en
va
ttin
g 
en
 d
isc
us
sie
Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with
interferon alfa. Gastroenterology 1993;105:1833-8.
Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-
up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med
1996;334:1422-7.
Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US,
Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg loss
after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b. Gastroenterol-
ogy 2008;135:459-467.
Cooksley G, Lau GKK, Liaw YF, Marcellin P, Chow WC, Thongsawat S, Gane E, Fried MW, Zahm FE.
Effects of genotype and other baseline factors on response to peginterferon alfa-2a (40 kDa) (Pegasys®)
in HBeAg-positive chronic hepatitis B: results from a large, randomised study. J Hepatol 2005;42:S30.
Bonino F, Lau GKK, Marcellin P, Hadziyannis S, Kitis G, Jin R, Yao GB, Piratvisuth T, Germanidis G,
Yurdaydin C, Diago M, Gurel S, Lai MY, McCloud P, Brunetto MR, Farci P. The first detailed analysis of
predictors of response in HBeAg-negative chronic hepatitis B: data from a multicenter, randomized,
partially double-blind study of peginterferon-alfa-2a (4-KD) (Pegasys®) alone or in combination with
lamivudine vs lamivudine alone. Hepatology 2004;40:A1142.
Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 2003;39
Suppl 1:S99-105.
van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen
HL, de Man RA, Schalm SW. Durability of HBeAg seroconversion following antiviral therapy for chronic
hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine ami-
notransferase. Gut 2003;52:420-4.
Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepa-
titis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-9.
Janssen HL, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, Hadziyannis S. Fatal hepatic decom-
pensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep). BMJ
1993;306:107-8.
Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine
therapy. Hepatology 2003;38:1267-73.
Ryu SH, Chung YH, Choi MH, Kim JA, Shin JW, Jang MK, Park NH, Lee HC, Lee YS, Suh DJ. Long-
term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective
study. J Hepatol 2003;39:614-9.
Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej
N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown
NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88.
Poynard T, Hou JL, Chutaputti A, Manns M, Naoumov N. Sustained durability of HBeAg seroconversion
in chronic hepatitis B patients after treatment with telbivudine. J Hepatol 2008;48:S263-S264.
Hadziyannis S, Lau GKK, Marcellin P, Piratvisuth T, Cooksley G, Bonino F, Chutaputti A, Diago M, Jin
R, Pluck N. Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with
peginterferon alpha-2a (40kDa) (Pegasys®). J Hepatol 2005;42:S178.
Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon
therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-30.
Buti M, Cotrina M, Valdes A, Jardi R, Rodriguez-Frias F, Esteban R. Is hepatitis B virus subtype testing
useful in predicting virological response and resistance to lamivudine? J Hepatol 2002;36:445-6.
Lurie Y, Manns MP, Gish RG, Chang TT, Yurdaydin C, Lai CL, Shouval D, Brown Jr. RS, Apelian D,
Fernandes L, Klesczewski KS, Cross A, Wilber R. The efficacy of entecavir is similar regardless of
disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
209Immuunmodulatie of virale suppressie
with chronic hepatitis B. J Hepatol 2005;42:184.
Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AO, Wang BC, Lai CL. Hepatitis B
virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003;8:531-4.
Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S,
Schiff E. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology
2003;37:748-55.
Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine
therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6.
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON,
Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver dis-
ease. N Engl J Med 2004;351:1521-31.
Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M,
Kuiken C. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommenda-
tions for management. Hepatology 2007;46:254-65.
Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H, Holzmann H, de Schryver A, Reynders D,
Connell J, Gerlich WH, Marinho RT, Tsantoulas D, Rigopoulou E, Rosenheim M, Valla D, Puro V, Struwe
J, Tedder R, Aitken C, Alter M, Schalm SW, Carman WF. Hepatitis B virus (HBV) and hepatitis C virus
(HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and
HCV from HCW to patients. J Clin Virol 2003;27:213-30.
41.
42.
43.
44.
45.
46.
  210
Dankwoord
Allereerst moet ik zeggen dat ik mijn promotieonderzoek als een erg leuke tijd heb ervaren. Het onderzoek zelf,
maar zeker de samenwerking met alle collega's waren daarvoor doorslaggevend.
Ik wil mijn promotor, prof.dr. Harry Janssen, bedankten voor de begeleiding tijdens het promotieonderzoek.
Harry, je werkwijze vond ik erg prettig en motiverend. Ondanks je drukke agenda wist je altijd tijd te maken als
dat nodig was. Ook enorm bedankt voor alle mogelijkheden die je me naast het promotieonderzoek geboden.
Ik denk hierbij aan presentaties op congressen en symposia en natuurlijk de mogelijkheid om deel uit te
maken van de commissie voor de ontwikkeling van de Nederlandse richtlijnen voor de behandeling van hepatitis
B en C.
Uiteindelijk is alles begonnen met een afstudeeronderzoek onder supervisie van prof.dr. Solko Schalm naar de
mogelijkheden voor antivirale behandeling bij gezondheidszorgwerkers met hepatitis B. Solko, je enthausiasme
voor wetenschappelijk onderzoek is ongekend en heb je zeker over weten te brengen. Ook wil ik je bedanken
voor de alle vrijheid om bij ExpertDoc te werken aan de beslisbomen voor de behandeling van hepatitis B en
andere leverziekten.
Mijn opleider dr. Rob de Man en ook prof.dr. Ernst Kuipers wil bedanken voor het in mij gestelde vertrouwen voor
de opleiding tot Maag-Darm-Leverarts.
De samenwerking met de collega’s van de hepatitis B groep, Martijn ter Borg, Marjolein op den Brouw, Annemiek
van der Eijk, Wim Leemans, Jurriën Reijnders, Eric Tjwa, Hanneke van Vuuren, Andrea Woltman en Vincent
Rijckborst was super. Altijd was het mogelijk om bij het HBV-overleg of tussendoor samen wat te bespreken of
door te nemen. Natuurlijk mogen ook mijn voorgangers, en met name Hajo Flink, niet onbenoemd blijven omdat
er al zo veel werk was gedaan voor de LTFU studie.
Statistiek is het onderdeel waar de meeste beginnende promovendi denk ik het meest tegenop zien. Als je
echter terecht kunt bij jou Bettina, weet je dat er altijd wat moois uitkomt. Zonder jouw hulp was veel van het
statistisch onderzoek niet gelukt ben ik bang. Wat een geweldige publicatie hebben we van het predictiemodel
gemaakt, wie had dat gedacht. Ewout ook erg veel dank voor je advies bij dit artikel wat natuurlijk helemaal
aansluit bij jouw expertise.
De meeste tijd heb ik doorgebracht op de al vaak geroemde en vervloekte dakpoli. Warm en gezellig was het
in ieder geval altijd. Met mijn kamergenoten Els, Geert, Paul en Daphne heb ik een zeer goede tijd gehad in dat
kleine kamertje. We hebben veel gelachen samen, nog meer koffie gehaald, maar ook op zijn tijd de perikelen
rondom het onderzoek besproken. Ook de overige collega-onderzoekers: Aafke, Arjun, Claudia, Désirée, Edith,
Femme, Gijs, Jildou, Jilling, Joyce, Judith, Lieke, Madeleen, Manon, Margot, Mark, Nicoline, Rachel, Robert,
Sarwa, Suzanne en alle anderen heel erg bedankt voor de leuke tijd, de koffiepauzes, lunches, etentjes,
borrels, skireis en niet te vergeten de congressen.
De secretaresses van de sectie Hepatologie, Marion en Margriet, stonden werkelijk altijd klaar om te helpen.
Jullie hulp en kennis bij de gang van zaken rondom de promotie en in het ziekenhuis is echt onmisbaar! Marion
in het bijzonder bedankt voor je hulp bij de correspondentie rondom de promotie en natuurlijk bij het (re-re-re-)
submitten van alle artikelen tijdens de opleiding...
211Dankwoord
De dames van het clinical research bureau, Wanda, Elke, Claudia, Gaalda en Irene wil ik enorm bedanken voor
de hulp bij het schrijven van de protocollen, het invoeren en controleren van de data en natuurlijk het feit dat
jullie ervoor gezorgd hebben dat alles ook gebeurt zoals het behoort te gaan (er is natuurlijk vaak een makkelijkere
weg...)!
Promovendi komen en gaan, maar de research verpleegkundigen Cokki, Anneke, Heleen en Lucille zorgen er
al jaren voor dat altijd het hele traject van inclusie, behandeling, follow-up en alles daaromheen strak werd
gepland. Bedankt voor al jullie hulp.
Een zeer leuke afwisseling tijdens het onderzoek was de HBV-poli op de dinsdagmiddag, met de polidames
(Ester, Wilma, Nermin, Lakshmie, Ellen en Esther) en heer (Ronald) was het er altijd gezellig. Ook kon ik er
altijd terecht voor vermiste voorwerpen (lees statussen).
Ook met de collega’s van andere afdeling van het Erasmus MC heb ik met veel plezier samengewerkt. Vooral
bij Suzan en Martin van de afdeling Virologie heb ik regelmatig aangeklopt voor aanvullende analyses. Bedankt
voor jullie snelle hulp altijd. Aardig wat uurtje heb ik achter de microscoop gezeten. Pieter, bedankt voor de tijd
die je hiervoor uittrok en je koffie is natuurlijk onovertroffen.
Ingrid en Martijn, super dat jullie mijn paranimfen willen zijn! Ook al wonen we inmiddels wat verder uit elkaar,
hopelijk blijven we elkaar veel zien. Dat geldt natuulijk ook voor mijn andere zus Mirjam, jullie zijn weliswaar
Nederbelgen maar gelukkig altijd in de buurt. Martin en Martijn, we hebben veel meegemaakt samen! Hartstikke
leuk dat we alledrie zo kort na elkaar een kleine krijgen, dat ze snel vriendjes en vriendinnetjes mogen worden.
Papa en mama, heel erg bedankt voor alle steun, maar vooral ook alle vrijheid die jullie me altijd hebben
gegeven. Jullie staan echt altijd voor ons klaar en ik denk nog altijd terug aan een geweldige tijd bij jullie thuis
in Rijen. Het is fantastisch om nu te zien hoe blij jullie zijn met jullie eerste kleinkind.
Het laatste plekje heb ik bewaard voor jou Ineke. Bedankt voor al je interesse in mijn onderzoek en natuurlijk
voor de hulp bij het opmaken van mijn promotieboekje. Ik ben hartstikke trots op je, je bent een geweldige
verloskundige. Ik kan echt niet beschrijven hoe blij je me hebt gemaakt met onze prachtige dochter Nine!
  212
Curriculum Vitae
De auteur van dit proefschrift werd geboren op 23 juni 1980 te Goirle. Na het behalen van zijn
V.W.O. diploma aan de Nassau Scholengemeenschap te Breda in 1998, studeerde hij Gezondheids-
wetenschappen aan de Universiteit Maastricht. Hij behaalde het propedeusediploma in 1999.
Aansluitend startte hij met de opleiding Geneeskunde aan de Erasmus Universiteit te Rotterdam.
Op de afdeling Maag-, Darm- en Leverziekten van het Erasmus MC te Rotterdam (afdelingshoofd
prof.dr. E.J. Kuipers) verrichtte hij zijn afstudeeronderzoek met als onderwerp “Doctor to patient
transmission of hepatitis B virus” onder supervisie van prof.dr. S.W. Schalm. Hij ontving hiervoor
de Gerrit Jan Mulderprijs voor veelbelovend wetenschappelijk onderzoek. Het doctoraalexamen
werd behaald in juli 2003 en het artsexamen in november 2005. Aansluitend werkte hij als arts-
onderzoeker onder supervisie van prof.dr. H.L.A. Janssen aan het onderzoek beschreven in dit
proefschrift. Tijdens het promotieonderzoek was hij tevens secretaris van de Commissie Richtlijnen
behandeling chronische hepatitis B en C virusinfectie van de Nederlandse Vereniging van Maag-
Darm-Leverartsen. In januari 2009 werd begonnen met de opleiding tot Maag-Darm-Leverarts
vanuit het  Erasmus MC te Rotterdam (opleider dr. R.A. de Man) in het Albert Schweitzer ziekenhuis
te Dordrecht (opleider Interne Geneeskunde: dr. E.F.H. van Bommel, opleider Maag-Darm-
Leverziekten: dr. W. Lesterhuis). Hij is samenwonend met Ineke Beens in Breda, ze hebben een
dochter Nine.Cu
rri
cu
lum
 V
ita
e
213Bibliography
Bibliography
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Schalm SW, Buster EH. Management of hepatitis B virus infected health care workers based on HBV
DNA levels. J Clin Virol. 2003;27(3):231-234
Buster EH, van der Eijk AA, Schalm SW. Doctor to patient transmission of hepatitis B virus: Implica-
tions of HBV DNA levels and potential new solutions. Antiviral Res. 2003;60(2):79-85.
Buster EH, van der Eijk AA, de Man RA, Schalm SW. Doctor to patient transmission of hepatitis B
virus: The potential of antiviral therapy for prevention. Scand J Gastroenterol. 2004;Suppl.(241):45-49.
Buster EH, ter Borg MJ, Vingerling JR, Janssen HL. Low incidence of retinopathy during peginterferon
alpha-2b and lamivudine therapy for chronic hepatitis B. J Hepatol. 2006;45(1):160-161.
Buster EH, Janssen HL. Antiviral treatment for chronic hepatitis B virus infection - Immune modulation
or viral suppression? Neth J Med. 2006;64(6):175-185.
ter Borg MJ, Buster EH, Janssen HL. Interferon and pegylated interferon in chronic hepatitis B. In: Buti
M and Esteban R. BC)VH Viral Hepatitis. Barcelona, Spain 2006: 32-45.
Buster EH, ter Borg MJ, Janssen HL. Pegylated interferon alpha for chronic hepatitis B - alone or in
combination with lamivudine. In: Negro F. Hot Topics in Viral Hepatitis. Treatment of chronic hepatitis
B: an update. Modena, Italy 2007: 21-27 (ISBN 978-88-89881-28-6).
Buster EH, van der Eijk AA, de Man RA, Janssen HL, Schalm SW. Prolonged antiviral therapy for
hepatitis B virus infected health care workers: A feasible option to prevent work restriction without
jeopardizing patient safety. J Viral Hepat. 2007;14(5):350-354.
Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen P, Flisiak R, Zondervan PE,
Schalm SW, Janssen HL. Peginterferon alpha-2b is safe and effective in HBeAg positive chronic hepa-
titis B patients with advanced fibrosis. Hepatology 2007;46(2):388-394.
Flink HJ, Buster EH, Merican I, Nevens F, Kitis G, Cianciara J, de Vries RA, Hansen BE, Schalm SW,
Janssen HL. Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine
in HBeAg positive chronic hepatitis B. Gut 2007;56(10):1485-1486.
Buster EH, van Vuuren AJ, Zondervan PE, Metselaar HJ, Tilanus HW, de Man RA. Thiopurine-
methyltransferase and inosine triphosphate pyrophosphatase polymor-phism in a liver transplant re-
cipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur J Gastroenterol Hepatol.
2008; 20(1): 68-72.
Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TMK, Feinman SV, Mach T, Akarca
US, Schutten M, Tielemans W, Van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and
HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b.
Gastroenterology 2008;135(2):459-467.
Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ,
Bakker CM, Reesink HW, Janssen HL; Netherlands Association of Gastroenterologists and
Hepatologists. Treatment of chronic hepatitis B virus infection - Dutch national guidelines. Neth J Med.
2008;66(7):292-306.
de Bruijne J, Buster EH, Gelderblom HC, Brouwer JT, de Knegt RJ, van Erpecum KJ, Schalm SW,
Bakker CM, Zaaijer HL, Janssen HL, Reesink HW; Netherlands Association of Gastroenterologists
and Hepatologists. Treatment of chronic hepatitis C virus infection - Dutch national guidelines. Neth J
Med. 2008;66(7):311-322.
Schalm SW, Buster EH. The practice guideline 'Viral hepatitis and other liver diseases' (second revi-
sion) from the Dutch College of General Practitioners; a response from the perspective of gastroenter-
ology. Ned Tijdschr Geneeskd. 2008;152(49):2658-61.
Janssen HL, Buster EH. Comments on the EASL practice guidelines for the management of chronic
hepatitis B: controversies in interferon-based therapy. J Hepatol. 2009;51(1):224-226.
  214
Buster EH, Schalm SW, Janssen HL. Peginterferon for the treatment of chronic hepatitis B in the era
of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol. 2008;22(6):1093-1108.
Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, Gerken G, Buti M, de Vries RA,
Verhey E, Hansen BE, Janssen HL. Early HBeAg Loss During Peginterferon alpha-2b Therapy Pre-
dicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients. Am J
Gastroenterol. in press.
Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Predicting
response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gas-
troenterology in press.
17.
18.
19.
215
PhD Portfolio Summary
Summary of PhD training and teaching activities
:tnedutsDhPemaN
:tnemtrapedCMsumsarE
retsuB.J.C.HkirE
ygolotapeHdnaygoloretneortsaG
:doirePDhP
:rotomorP
8002-5002
nessnaJ.A.L.H.rd.forp
gniniartDhP.1 raeY daolkroW
spohskrowdnasnoitatneserP
fogniteemlaunnaeciwT.surivBsititapehfonoissimsnarttneitapotrotcoD
ehT,nevohdleV,02hcraM.ygolotapeHfonoitaicossAsdnalrehteNeht
.sdnalrehteN 3002 sruoh21
nopohskrowsumsarElanoitanretnI.srekrowerachtlaehdetcefnirofsnoituloS
.sdnalrehteNehT,madrettoR,9enuJ.Bsititapehcinorhc 6002 sruoh21
setardesaercninistluserssolgAeBHdecudnib2-ahplanorefretnigepylraE
ehtfogniteemlaunnaeciwT.ANDVBHelbatcetednudnassolgAsBHfo
ehT,nevohdleV,6rebotcO.ygolotapeHfonoitaicossAsdnalrehteN
.sdnalrehteN 6002 sruoh81
dnalacigolorivhgihotsdaeldnadetarelotllewsib2-ahplanorefretnigeP
decnavdahtiwstneitapBsititapehcinorhcnisetaresnopserlacigolotsih
.ygolotapeHfonoitaicossAsdnalrehteNehtfogniteemlaunnaeciwT.sisorbif
.sdnalrehteNehT,nevohdleV,6rebotcO 6002 sruoh81
rebrevoN.muisopmysDLSAA-tsoPht4.)etadpuDLSAA(surivBsititapeH
.sdnalrehteNehT,madrettoR,32 6002 sruoh81
ehtfogniteemretniWhtIX.tneitaptnalpsnartrevilanimsihpromylop-APTI
,segurB,51rebmeceD.)LSAB(reviLehtfoydutSehtrofnoitaicossAnaigleB
.muigleB 6002 sruoh8
.keeWsititapeH.yparehtlarivitnaotsurivmorf:CdnaBsititapeH-pohskroW
.sdnalrehteNehT,troofsremA,61yraurbeF 7002 sruoh8
niroenolab2-ahplanorefretnigephtiwtnemtaertretfaseralflawardhtiW
eciwT.Bsititapehcinorhcevitisop-gAeBHnieniduvimalhtiwnoitanibmoc
,32hcraM.ygolotapeHfonoitaicossAsdnalrehteNehtfogniteemlaunna
.sdnalrehteNehT,nevohdleV 7002 sruoh21
CdnaBsititapeHmuisopmyS.yparehtlarivitnaVBHnisthgisniweN
fonoitaicossAsdnalrehteNehtfogniteemlaunnaeciwT.senilediug
.sdnalrehteNehT,nevohdleV,5rebotcO.ygolotapeH 7002 sruoh81
:b2-ahplanorefretnigephtiwtnemtaertretfassolgAeBHdeniatsusgnitciderP
ehtfogniteemlaunnaeciwT.ledomlacitcarpafonoitadilavdnatnempoleved
ehT,nevohdleV,5rebotcO.ygolotapeHfonoitaicossAsdnalrehteN
.sdnalrehteN 7002 sruoh21
sititapeHlanoitanretnIamrahPehcoR.senilediugecitcarpVBHDLSAA
,hcekarraM,ht03rebmevoN.sseccusesimixam,segnellahcehtecaf:gniteeM
.occoroM 7002 sruoh21
PhD Portfolio Summary
  216
DLSAA-tsopht5?tonroenibmocot:BsititapehcinorhcrofyparehtlarivitnA
.sdnalrehteNehT,madrettoR,6rebmeceD.muisopmys 7002 sruoh21
niscipoTtnerruCmuisopmyslanoitanretniht11.ydutsEBOLGeht:BsititapeH
,03yraunaJ.muisopmysetilletassitravoN.)DITC(sesaesiDsuoitcefnI
.dnalreztiwS,dlawlednirG 8002 sruoh4
VCHsnemeiSdnoceS.CdnaBsititapeHfotnemtaerTdnasisongaiD
.sdnalrehteNehT,aderB,72hcraM.elbatdnuor 8002 sruoh4
.yparehtlarivitnarofsenilediugwen-noitcefnisurivBsititapehehcsinorhC
,edlowsretaP,13hcraM.sesaesiDsuoitcefnIrofyrotarobaLehtfogniteeM
.sdnalrehteNehT 8002 sruoh21
ehtfogniteeM?esnopserdeniatsusrofmiaewdluohs-BsititapehcinorhC
.sdnalrehteNehT,nevohdniE,7lirpA.ygolotapeHfoytrapgnikrowgrubmiL 8002 sruoh6
dlroW.noitcefnisurivBsititapehcinorhcfotnemtaertehtrofsenilediuG
.sdnalrehteNehT,nevohtliB,91yaM.yaDsititapeH 8002 sruoh4
esnopsertnemtaert-ffodeniatsusforotciderptnatropminasiepytonegVBH
cinorhcevitisopgAeBHnirivacetnednaB2-ahplanorefretnigephtobot
fonoitaicossAsdnalrehteNehtfogniteemlaunnaeciwT.Bsititapeh
.sdnalrehteNehT,nevohdleV,2rebotcO.ygolotapeH 8002 sruoh21
ssolgAsBHstciderpyparehtb2-ahplanorefretnigepgnirudssolgAeBHylraE
launnaeciwT.Bsititapehcinorhcniydutspu-wollofmret-gnolafostluseR-
,nevohdleV,2rebotcO.ygolotapeHfonoitaicossAsdnalrehteNehtfogniteem
.sdnalrehteNehT 8002 sruoh21
cinorhcevitisopgAeBHniafla-norefretnigepotesnopserfonoitciderP
ehtfogniteemlaunnaeciwT.stneitap127nodesabledoma:Bsititapeh
ehT,nevohdleV,dn2rebotcO.ygolotapeHfonoitaicossAsdnalrehteN
.sdnalrehteN 8002 sruoh21
muisopmyS.eiparehtneesongaidrooveigoloressititapehnavgnaleB
.92rebotcO,teepsnuN."sititapehelarivjibnegnigadtiU" 8002 sruoh4
snoitatneserpretsoP
dnalacigolorivhgihotsdaeldnadetarelotllewsib2-ahplanorefretnigeP
decnavdahtiwstneitapBsititapehcinorhcnisetaresnopserlacigolotsih
foydutSehtfonoitaicossAnaciremAehtfogniteemlaunnAht75.sisorbif
detinU,AM,notsoB,03rebotcO.479tcartsba,)DLSAA(sesaesiDreviL
.aciremAfosetatS 6002 sruoh42
setardesaercninistluserssolgAeBHdecudnib2-ahplanorefretnigepylraE
ehtfogniteemlaunnAht75.ANDVBHelbatcetednudnassolgAsBHfo
tcartsba,)DLSAA(sesaesiDreviLfoydutSehtrofnoitaicossAnaciremA
.aciremAfosetatSdetinU,AM,notsoB,03rebotcO.579 6002 sruoh23
niroenolab2-ahplanorefretnigephtiwtnemtaertretfaseralflawardhtiW
dn24.Bsititapehcinorhcevitisop-gAeBHnieniduvimalhtiwnoitanibmoc
,)LSAE(reviLehtfoydutSehtrofnoitaicossAnaeporuEfogniteemlaunnA
.niapS,anolecraB,11lirpA.3802tcartsba 7002 sruoh23
:b2-ahplanorefretnigephtiwtnemtaertretfassolgAeBHdeniatsusgnitciderP
ehtfogniteemlaunnAht85.ledomlacitcarpafonoitadilavdnatnempoleved
tcartsba,)DLSAA(sesaesiDreviLfoydutSehtrofnoitaicossAnaciremA
.aciremAfosetatSdetinU,AM,notsoB,5rebmevoN.2001 7002 sruoh42
gAeBHfopu-wollofmret-gnolretfassolgAsBHdnagAeBHdeniatsuS
fogniteemlaunnAht85.b2-ahplanorefretnigephtiwdetaertstneitapevitisop
tcartsba,)DLSAA(sesaesiDreviLfoydutSehtrofnoitaicossAnaciremAeht
.aciremAfosetatSdetinU,AM,notsoB,5rebmevoN.569 8002 sruoh42
esnopsertnemtaert-ffodeniatsusforotciderptnatropminasiepytonegVBH
cinorhcevitisopgAeBHnirivacetnednaB2-ahplanorefretnigephtobot
foydutSehtrofnoitaicossAnaciremAehtfogniteemlaunnAht95.Bsititapeh
,AC,ocsicnarFnaS,5rebmevoN.519tcartsba,)DLSAA(sesaesiDreviL
.aciremAfosetatSdetinU 8002 sruoh23
217
ssolgAsBHstciderpyparehtb2-ahplanorefretnigepgnirudssolgAeBHylraE
launnAht95.Bsititapehcinorhcniydutspu-wollofmret-gnolafostluseR-
sesaesiDreviLfoydutSehtrofnoitaicossAnaciremAehtfogniteem
fosetatSdetinU,AC,ocsicnarFnaS,5rebmevoN.829tcartsba,)DLSAA(
.aciremA 8002 sruoh23
cinorhCevitisoPgAeBHniaflA-norefretnigePotesnopseRfonoitciderP
ehtfogniteemlaunnAht95.stneitaP127nodesaBledoMA:BsititapeH
tcartsba,)DLSAA(sesaesiDreviLfoydutSehtrofnoitaicossAnaciremA
.aciremAfosetatSdetinU,AC,ocsicnarFnaS,5rebmevoN.929 8002 sruoh63
secnerefnoClanoitanretnI
lirpA.htlaeHfosetutitsnIlanoitaN.6002:BsititapeHcinorhCfotnemeganaM
.aciremAfosetatSdetinU,DM,adsehteB,8-6 6002 sruoh81
reviLehtfoydutSehtrofnoitaicossAnaeporuEehtfogniteeMlaunnAts14
.airtsuA,anneiV,03-62lirpA.)LSAE( 6002 sruoh82
rofnoitaicossAnaciremAehtfogniteeMlaunnAht75,6002gniteeMreviLehT
fosetatSdetinU,AM,notsoB,13-72rebotcO.sesaesiDreviLfoydutSeht
.aciremA 6002 sruoh82
reviLehtfoydutSehtrofnoitaicossAnaeporuEehtfogniteeMlaunnAdn24
.niapS,anolecraB,51-11lirpA.)LSAE( 7002 sruoh82
rofnoitaicossAnaciremAehtfogniteeMlaunnAht85,7002gniteeMreviLehT
fosetatSdetinU,AM,notsoB,6-2rebmevoN.sesaesiDreviLfoydutSeht
.aciremA 7002 sruoh82
,segnellahcehtecaF:gniteeMsititapeHlanoitanretnIamrahPehcoR
.occoroM,hcekarraM,03-92rebmevoN.sseccusesimixam 7002 sruoh41
reviLehtfoydutSehtrofnoitaicossAnaeporuEehtfogniteeMlaunnAdr34
.ylatI,naliM,72-32lirpA.)LSAE( 8002 sruoh82
rofnoitaicossAnaciremAehtfogniteeMlaunnAht95,8002gniteeMreviLehT
,AC,ocsicnarFnaS,4rebmevoN-13rebotcO.sesaesiDreviLfoydutSeht
.aciremAfosetatSdetinU 8002 sruoh82
spohskrowdnasranimesdednettA
,9-8enuJ.BsititapeHcinorhCnopohskroWsumsarElanoitanretnI
.sdnalrehteNehT,madrettoR 6002 sruoh8
DLSAAtsoPe4.sdnalrehteNehT,thcertU,9yaM.muisopmysLSAE-tsoP
.sdnalrehteNehT,madrettoR,32rebmevoN.muisopmys 6002 sruoh2
ehT,musrevliH,31rebmetpeS.CneBsititapeHlekahcSetskretSeD
.sdnalrehteN 6002 sruoh2
ehT,thcertU,62rebmetpeS.CneBsititapeHlekahcSetskretSeD
.sdnalrehteN 6002 sruoh2
.sdnalrehteNehT,madrettoR,6rebmeceD.muisopmysDLSAAtsoPe5 7002 sruoh2
BsititapehehcsinorhC:netkeizeitcefnIroovmuirotarobaLdnovareerefeR
,13hcraM.gnilednahebnekeitsongaidroovnenjilthcirewueiN-eitcefnisuriv
.sdnalrehteNehT,edlowsretaP 7002 sruoh2
BsititapehehcsinorhC:sititapeHroovpeorgkreWesgrubmiLdnovareerefeR
,7lirpA.gnilednahebnekeitsongaidroovnenjilthcirewueiN-eitcefnisuriv
.sdnalrehteNehT,nevohdniE 8002 sruoh2
,91hcraM?lihcsrevtehretkodedtkaaM:BsititapehneVIHgaddimeidutS
.sdnalrehteNehT,madrettoR 8002 sruoh2
.52rebmetpeS,madretsmA.CneBsititapeHtabedsiuhregaLetsreE 8002 sruoh2
.72-62rebmetpeS,nettuP.grubnenaVeDnavruu-42eD 8002 sruoh6
PhD Portfolio Summary
  218
rehtO
sdnalrehteNehtfoeettimmocsenilediugCdnaBsititapehehtfoyraterceS
stsigolotapeHdnastsigoloretneortsaGfonoitaicossA 8002-6002 sruoh441
seitivitcagnihcaeT.2
gnirutceL
keew-4anignitapicitrapstnedutslacidemCMsumsarEraeydr3.BsititapeH
,madrettoR,52yraunaJ.margorpgniniartygolotapeHdnaygoloretneortsaG
.sdnalrehteNehT 7002 sruoh8
-4anignitapicitrapstnedutslacidemCMsumsarEraeydn2.BsititapeH
ehT,madrettoR,7enuJ.margorpgniniartsesaesiDsuoitcefnIkeew
.sdnalrehteN 7002 sruoh8
-4anignitapicitrapstnedutslacidemCMsumsarEraeydn2.BsititapeH
ehT,madrettoR,5enuJ.margorpgniniartsesaesiDsuoitcefnIkeew
.sdnalrehteN 8002 sruoh4
snoisrucxednaslacitcarpgnisivrepuS
-tsop:stneitaperuc-ot-tluciffidgnitaertrofseigetartsnospohskrowevitcaretnI
sititapeHlanoitanretnIamrahPehcoR.VCHtnerrucerhtiwstneitaptnalpsnart
,hcekarraM,92rebmevoN.sseccusesimixam,segnellahcehtecaf:gniteeM
.occoroM 7002 sruoh8
sesehtgnisivrepuS
fotnemeganaM":yreviwdiMfoloohcstuohnruTstnedutssisehtetaudargrednU
"sefiwdimrofelortnatropminA-ycnangerpniBsititapeh 8002 sruoh04


